0001628280-21-015843.txt : 20210805 0001628280-21-015843.hdr.sgml : 20210805 20210805160704 ACCESSION NUMBER: 0001628280-21-015843 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 71 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210805 DATE AS OF CHANGE: 20210805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CareTrust REIT, Inc. CENTRAL INDEX KEY: 0001590717 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 463999490 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36181 FILM NUMBER: 211148162 BUSINESS ADDRESS: STREET 1: 905 CALLE AMANECER, SUITE 300 CITY: SAN CLEMENTE STATE: CA ZIP: 92673 BUSINESS PHONE: (949) 542-3140 MAIL ADDRESS: STREET 1: 905 CALLE AMANECER, SUITE 300 CITY: SAN CLEMENTE STATE: CA ZIP: 92673 10-Q 1 ctre-20210630.htm 10-Q ctre-20210630
0001590717--12-312021Q2falsehttp://fasb.org/us-gaap/2021-01-31#HealthCareResidentServiceMemberhttp://fasb.org/us-gaap/2021-01-31#HealthCareResidentServiceMemberhttp://fasb.org/us-gaap/2021-01-31#HealthCareResidentServiceMemberhttp://fasb.org/us-gaap/2021-01-31#HealthCareResidentServiceMemberhttp://fasb.org/us-gaap/2021-01-31#HealthCareResidentServiceMemberhttp://fasb.org/us-gaap/2021-01-31#HealthCareResidentServiceMemberhttp://fasb.org/us-gaap/2021-01-31#HealthCareResidentServiceMemberhttp://fasb.org/us-gaap/2021-01-31#HealthCareResidentServiceMemberP5DP1Y00015907172021-01-012021-06-30xbrli:shares00015907172021-08-04iso4217:USD00015907172021-06-3000015907172020-12-31iso4217:USDxbrli:shares00015907172021-04-012021-06-3000015907172020-04-012020-06-3000015907172020-01-012020-06-300001590717us-gaap:CommonStockMember2020-12-310001590717us-gaap:AdditionalPaidInCapitalMember2020-12-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2020-12-310001590717us-gaap:CommonStockMember2021-01-012021-03-310001590717us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100015907172021-01-012021-03-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2021-01-012021-03-310001590717us-gaap:CommonStockMember2021-03-310001590717us-gaap:AdditionalPaidInCapitalMember2021-03-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2021-03-3100015907172021-03-310001590717us-gaap:CommonStockMember2021-04-012021-06-300001590717us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2021-04-012021-06-300001590717us-gaap:CommonStockMember2021-06-300001590717us-gaap:AdditionalPaidInCapitalMember2021-06-300001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2021-06-300001590717us-gaap:CommonStockMember2019-12-310001590717us-gaap:AdditionalPaidInCapitalMember2019-12-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2019-12-3100015907172019-12-310001590717us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-3100015907172020-01-012020-03-310001590717us-gaap:CommonStockMember2020-01-012020-03-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2020-01-012020-03-310001590717us-gaap:CommonStockMember2020-03-310001590717us-gaap:AdditionalPaidInCapitalMember2020-03-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2020-03-3100015907172020-03-310001590717us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001590717us-gaap:CommonStockMember2020-04-012020-06-300001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2020-04-012020-06-300001590717us-gaap:CommonStockMember2020-06-300001590717us-gaap:AdditionalPaidInCapitalMember2020-06-300001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2020-06-3000015907172020-06-30ctre:facility0001590717ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember2021-06-30ctre:bed0001590717ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember2021-01-012021-06-30ctre:state0001590717ctre:SeniorUnsecuredNotesMemberctre:FivePointTwoFiveSeniorNotesDue2025Member2021-06-30xbrli:purectre:property0001590717ctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2034NextOption2022Memberctre:AssistedLivingFacilityMember2021-06-300001590717ctre:SkilledNursingFacilityMemberctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2030NextOption2022Member2021-06-300001590717ctre:PropertiesWithPurchaseOptionLeaseExpirationMarch2029NextOption2022Memberctre:SkilledNursingFacilityMember2021-06-300001590717ctre:SkilledNursingAndCampusFacilitiesMemberctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2032NextOption2023Member2021-06-300001590717ctre:SkilledNursingFacilityMemberctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2034NextOption2024Member2021-06-300001590717ctre:AssistedLivingFacilityMemberctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2034NextOption2026Member2021-06-300001590717ctre:SkilledNursingPropertiesMember2021-01-012021-06-30ctre:unit0001590717ctre:MultiServiceCampusPropertiesMember2021-01-012021-06-300001590717srt:ScenarioForecastMemberctre:MultiServiceCampusPropertiesMember2022-01-012022-12-310001590717ctre:FiveOaksHealthcareLLCMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2020-12-310001590717us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberctre:FiveOaksHealthcareLLCMember2021-02-012021-02-010001590717us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberctre:FiveOaksHealthcareLLCMember2021-02-010001590717us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberctre:FiveOaksHealthcareLLCMember2021-01-012021-06-300001590717us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberctre:MetronSkilledNursingFacilitiesMember2020-02-140001590717us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberctre:MetronSkilledNursingFacilitiesMember2020-02-142020-02-140001590717us-gaap:MortgageReceivablesMemberctre:CascadeCapitalGroupLLCMember2020-02-140001590717us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberctre:MetronSkilledNursingFacilitiesMember2020-01-012020-03-310001590717us-gaap:MortgageReceivablesMemberctre:CascadeCapitalGroupLLCMember2020-04-012020-04-300001590717us-gaap:MortgageReceivablesMemberctre:CascadeCapitalGroupLLCMember2020-04-300001590717us-gaap:MortgageReceivablesMemberctre:CascadeCapitalGroupLLCMember2020-07-012020-07-310001590717ctre:SkilledNursingFacilityMemberctre:EnsignMember2021-06-010001590717ctre:EnsignAmendedTripleNetMasterLeaseMember2021-06-01ctre:extension_option0001590717ctre:EnsignAmendedTripleNetMasterLeaseMember2021-06-012021-06-010001590717ctre:NobleVAHoldingsLLCMemberctre:AssistedLivingFacilityMember2020-12-010001590717ctre:NobleTripleNetMasterLeaseMember2020-12-010001590717ctre:NobleTripleNetMasterLeaseMember2020-12-012020-12-010001590717ctre:MezzanineLoanMemberctre:NextVAStarRealtyHoldingsLLCMember2020-11-300001590717srt:MinimumMemberctre:MezzanineLoanMemberctre:NextVAStarRealtyHoldingsLLCMember2020-11-300001590717srt:MaximumMemberctre:MezzanineLoanMemberctre:NextVAStarRealtyHoldingsLLCMember2020-11-300001590717ctre:MezzanineLoanMemberctre:NextVAStarRealtyHoldingsLLCMember2020-11-012020-11-300001590717ctre:MezzanineLoanMemberctre:NextVAStarRealtyHoldingsLLCMember2021-04-012021-06-300001590717ctre:MezzanineLoanMemberctre:NextVAStarRealtyHoldingsLLCMember2021-01-012021-06-300001590717ctre:MantecaValleyPostAcuteMemberus-gaap:MortgageReceivablesMember2019-07-012019-07-310001590717ctre:MantecaValleyPostAcuteMemberus-gaap:MortgageReceivablesMember2019-07-310001590717ctre:MantecaValleyPostAcuteMember2019-07-012019-07-310001590717ctre:CommuniCareMemberus-gaap:MortgageReceivablesMember2019-09-300001590717us-gaap:MortgageReceivablesMemberctre:CascadeCapitalGroupLLCMember2020-02-290001590717us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberctre:MetronSkilledNursingFacilitiesMember2020-02-290001590717ctre:CascadeCapitalGroupLLCMember2020-04-300001590717us-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:MortgageReceivablesMemberctre:CascadeCapitalGroupLLCMember2020-04-300001590717us-gaap:MortgageReceivablesMember2021-06-300001590717us-gaap:MortgageReceivablesMember2021-01-012021-06-300001590717us-gaap:MortgageReceivablesMember2021-04-012021-06-300001590717us-gaap:MortgageReceivablesMember2020-04-012020-06-300001590717us-gaap:MortgageReceivablesMember2020-01-012020-06-300001590717us-gaap:LoansReceivableMember2021-04-012021-06-300001590717us-gaap:LoansReceivableMember2021-01-012021-06-300001590717us-gaap:LoansReceivableMember2020-04-012020-06-300001590717us-gaap:LoansReceivableMember2020-01-012020-06-300001590717ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember2016-09-300001590717us-gaap:PrimeRateMemberctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember2016-09-012016-09-300001590717ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember2016-09-012016-09-300001590717ctre:SkilledNursingPropertiesMember2020-01-012020-01-310001590717ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember2020-01-012020-01-310001590717ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember2020-01-012020-06-300001590717us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberctre:MezzanineLoanMember2021-06-300001590717us-gaap:FairValueMeasurementsRecurringMemberctre:MezzanineLoanMemberus-gaap:FairValueInputsLevel2Member2021-06-300001590717us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberctre:MezzanineLoanMember2021-06-300001590717us-gaap:FairValueMeasurementsRecurringMemberctre:MezzanineLoanMember2021-06-300001590717us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberctre:MezzanineLoanMember2020-12-310001590717us-gaap:FairValueMeasurementsRecurringMemberctre:MezzanineLoanMemberus-gaap:FairValueInputsLevel2Member2020-12-310001590717us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberctre:MezzanineLoanMember2020-12-310001590717us-gaap:FairValueMeasurementsRecurringMemberctre:MezzanineLoanMember2020-12-310001590717us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember2021-06-300001590717us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember2020-12-310001590717ctre:ThreePointEightSevenFiveSeniorNotesDue2028Memberus-gaap:SeniorNotesMember2021-06-300001590717ctre:ThreePointEightSevenFiveSeniorNotesDue2028Memberus-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-06-300001590717us-gaap:EstimateOfFairValueFairValueDisclosureMemberctre:ThreePointEightSevenFiveSeniorNotesDue2028Memberus-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMember2021-06-300001590717ctre:ThreePointEightSevenFiveSeniorNotesDue2028Memberus-gaap:SeniorNotesMember2020-12-310001590717ctre:ThreePointEightSevenFiveSeniorNotesDue2028Memberus-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2020-12-310001590717us-gaap:EstimateOfFairValueFairValueDisclosureMemberctre:ThreePointEightSevenFiveSeniorNotesDue2028Memberus-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMember2020-12-310001590717ctre:FivePointTwoFiveSeniorNotesDue2025Memberus-gaap:SeniorNotesMember2021-06-300001590717ctre:FivePointTwoFiveSeniorNotesDue2025Memberus-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-06-300001590717us-gaap:EstimateOfFairValueFairValueDisclosureMemberctre:FivePointTwoFiveSeniorNotesDue2025Memberus-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMember2021-06-300001590717ctre:FivePointTwoFiveSeniorNotesDue2025Memberus-gaap:SeniorNotesMember2020-12-310001590717ctre:FivePointTwoFiveSeniorNotesDue2025Memberus-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2020-12-310001590717us-gaap:EstimateOfFairValueFairValueDisclosureMemberctre:FivePointTwoFiveSeniorNotesDue2025Memberus-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMember2020-12-310001590717ctre:SeniorUnsecuredTermLoanMember2021-06-300001590717ctre:SeniorUnsecuredTermLoanMember2020-12-310001590717us-gaap:LineOfCreditMember2021-06-300001590717us-gaap:LineOfCreditMember2020-12-310001590717ctre:FivePointTwoFiveSeniorNotesDue2025Memberus-gaap:SeniorNotesMember2017-05-100001590717ctre:FivePointTwoFiveSeniorNotesDue2025Memberus-gaap:SeniorNotesMember2017-05-102017-05-100001590717ctre:FivePointTwoFiveSeniorNotesDue2025Memberus-gaap:SubsequentEventMemberus-gaap:SeniorNotesMember2021-07-012021-07-010001590717ctre:ThreePointEightSevenFiveSeniorNotesDue2028Memberus-gaap:SeniorNotesMember2021-06-170001590717ctre:ThreePointEightSevenFiveSeniorNotesDue2028Memberus-gaap:SeniorNotesMember2021-06-172021-06-170001590717ctre:ThreePointEightSevenFiveSeniorNotesDue2028Memberus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2021-06-172021-06-170001590717us-gaap:DebtInstrumentRedemptionPeriodThreeMemberctre:ThreePointEightSevenFiveSeniorNotesDue2028Memberus-gaap:SeniorNotesMember2021-06-172021-06-170001590717us-gaap:DebtInstrumentRedemptionPeriodOneMemberctre:ThreePointEightSevenFiveSeniorNotesDue2028Memberus-gaap:SeniorNotesMember2021-06-172021-06-170001590717ctre:NewRevolvingFacilityMemberus-gaap:RevolvingCreditFacilityMember2019-02-080001590717us-gaap:LetterOfCreditMember2019-02-080001590717ctre:SwinglineLoanMember2019-02-080001590717ctre:NewTermLoanFeb2019Memberctre:SeniorUnsecuredTermLoanMember2019-02-080001590717ctre:NewRevolvingFacilityMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2019-02-082019-02-080001590717ctre:NewRevolvingFacilityMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2019-02-082019-02-080001590717ctre:NewRevolvingFacilityMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2019-02-082019-02-080001590717ctre:NewRevolvingFacilityMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2019-02-082019-02-080001590717ctre:NewTermLoanFeb2019Membersrt:MinimumMemberctre:SeniorUnsecuredTermLoanMemberus-gaap:BaseRateMember2019-02-082019-02-080001590717ctre:NewTermLoanFeb2019Membersrt:MaximumMemberctre:SeniorUnsecuredTermLoanMemberus-gaap:BaseRateMember2019-02-082019-02-080001590717ctre:NewTermLoanFeb2019Membersrt:MinimumMemberus-gaap:LondonInterbankOfferedRateLIBORMemberctre:SeniorUnsecuredTermLoanMember2019-02-082019-02-080001590717ctre:NewTermLoanFeb2019Membersrt:MaximumMemberus-gaap:LondonInterbankOfferedRateLIBORMemberctre:SeniorUnsecuredTermLoanMember2019-02-082019-02-080001590717ctre:NewRevolvingFacilityMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2019-02-082019-02-080001590717ctre:NewRevolvingFacilityMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2019-02-082019-02-080001590717us-gaap:SubsequentEventMemberus-gaap:LineOfCreditMember2021-07-012021-08-050001590717ctre:NewRevolvingFacilityMemberus-gaap:RevolvingCreditFacilityMember2019-02-082019-02-080001590717srt:MaximumMemberctre:AtTheMarketOfferingProgramMember2020-03-100001590717ctre:AtTheMarketOfferingProgramMember2020-01-012020-06-300001590717ctre:AtTheMarketOfferingProgramMember2020-04-012020-06-300001590717ctre:AtTheMarketOfferingProgramMember2021-04-012021-06-300001590717ctre:AtTheMarketOfferingProgramMember2021-01-012021-06-300001590717ctre:AtTheMarketOfferingProgramMember2021-06-3000015907172020-03-200001590717us-gaap:RestrictedStockMemberctre:EnsignEmployeesMember2014-06-012014-06-010001590717us-gaap:RestrictedStockMemberctre:EnsignEmployeesMember2020-01-012020-12-310001590717us-gaap:RestrictedStockMemberctre:EnsignEmployeesMember2021-06-300001590717ctre:OfficerAndEmployeeMemberus-gaap:RestrictedStockMember2021-01-012021-01-310001590717ctre:OfficerAndEmployeeMemberus-gaap:RestrictedStockMember2021-02-012021-02-28ctre:installment0001590717ctre:OfficerAndEmployeeMemberus-gaap:RestrictedStockMember2021-01-310001590717ctre:OfficerAndEmployeeMemberus-gaap:RestrictedStockMember2021-02-280001590717srt:OfficerMemberus-gaap:PerformanceSharesMember2021-01-012021-01-310001590717srt:MinimumMembersrt:OfficerMemberus-gaap:PerformanceSharesMember2021-01-012021-01-310001590717srt:MaximumMembersrt:OfficerMemberus-gaap:PerformanceSharesMember2021-01-012021-01-310001590717srt:OfficerMemberus-gaap:PerformanceSharesMember2021-02-012021-02-28ctre:company0001590717srt:MinimumMembersrt:OfficerMemberus-gaap:PerformanceSharesMember2021-02-012021-02-280001590717srt:MaximumMembersrt:OfficerMemberus-gaap:PerformanceSharesMember2021-02-012021-02-280001590717us-gaap:PerformanceSharesMember2021-01-012021-02-280001590717us-gaap:RestrictedStockMembersrt:DirectorMember2021-04-012021-04-300001590717ctre:EnsignAndPennantMember2021-06-300001590717ctre:CapitalImprovementsAtTripleNetLeasedFacilitiesMember2021-06-300001590717ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMemberctre:EnsignMember2021-06-30ctre:unit_bed0001590717ctre:EnsignMember2021-01-012021-06-300001590717ctre:EnsignMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-04-012021-06-300001590717ctre:EnsignMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-06-300001590717ctre:EnsignMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-06-300001590717ctre:EnsignMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-04-012020-06-300001590717ctre:PriorityManagementGroupLLCMemberctre:SkilledNursingAndCampusFacilitiesMember2021-06-300001590717ctre:PriorityManagementGroupLLCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-04-012021-06-300001590717ctre:PriorityManagementGroupLLCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-06-300001590717ctre:PriorityManagementGroupLLCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-06-300001590717ctre:PriorityManagementGroupLLCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-04-012020-06-300001590717srt:ScenarioForecastMemberctre:FivePointTwoFiveSeniorNotesDue2025Memberus-gaap:SeniorNotesMember2021-07-012021-09-300001590717ctre:SkilledNursingFacilityMemberus-gaap:SubsequentEventMember2021-08-012021-08-050001590717us-gaap:SubsequentEventMemberctre:EnsignMemberctre:EnsignMasterLeaseAmendedMember2021-08-050001590717us-gaap:SubsequentEventMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2021-08-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2021
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     

Commission File Number: 001-36181
CareTrust REIT, Inc.
(Exact name of registrant as specified in its charter)
Maryland46-3999490
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
905 Calle Amanecer, Suite 300, San Clemente, CA
92673
(Address of principal executive offices)(Zip Code)
(949) 542-3130
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareCTREThe Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.      Yes      No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).      Yes      No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).      Yes      No
As of August 4, 2021, there were 97,035,096 shares of common stock outstanding.





INDEX






PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
(Unaudited)
 
June 30, 2021December 31, 2020
Assets:
Real estate investments, net$1,575,403 $1,448,099 
Other real estate investments15,150 15,000 
Assets held for sale, net 7,226 
Cash and cash equivalents1,771 18,919 
Restricted cash309,187  
Accounts and other receivables1,786 1,823 
Prepaid expenses and other assets, net7,570 10,450 
Deferred financing costs, net1,552 2,042 
Total assets$1,912,419 $1,503,559 
Liabilities and Equity:
Senior unsecured notes payable, net$690,890 $296,669 
Senior unsecured term loan, net199,031 198,925 
Unsecured revolving credit facility50,000 50,000 
Accounts payable and accrued liabilities16,804 19,572 
Dividends payable26,085 24,251 
Total liabilities982,810 589,417 
Commitments and contingencies (Note 10)
Equity:
Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued and outstanding as of June 30, 2021 and December 31, 2020
  
Common stock, $0.01 par value; 500,000,000 shares authorized, 96,296,673 and 95,215,797 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively
963 952 
Additional paid-in capital1,189,402 1,164,402 
Cumulative distributions in excess of earnings(260,756)(251,212)
Total equity929,609 914,142 
Total liabilities and equity$1,912,419 $1,503,559 










See accompanying notes to condensed consolidated financial statements.

1

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED INCOME STATEMENTS
(in thousands, except per share amounts)
(Unaudited)
 
 For the Three Months Ended June 30,For the Six Months Ended June 30,
 2021202020212020
Revenues:
Rental income$47,744 $42,507 $92,990 $84,971 
Independent living facilities 615  1,240 
Interest and other income514 1,046 1,019 2,297 
Total revenues48,258 44,168 94,009 88,508 
Expenses:
Depreciation and amortization13,843 13,239 27,316 26,399 
Interest expense6,534 5,849 12,296 12,563 
Property taxes766 837 1,462 1,322 
Independent living facilities  546  1,092 
General and administrative5,798 4,762 10,940 8,816 
Total expenses26,941 25,233 52,014 50,192 
Other loss:
Loss on sale of real estate  (192)(56)
Net income$21,317 $18,935 $41,803 $38,260 
Earnings per common share:
Basic$0.22 $0.20 $0.43 $0.40 
Diluted$0.22 $0.20 $0.43 $0.40 
Weighted-average number of common shares:
Basic96,082 95,208 95,732 95,185 
Diluted96,120 95,208 95,755 95,185 













See accompanying notes to condensed consolidated financial statements.
2

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(in thousands, except share and per share amounts)
(Unaudited)


Common StockAdditional
Paid-in
Capital
Cumulative
Distributions in Excess of Earnings
Total
Equity
SharesAmount
Balance at January 1, 202195,215,797 $952 $1,164,402 $(251,212)$914,142 
Issuance of common stock, net702,000 7 16,184 — 16,191 
Vesting of restricted common stock, net of shares withheld for employee taxes63,265 1 (1,331)— (1,330)
Amortization of stock-based compensation— — 1,585 — 1,585 
Common dividends ($0.265 per share)
— — — (25,633)(25,633)
Net income— — — 20,486 20,486 
Balance at March 31, 202195,981,062 $960 $1,180,840 $(256,359)$925,441 
Issuance of common stock, net288,000 3 6,752 — 6,755 
Vesting of restricted common stock, net of shares withheld for employee taxes27,611 — — — — 
Amortization of stock-based compensation— — 1,810 — 1,810 
Common dividends ($0.265 per share)
— — — (25,714)(25,714)
Net income— — — 21,317 21,317 
Balance at June 30, 202196,296,673 $963 $1,189,402 $(260,756)$929,609 

































See accompanying notes to condensed consolidated financial statements.
3


CARETRUST REIT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(in thousands, except share and per share amounts)
(Unaudited)
 Common StockAdditional
Paid-in
Capital
Cumulative
Distributions in Excess of Earnings
Total
Equity
SharesAmount
Balance at January 1, 202095,103,270 $951 $1,162,990 $(236,350)$927,591 
Issuance of common stock, net— — (90)— (90)
Vesting of restricted common stock, net of shares withheld for employee taxes93,061 1 (1,987)— (1,986)
Amortization of stock-based compensation— — 884 — 884 
Common dividends ($0.25 per share)
— — — (23,931)(23,931)
Net income— — — 19,325 19,325 
Balance at March 31, 202095,196,331 $952 $1,161,797 $(240,956)$921,793 
Issuance of common stock, net— — (314)— (314)
Vesting of restricted common stock, net of shares withheld for employee taxes17,749 — — — — 
Amortization of stock-based compensation— — 963 — 963 
Common dividends ($0.25 per share)
— — — (23,931)(23,931)
Net income— — — 18,935 18,935 
Balance at June 30, 202095,214,080 $952 $1,162,446 $(245,952)$917,446 



















See accompanying notes to condensed consolidated financial statements.
4

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)
 For the Six Months Ended June 30,
 20212020
Cash flows from operating activities:
Net income$41,803 $38,260 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization (including below-market ground leases)27,345 26,428 
Amortization of deferred financing costs1,012 975 
Amortization of stock-based compensation3,395 1,847 
Straight-line rental income(20)(48)
Loss on sale of real estate192 56 
Interest income distribution from other real estate investment 1,346 
Change in operating assets and liabilities:
Accounts and other receivables(93)806 
Prepaid expenses and other assets, net88 528 
Accounts payable and accrued liabilities(3,165)(2,256)
Net cash provided by operating activities70,557 67,942 
Cash flows from investing activities:
Acquisitions of real estate, net of deposits applied(147,807)(25,905)
Purchases of equipment, furniture and fixtures and improvements to real estate(3,463)(6,234)
Investment in real estate mortgage and other loans receivable(700)(13,958)
Principal payments received on real estate mortgage and other loans receivable 113 66,961 
Repayment of other real estate investment 2,327 
Net proceeds from sales of real estate6,814 2,134 
Net cash (used in) provided by investing activities(145,043)25,325 
Cash flows from financing activities:
Proceeds from (costs paid for) the issuance of common stock, net22,946 (404)
Proceeds from the issuance of senior unsecured notes payable400,000  
Borrowings under unsecured revolving credit facility170,000 15,000 
Payments on unsecured revolving credit facility(170,000)(75,000)
Payments of deferred financing costs(5,577) 
Net-settle adjustment on restricted stock(1,331)(1,986)
Dividends paid on common stock(49,513)(45,406)
Net cash provided by (used in) financing activities366,525 (107,796)
Net increase (decrease) in cash, cash equivalents, and restricted cash292,039 (14,529)
Cash, cash equivalents, and restricted cash as of the beginning of period18,919 20,327 
Cash, cash equivalents, and restricted cash as of the end of period$310,958 $5,798 
Supplemental disclosures of cash flow information:
Interest paid$10,664 $11,586 
Supplemental schedule of noncash investing and financing activities:
Increase in dividends payable$1,834 $2,456 
Right-of-use asset obtained in exchange for new operating lease obligation$ $599 
Increased in deferred financing costs payable$618 $ 
Transfer of pre-acquisition costs to acquired assets$358 $167 
Sale of real estate settled with note receivable$ $32,400 


See accompanying notes to condensed consolidated financial statements.
5

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)



1. ORGANIZATION
Description of Business—CareTrust REIT, Inc.’s (“CareTrust REIT” or the “Company”) primary business consists of acquiring, financing, developing and owning real property to be leased to third-party tenants in the healthcare sector. As of June 30, 2021, the Company owned and leased to independent operators, 223 skilled nursing, multi-service campuses, assisted living and independent living facilities consisting of 23,301 operational beds and units located in 28 states with the highest concentration of properties by rental revenues located in California, Texas, Louisiana, Idaho and Arizona. As of June 30, 2021, the Company also had other real estate investments consisting of one mezzanine loan receivable with a carrying value of $15.2 million.
COVID-19—The COVID-19 pandemic has led governments and other authorities around the world, including federal, state and local authorities in the United States, to impose measures intended to reduce its spread, including restrictions on freedom of movement and business operations such as travel bans, border closings, business limitations and closures (subject to exceptions for essential operations and businesses), quarantines and shelter-in-place orders. Although most of these governmental restrictions have since been lifted or scaled back, resurgences of COVID-19 and the emergence of new variants thereof have resulted in the reimposition of certain restrictions and may lead to other restrictions being reimplemented in response to efforts to reduce the spread of COVID-19. Given the dynamic nature of these circumstances and the related adverse impact these restrictions have had, and may continue to have, on the economy generally, the Company’s business, results of operations and financial condition may be adversely impacted by the COVID-19 pandemic.
The duration and extent of the COVID-19 pandemic’s effect on the Company’s operational and financial performance, and the operational and financial performance of the Company’s tenants, will depend on future developments, which are highly uncertain and cannot be predicted at this time, including the rate of public acceptance and usage of vaccines and the effectiveness of vaccines in limiting the spread of COVID-19 and its variants, resurgences of COVID-19 and, in particular, new and more contagious and/or vaccine resistant variants, actions taken to contain the spread of COVID-19 and how quickly and to what extent normal economic and operating conditions can resume. The adverse impact of the COVID-19 pandemic on the Company’s business, results of operations and financial condition could be material.
 
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. All intercompany transactions and account balances within the Company have been eliminated.
Restricted Cash—The Company presents cash and cash equivalents separately from restricted cash within the Company’s condensed consolidated balance sheets. The Company includes restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the condensed consolidated statements of cash flows. The Company provides a reconciliation between the balance sheets and statements of cash flows, as required when the balance includes more than one line item for cash, cash equivalents, and restricted cash. The Company also provides a disclosure of the nature of the restrictions related to material restricted cash balances.
As of June 30, 2021, the Company had $309.2 million in restricted cash related to the cash deposited with the trustee to pay the redemption price of the $300.0 million aggregate principal amount of 5.25% Senior Notes due 2025 (the “2025 Notes”). The 2025 Notes were redeemed on July 1, 2021. See Note 6, Debt, and Note 12, Subsequent Events, for further detail.
6

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


Cash, cash equivalents and restricted cash consisted of the following as of June 30, 2021 and December 31, 2020 (dollars in thousands):
June 30, 2021December 31, 2020
Cash and cash equivalents$1,771 $18,919 
Restricted cash309,187  
Cash, cash equivalents and restricted cash$310,958 $18,919 
 Recent Accounting Pronouncements— In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), that provides optional relief to applying reference rate reform to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”). For U.S. Dollar LIBOR, the overnight, one-month, three-month, six-month and one-year LIBOR rates will be discontinued in June 2023, while other U.S. Dollar LIBOR rates will be discontinued at the end of 2021. The amendments in this update are effective immediately and may be applied through December 31, 2022. The Company is still evaluating the impact of ASU 2020-04 and expects to take full advantage of the offered optional expedients and exceptions, but does not expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements.

3. REAL ESTATE INVESTMENTS, NET
The following table summarizes the Company’s investment in owned properties as of June 30, 2021 and December 31, 2020 (dollars in thousands):
June 30, 2021December 31, 2020
Land$244,740 $205,356 
Buildings and improvements1,588,961 1,477,849 
Integral equipment, furniture and fixtures101,441 97,836 
Identified intangible assets2,658 2,352 
Real estate investments1,937,800 1,783,393 
Accumulated depreciation and amortization(362,397)(335,294)
Real estate investments, net$1,575,403 $1,448,099 
As of June 30, 2021, all 223 of the Company’s facilities were leased to various operators under triple-net leases. All of these leases contain annual escalators based on the percentage change in the Consumer Price Index (“CPI”) (but not less than zero), some of which are subject to a cap, or fixed rent escalators.
7

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


As of June 30, 2021, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements, were (dollars in thousands):
YearAmount
2021 (six months)$93,754 
2022188,644 
2023188,438 
2024187,091 
2025187,062 
2026187,166 
Thereafter1,020,115 
Total$2,052,270 
Tenant Purchase Options
Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):
Asset TypePropertiesLease ExpirationNext Option Open Date
Option Type(1)
Current Cash Rent(2)
ALF7October 20341/1/2022A$3,282 
SNF11November 20301/1/2022C4,800 
SNF1March 20294/1/2022
B / C(3)
779 
SNF / Campus2October 20321/1/2023B959 
SNF4November 203412/1/2024B3,789 
ALF2October 20341/1/2026A1,559 
(1) Option type includes:
A - Fixed base price plus a specified share on any appreciation.
B - Fixed base price.
C - Fixed capitalization rate on lease revenue.
(2) Based on annualized cash revenue for contracts in place as of June 30, 2021.
(3) Purchase option reflects two option types.
8

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


Rental Income
The following table summarizes components of the Company’s rental income (dollars in thousands):
For the Three Months Ended June 30,
For the Six Months Ended June 30,
Rental Income2021202020212020
Contractual rent due(1)
$47,736 $42,485 $92,907 $84,923 
Straight-line rent8 22 20 48 
Lease termination revenue(2)
  63  
Total$47,744 $42,507 $92,990 $84,971 
(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received.
(2) During the six months ended June 30, 2021, in connection with the agreement to terminate its lease agreements with affiliates of Metron Integrated Health Systems (“Metron”) and to sell the facilities to a third-party, the Company received $0.1 million from Metron affiliates.
Recent Real Estate Acquisitions
The following table summarizes the Company’s acquisitions for the six months ended June 30, 2021 (dollars in thousands):
Type of Property
Purchase Price(1)
Initial Annual Cash RentNumber of Properties
Number of Beds/Units(2)
Skilled nursing$25,457 $2,295 (4)2 268 
Multi-service campuses(3)
125,708 8,604 4 640 
Total$151,165 $10,899 6 908 
(1) Purchase price includes capitalized acquisition costs.
(2) The number of beds/units includes operating beds at the acquisition date.
(3) Initial annual cash rent represents the first twelve months of rent upon commencement of the Company’s long-term net leases, which occurred during the three months ended June 30, 2021, upon the tenants’ receipt of licensing approval and increases to $9.4 million in the second year with CPI-based annual escalators thereafter.
(4) Included within initial annual cash rent is approximately $0.8 million of initial rent which is subject to a fixed escalator in the first twelve months and increases to $0.9 million in the second year with CPI-based annual escalators thereafter.

Asset Sales and Assets Held for Sale
As of June 30, 2021, there were no assets classified as held for sale. During the fourth quarter of 2020, the Company met the criteria to classify one skilled nursing facility operated by affiliates of Five Oaks Healthcare, LLC as held for sale. Assets held for sale include the net book value of property the Company plans to sell within the next year. If the determination is made that the Company no longer expects to sell an asset within the next year, the asset is reclassified out of assets held for sale. On February 1, 2021, the Company closed on the sale of the one skilled nursing facility consisting of 90 beds located in Washington with a carrying value of $7.2 million, for net sales proceeds of $7.0 million. During the six months ended June 30, 2021, the Company recorded a loss of $0.2 million in connection with the sale.
On February 14, 2020, the Company closed on the sale of six skilled nursing facilities formerly operated by affiliates of Metron. In connection with the sale for $36.0 million, the Company received $3.5 million in cash and provided subsidiaries of Cascade Capital Group, LLC (“Cascade”), the purchaser of the properties, with a short-term mortgage loan secured by these properties for $32.4 million. The mortgage loan bore interest at 7.5% and initially had a maturity date of March 31, 2020. In connection with the sale, the Company recognized a loss of approximately $0.1 million during the three months ended March 31, 2020. In April 2020, the mortgage loan was settled with $18.9 million in cash and a new mortgage loan for $13.9 million. In July 2020, the Company received prepayment in full, including accrued interest, for the new $13.9 million mortgage loan. See Note 4, Other Real Estate Investments, Net, for further detail on the mortgage loan.
9

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


Lease Amendments
Five Oaks Lease Termination and Amended Ensign Master Lease. On June 1, 2021, operating affiliates of The Ensign Group, Inc. (“Ensign”) acquired certain operations and assets of Five Oaks Healthcare, LLC (“Five Oaks”) under an agreement with Five Oaks. The agreement granted Ensign the right to occupy and operate four of the Company’s skilled nursing facilities in Washington that were previously being operated by Five Oaks. In conjunction with consenting to the transfer, the Company terminated the existing Five Oaks master lease, and amended and extended the term of an existing triple-net master lease with Ensign to include the four skilled nursing facilities. The Ensign lease, as amended, has a remaining term of approximately 15 years, with three five-year renewal options and CPI-based rent escalators. Annual cash rent under the terminated Five Oaks master lease was approximately $2.6 million, and annual cash rent under the amended Ensign lease increased by the same amount.
Twenty/20 Lease Termination and New Noble Master Lease. On December 1, 2020, five assisted living facilities in Virginia operated by Twenty/20 Management, Inc. (“Twenty/20”) were transferred to affiliates of Noble VA Holdings, LLC (“Noble”). In connection with the transfer, the Company entered into a new triple-net master lease with Noble. The new lease has a remaining initial term of approximately 14 years, with two five-year renewal options and CPI-based rent escalators. Initial annual cash rent under the new lease is approximately $3.2 million.

4. OTHER REAL ESTATE INVESTMENTS, NET
Mezzanine Loan Receivable—In November 2020, the Company provided Next VA Star Realty Holdings, LLC a mezzanine loan for nine skilled nursing facilities secured by membership interests in affiliates of Next VA Star Realty Holdings, LLC for approximately $15.0 million, at an annual interest rate of 12%. The loan requires monthly interest payments, is set to mature on November 30, 2025, and may (subject to certain restrictions) be prepaid before the maturity date if paid in full and for an exit fee ranging from 1% to 3% of the loan plus unpaid interest payments equal to 24 months (less the amount of monthly interest payments made by the borrower through the date of prepayment). During the three and six months ended June 30, 2021, the Company recognized $0.4 million and $0.9 million, respectively, of interest income related to its mezzanine loan.
Mortgage Loans Receivable—In July 2019, the Company provided MCRC, LLC a real estate loan secured by a 176-bed skilled nursing facility in Manteca, California for $3.0 million, which bore a fixed interest rate of 8% and required monthly interest payments. Concurrently, the Company entered into a purchase and sale agreement to purchase the Manteca facility from MCRC, LLC for approximately $16.4 million subject to normal diligence and other contingencies. The loan documents provided for a maturity date of the earlier to occur of the closing date of the acquisition, or five business days following the termination of the purchase and sale agreement.  MCRC, LLC breached its obligation to sell the Manteca facility to the Company on the terms outlined in the purchase and sale agreement and to repay the real estate loan upon its stated maturity. As a result, the Company commenced non-judicial foreclosure proceedings with respect to the Manteca facility. In January 2020, the borrower further collateralized the loan by causing one of its affiliates to grant the Company a deed of trust in the real estate and improvements that constitute Palm Gardens Assisted Living Facility in Yolo County, California. During the three months ended June 30, 2020, payment for the loan principal and accrued interest, including default interest, as well as reimbursement for attorney’s fees and certain other costs of suit, were received in full by the Company and, as a result, the Company withdrew all foreclosure-related proceedings related to the Manteca facility loan.
In September 2019, the Company provided affiliates of CommuniCare Family of Companies (“CommuniCare”) a $26.5 million loan secured by mortgages on the three skilled nursing facilities sold to CommuniCare, which bore a fixed interest rate of 10%. The mortgage loan, which required CommuniCare to make monthly interest payments, was set to mature on February 29, 2020 and included an option to be prepaid before the maturity date. In January 2020, the Company amended the mortgage loan’s maturity date to April 30, 2020. In April 2020, the Company amended the mortgage loan’s maturity date to May 29, 2020. During the three months ended June 30, 2020, payment for the mortgage loan and accrued interest was received in full by the Company.
In February 2020, the Company provided subsidiaries of Cascade a $32.4 million loan secured by mortgages on the six skilled nursing facilities formerly operated by affiliates of Metron and sold to Cascade in February 2020, as discussed in Note 3, Real Estate Investments, Net. The mortgage loan bore interest at 7.5% and initially had a maturity date of March 31, 2020. In April 2020, the mortgage loan was settled in connection with a new mortgage loan transaction between the Company and a third-party institutional lender as co-lenders, pursuant to which the Company received $18.9 million in cash and a new mortgage loan for $13.9 million. The new mortgage loan with Cascade was secured by the same six skilled nursing facilities purchased by Cascade and was for a combined principal amount of $33.9 million, with the Company’s $13.9 million portion of the indebtedness initially bearing interest at a variable rate equal to LIBOR plus 4.00%, subject to a LIBOR floor of 1.75%. The
10

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


new mortgage loan had a maturity date of April 29, 2022 and included two six-month extension options. In July 2020, prepayment for the mortgage loan of $13.9 million and accrued interest was received in full by the Company.
As of June 30, 2021, the Company had no mortgage loan receivables.
During both the three and six months ended June 30, 2021, the Company recognized no interest income related to mortgage loans. During the three and six months ended June 30, 2020, the Company recognized $0.9 million and $2.0 million of interest income, respectively, related to its mortgage loans. During the three and six months ended June 30, 2021, the Company recognized less than $0.1 million and $0.1 million of interest income, respectively, related to its other loans receivable. During the three and six months ended June 30, 2020, the Company recognized $0.1 million and $0.2 million of interest income, respectively, related to its other loans receivable.
Preferred Equity Investments—In September 2016, the Company completed a $2.3 million preferred equity investment with an affiliate of Cascadia Development, LLC. The preferred equity investment yielded a return equal to prime plus 9.5% but in no event less than 12.0% calculated on a quarterly basis on the outstanding carrying value of the investment. The investment was used to develop a 99-bed skilled nursing facility in Boise, Idaho. In connection with its investment, the Company obtained an option to purchase the development at a fixed-formula price upon stabilization, with an initial lease yield of at least 9.0%. The project was completed in the first quarter of 2018 and began lease-up during the second quarter of 2018. In January 2020, the Company purchased the skilled nursing facility for approximately $18.7 million, inclusive of transaction costs. The Company paid $15.0 million after receiving back its initial investment of $2.3 million and cumulative contractual preferred return through January 17, 2020, the acquisition date, of $1.4 million, of which less than $0.1 million was recognized as interest income during the six months ended June 30, 2020. The Company did not recognize any interest income during the three months ended June 30, 2020 or the three and six months ended June 30, 2021 related to preferred equity investments. As of June 30, 2021, the Company had no preferred equity investments.
5. FAIR VALUE MEASUREMENTS
The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.

Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.

The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.
11

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


Items Measured at Fair Value on a Recurring Basis
The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):
Level 1Level 2Level 3
Balance as of June 30, 2021
Assets:
Mezzanine loan receivable$ $ $15,150 $15,150 
Level 1Level 2Level 3
Balance as of December 31, 2020
Assets:
Mezzanine loan receivable$ $ $15,000 $15,000 

Mezzanine loan receivable: The fair value of the mezzanine loan receivable was estimated using an internal valuation model that considered the expected future cash flows of the investment, the underlying collateral value, market interest rates and other credit enhancements. As such, the Company classifies the instrument as Level 3 due to the significant unobservable inputs used in determining market interest rates for investments with similar terms. Future changes in market interest rates could materially impact the estimated discounted cash flows. As of June 30, 2021 and December 31, 2020, the Company did not have any loans that were 90 days or more past due.
For the three and six months ended June 30, 2021, there were no classification changes in assets and liabilities with Level 3 inputs in the fair value hierarchy.

Items Disclosed at Fair Value

Considerable judgment is necessary to estimate the fair value disclosure of financial instruments. The estimates of fair value presented herein are not necessarily indicative of the amounts that could be realized upon disposition of the financial instruments. A summary of the face values, carrying amounts and fair values of the Company’s financial instruments as of June 30, 2021 and December 31, 2020 using Level 2 inputs for the Notes (as defined in Note 6, Debt, below), is as follows (dollars in thousands):  
 June 30, 2021December 31, 2020
 LevelFace
Value
Carrying
Amount
Fair
Value
Face
Value
Carrying
Amount
Fair
Value
Financial liabilities:
2028 Senior unsecured notes payable2$400,000 $393,842 $410,000 $ $ $ 
2025 Senior unsecured notes payable(1)
2300,000 297,048 307,875 300,000 296,669 311,430 
(1) The $300.0 million aggregate principal amount of the 2025 Notes were redeemed on July 1, 2021. See Note 12, Subsequent Events, for further detail.

Cash and cash equivalents, restricted cash, accounts and other receivables, other loans receivable, and accounts payable and accrued liabilities: These balances approximate their fair values due to the short-term nature of these instruments.

Unsecured revolving credit facility and senior unsecured term loan: The fair values approximate their carrying values as the interest rates are variable and approximate prevailing market interest rates for similar debt arrangements.

12

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


6. DEBT
The following table summarizes the balance of the Company’s indebtedness as of June 30, 2021 and December 31, 2020 (dollars in thousands):
June 30, 2021December 31, 2020
Principal AmountDeferred Loan FeesCarrying ValuePrincipal AmountDeferred Loan FeesCarrying Value
2028 Senior unsecured notes payable$400,000 $(6,158)$393,842 $ $ $ 
2025 Senior unsecured notes payable300,000 (2,952)297,048 300,000 (3,331)296,669 
Senior unsecured term loan200,000 (969)199,031 200,000 (1,075)198,925 
Unsecured revolving credit facility50,000  50,000 50,000  50,000 
$950,000 $(10,079)$939,921 $550,000 $(4,406)$545,594 

Senior Unsecured Notes Payable
2025 Senior Notes. On May 10, 2017, the Company’s wholly owned subsidiary, CTR Partnership, L.P. (the “Operating Partnership”), and its wholly owned subsidiary, CareTrust Capital Corp. (together with the Operating Partnership, the “Issuers”), completed an underwritten public offering of $300.0 million aggregate principal amount of 5.25% Senior Notes due 2025. The 2025 Notes were issued at par, resulting in gross proceeds of $300.0 million and net proceeds of approximately $294.0 million after deducting underwriting fees and other offering expenses. The 2025 Notes were scheduled to mature on June 1, 2025 and bore interest at a rate of 5.25% per year. Interest on the 2025 Notes was payable on June 1 and December 1 of each year. On July 1, 2021, the Issuers redeemed all $300.0 million aggregate principal amount of the 2025 Notes. See Note 12, Subsequent Events, for additional information.
2028 Senior Notes. On June 17, 2021, the Issuers completed a private offering of $400.0 million aggregate principal amount of 3.875% Senior Notes due 2028 (the “Notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended. The Notes were issued at par, resulting in gross proceeds of $400.0 million and net proceeds of approximately $393.8 million after deducting underwriting fees and other offering expenses. The Notes mature on June 30, 2028. The Notes accrue interest at a rate of 3.875% per annum payable semiannually in arrears on June 30 and December 30 of each year, commencing on December 30, 2021.
The Issuers may redeem some or all of the Notes at any time prior to March 30, 2028 at a price equal to 100% of the principal amount of the Notes redeemed plus accrued and unpaid interest on the Notes, if any, to, but not including, the redemption date, plus a “make-whole” premium. At any time on or after March 30, 2028, the Issuers may redeem some or all of the Notes at a redemption price equal to 100% of the principal amount of the Notes redeemed plus accrued interest on the Notes, if any, to, but not including, the redemption date. In addition, at any time on or prior to June 30, 2024, up to 40% of the aggregate principal amount of the Notes may be redeemed with the net proceeds of certain equity offerings at a redemption price of 103.875% of the aggregate principal amount of Notes to be redeemed plus accrued and unpaid interest on the Notes, if any, to, but not including, the redemption date. If certain changes of control of the Company occur, the Issuers will be required to make an offer to holders of the Notes to repurchase their Notes at a price of 101% of their principal amount plus accrued and unpaid interest, if any, to, but not including, the repurchase date.
The obligations under the Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by the Company and all of CareTrust’s existing and future subsidiaries (other than the Issuers) that guarantee obligations under the Amended Credit Facility (as defined below); provided, however, that such guarantees are subject to automatic release under certain customary circumstances.
The indenture governing the Notes contains customary covenants such as limiting the ability of the Company and its restricted subsidiaries to: incur or guarantee additional indebtedness; incur or guarantee secured indebtedness; pay dividends or distributions on, or redeem or repurchase, capital stock; make certain investments or other restricted payments; sell assets; enter into transactions with affiliates; merge or consolidate or sell all or substantially all of their assets; and create restrictions on the ability of the Issuers and their restricted subsidiaries to pay dividends or other amounts to the Issuers. The indenture governing the Notes also requires the Company and its restricted subsidiaries to maintain a specified ratio of unencumbered
13

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


assets to unsecured indebtedness. These covenants are subject to a number of important and significant limitations, qualifications and exceptions. The indenture governing the Notes also contains customary events of default.
As of June 30, 2021, the Company was in compliance with all applicable financial covenants under the indenture governing the 2025 Notes and the indenture governing the Notes.

Unsecured Revolving Credit Facility and Term Loan
On February 8, 2019, the Operating Partnership, as the borrower, the Company, as guarantor, CareTrust GP, LLC, and certain of the Operating Partnership’s wholly owned subsidiaries entered into an amended and restated credit and guaranty agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender, and the lenders party thereto (the “Amended Credit Agreement”). The Amended Credit Agreement provides for: (i) an unsecured revolving credit facility (the “Revolving Facility”) with revolving commitments in an aggregate principal amount of $600.0 million, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments and (ii) an unsecured term loan credit facility (the “Term Loan” and, together with the Revolving Facility, the “Amended Credit Facility”) in an aggregate principal amount of $200.0 million. Borrowing availability under the Revolving Facility is subject to no default or event of default under the Amended Credit Agreement having occurred at the time of borrowing. The proceeds of the Term Loan were used, in part, to repay in full all outstanding borrowings under the Company’s prior term loan and revolving facility under its prior credit agreement. Future borrowings under the Amended Credit Facility will be used for working capital purposes, for capital expenditures, to fund acquisitions and for general corporate purposes.
The interest rates applicable to loans under the Revolving Facility are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.10% to 0.55% per annum or LIBOR plus a margin ranging from 1.10% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). The interest rates applicable to loans under the Term Loan are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.50% to 1.20% per annum or LIBOR plus a margin ranging from 1.50% to 2.20% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). In addition, the Operating Partnership will pay a facility fee on the revolving commitments under the Revolving Facility ranging from 0.15% to 0.35% per annum, based on the debt to asset value ratio of the Company and its consolidated subsidiaries (unless the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt and the Operating Partnership elects to decrease the applicable margin as described above, in which case the Operating Partnership will pay a facility fee on the revolving commitments ranging from 0.125% to 0.30% per annum based on the credit ratings of the Company’s senior long-term unsecured debt). As of June 30, 2021, the Operating Partnership had $200.0 million outstanding under the Term Loan and $50.0 million of borrowings outstanding under the Revolving Facility. Subsequent to June 30, 2021, the Operating Partnership borrowed an additional $50.0 million under the Revolving Facility. See Note 12, Subsequent Events for additional information.
The Revolving Facility has a maturity date of February 8, 2023, and includes, at the sole discretion of the Operating Partnership, two, six-month extension options. The Term Loan has a maturity date of February 8, 2026.
The Amended Credit Facility is guaranteed, jointly and severally, by the Company and its wholly owned subsidiaries that are party to the Amended Credit Agreement (other than the Operating Partnership). The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend organizational documents and pay certain dividends and other restricted payments. The Amended Credit Agreement requires the Company to comply with financial maintenance covenants to be tested quarterly, consisting of a maximum debt to asset value ratio, a minimum fixed charge coverage ratio, a minimum tangible net worth, a maximum cash distributions to operating income ratio, a maximum secured debt to asset value ratio, a maximum secured recourse debt to asset value ratio, a maximum unsecured debt to unencumbered properties asset value ratio, a minimum unsecured interest coverage ratio and a minimum rent coverage ratio. The Amended Credit Agreement also contains certain customary events of default, including the failure to make timely payments under the Amended Credit Facility or other material indebtedness, the failure to satisfy certain covenants (including the financial maintenance covenants), the occurrence of change of control and specified events of bankruptcy and insolvency.
14

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


As of June 30, 2021, the Company was in compliance with all applicable financial covenants under the Amended Credit Agreement.

7. EQUITY
Common Stock
At-The-Market Offering—On March 10, 2020, the Company entered into a new equity distribution agreement to issue and sell, from time to time, up to $500.0 million in aggregate offering price of its common stock through an “at-the-market” equity offering program (the “ATM Program”). In connection with the entry into the equity distribution agreement and the commencement of the ATM Program, the Company’s “at-the-market” equity offering program pursuant to the Company’s prior equity distribution agreement, dated as of March 4, 2019, was terminated (the “Prior ATM Program”).
There was no Prior ATM Program or ATM Program activity for the three and six months ended June 30, 2020. The following table summarizes the ATM Program activity for the three and six months ended June 30, 2021 (in thousands, except per share amounts).
For the Three Months EndedFor the Six Months Ended
June 30, 2021June 30, 2021
Number of shares288 990 
Average sales price per share$24.05 $23.74 
Gross proceeds(1)
$6,926 $23,505 
(1) Total gross proceeds is before $0.1 million and $0.3 million of commissions paid to the sales agents during the three and six months ended June 30, 2021, respectively, under the ATM Program.
As of June 30, 2021, the Company had $476.5 million available for future issuances under the ATM Program.
Share Repurchase Program—On March 20, 2020, the Company’s Board of Directors authorized a share repurchase program to repurchase up to $150.0 million of outstanding shares of the Company’s common stock (the “Repurchase Program”). Repurchases under the Repurchase Program, which expires on March 31, 2023, may be made through open market purchases, privately negotiated transactions, structured or derivative transactions, including accelerated share repurchase transactions, or other methods of acquiring shares, in each case subject to market conditions and at such times as shall be permitted by applicable securities laws and determined by management. Repurchases under the Repurchase Program may also be made pursuant to a plan adopted under Rule 10b5-1 promulgated under the Exchange Act. The Company expects to finance any share repurchases under the Repurchase Program using available cash and may also use short-term borrowings under the Revolving Facility. The Company did not repurchase any shares of common stock under the Repurchase Program during the three and six months ended June 30, 2021 and 2020. The Repurchase Program may be modified, discontinued or suspended at any time.
Dividends on Common StockThe following table summarizes the cash dividends on the Company’s common stock declared by the Company’s Board of Directors for the first six months of 2021 (dollars in thousands, except per share amounts):
For the Three Months Ended
March 31, 2021June 30, 2021
Dividends declared per share$0.265 $0.265 
Dividends payment dateApril 15, 2021July 15, 2021
Dividends payable as of record date$25,633 $25,714 
Dividends record dateMarch 31, 2021June 30, 2021

8. STOCK-BASED COMPENSATION
All stock-based awards are subject to the terms of the CareTrust REIT, Inc. and CTR Partnership, L.P. Incentive Award Plan (the “Plan”). The Plan provides for the granting of stock-based compensation, including stock options, restricted stock, performance awards, restricted stock units and other incentive awards to officers, employees and directors in connection with their employment with or services provided to the Company.
Restricted Stock Awards—In connection with the separation of the healthcare business and real estate business of Ensign into two separate and independent publicly traded companies (the “Spin-Off”) on June 1, 2014, employees of Ensign
15

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


who had unvested shares of restricted stock were given one share of CareTrust REIT unvested restricted stock totaling 207,580 shares at the Spin-Off. These restricted shares were subject to a time vesting provision only and the Company did not recognize any stock compensation expense associated with these awards. During the year ended December 31, 2020, 1,760 shares were forfeited. At June 30, 2021, there were no unvested restricted stock awards outstanding.
In January 2021 and February 2021, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted 140,514 and 99,189 shares of restricted stock, respectively, to officers and employees. Each share had a fair market value on the date of grant of $22.48 and $22.18 per share, respectively, based on the closing market price of the Company’s common stock on that date, and the shares vest in three equal annual installments beginning on the first anniversary of the grant date.
In January 2021, the Compensation Committee granted 108,414 performance stock awards to officers. Each share had a fair market value on the date of grant of $22.48 per share, based on the closing market price of the Company’s common stock on that date. Performance stock awards are subject to both time and performance based conditions and vest over a one-to three-year period. The amount of such performance awards that will ultimately vest is dependent on the Company’s Normalized Funds from Operations per share, as defined by the Compensation Committee, meeting or exceeding a specified per share amount for the applicable vesting period.
Additionally, in February 2021, the Compensation Committee granted 99,189 performance stock awards to officers. Each share had an estimated fair market value on the date of grant of $27.98 per share. Performance stock awards are subject to both time and performance based conditions and cliff vest after a three-year period. The amount of such performance awards that will ultimately vest is dependent on the Company’s total shareholder return (“TSR”) performance relative to a custom TSR peer group consisting of 16 other publicly traded healthcare REITs and will range from 0% to 200% of the TSR awards initially granted. Compensation expense for awards with performance-based vesting conditions is recognized based upon the grant date fair value per share multiplied by the estimated number of performance stock awards to be earned after considering the Company’s expectation of future performance and is recognized provided that the requisite service is rendered, regardless of when, if ever, the market condition is satisfied. Forfeitures of stock-based awards are recognized as they occur.
The fair value of the TSR-based performance stock awards is estimated on the date of the grant using a Monte Carlo valuation model. The risk-free rate is based on the U.S. Treasury yield curve in effect at the grant date for the expected performance period. Expected volatility is based on historical volatility for the most recent 2.84 year period ending on the grant date for the Company and the selected TSR peer group, and is calculated on a daily basis. The following are the key assumptions used in this valuation:
Risk-free interest rate0.27 %
Expected stock price volatility52.93 %
Expected service period2.84 years
Expected dividend yield (assuming full reinvestment) %
In April 2021, the Compensation Committee granted 20,266 shares of restricted stock to non-employee members of the Board of Directors. Each share had a fair market value on the date of grant of $24.18 per share, based on the closing market price of the Company’s common stock on that date, and the shares vest in full on the earlier to occur of April 30, 2022 or the Company’s 2022 Annual Meeting of Stockholders.
The following table summarizes the stock-based compensation expense recognized during the periods presented (dollars in thousands):
 For the Three Months Ended June 30,For the Six Months Ended June 30,
 2021202020212020
Stock-based compensation expense$1,810 $963 $3,395 $1,847 
As of June 30, 2021, there was $13.2 million of unamortized stock-based compensation expense related to unvested awards and the weighted-average remaining vesting period of such awards was 2.2 years. 
16

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


9. EARNINGS PER COMMON SHARE
The following table presents the calculation of basic and diluted earnings per common share (“EPS”) for the Company’s common stock for the three and six months ended June 30, 2021 and 2020, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (amounts in thousands, except per share amounts):
 
 For the Three Months Ended June 30,For the Six Months Ended June 30,
 2021202020212020
Numerator:
Net income$21,317 $18,935 $41,803 $38,260 
Less: Net income allocated to participating securities(116)(75)(234)(148)
Numerator for basic and diluted earnings available to common stockholders$21,201 $18,860 $41,569 $38,112 
Denominator:
Weighted-average basic common shares outstanding96,082 95,208 95,732 95,185 
Dilutive market condition stock awards38  23  
Weighted-average diluted common shares outstanding96,120 95,208 95,755 95,185 
Earnings per common share, basic$0.22 $0.20 $0.43 $0.40 
Earnings per common share, diluted$0.22 $0.20 $0.43 $0.40 
The Company’s unvested restricted shares associated with its incentive award plan and unvested restricted shares issued to employees of Ensign at the Spin-Off have been excluded from the above calculation of earnings per diluted share for the three and six months ended June 30, 2021 and 2020, as applicable, when their inclusion would have been anti-dilutive.
10. COMMITMENTS AND CONTINGENCIES
The Company and its subsidiaries are and may become from time to time a party to various claims and lawsuits arising in the ordinary course of business, which are not individually or in the aggregate anticipated to have a material adverse effect on the Company’s results of operations, financial condition or cash flows. Claims and lawsuits may include matters involving general or professional liability asserted against the Company’s tenants, which are the responsibility of the Company’s tenants and for which the Company is entitled to be indemnified by its tenants under the insurance and indemnification provisions in the applicable leases.
Capital expenditures for each property leased under the Company’s triple-net leases are generally the responsibility of the tenant, except that, for the facilities leased to subsidiaries of Ensign and The Pennant Group, Inc. (“Pennant”), the tenant will have an option to require the Company to finance certain capital expenditures up to an aggregate of 20% of the Company’s initial investment in such property, subject to a corresponding rent increase at the time of funding. For the Company’s other triple-net master leases, subject to approval by the Company, the tenants may request capital expenditure funding that would generally be subject to a corresponding rent increase at the time of funding and which are subject to tenant compliance with the conditions to the Company’s approval and funding of their requests. As of June 30, 2021, the Company had committed to fund certain capital improvements at certain triple-net leased facilities totaling $13.1 million, of which $11.6 million is subject to rent increase at the time of funding.

11. CONCENTRATION OF RISK
Major operator concentrations – As of June 30, 2021, Ensign leased 93 skilled nursing, multi-service campuses, assisted living and independent living facilities which had a total of 9,907 beds and units and are located in Arizona, California, Colorado, Idaho, Iowa, Nebraska, Nevada, Texas, Utah and Washington. The four states in which Ensign leases the highest concentration of properties by rental revenues as of June 30, 2021 are Texas, California, Arizona and Utah. During the three and six months ended June 30, 2021, Ensign represented 31% and 32%, respectively, of the Company’s rental income,
17

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


exclusive of operating expense reimbursements. During both the three and six months ended June 30, 2020, Ensign represented 32% of the Company’s rental income, exclusive of operating expense reimbursements.
Ensign is subject to the registration and reporting requirements of the SEC and is required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. Ensign’s financial statements, as filed with the SEC, can be found at http://www.sec.gov. The Company has not verified this information through an independent investigation or otherwise.
As of June 30, 2021, Priority Management Group (“PMG”) leased 15 skilled nursing and campus facilities which had a total of 2,144 beds and units, and are located in Louisiana and Texas. During both the three and six months ended June 30, 2021, PMG represented 15% of the Company’s rental income, exclusive of operating expense reimbursements. During both the three and six months ended June 30, 2020, PMG represented 17% of the Company’s rental income, exclusive of operating expense reimbursements.

12. SUBSEQUENT EVENTS
The Company evaluates subsequent events in accordance with ASC 855, Subsequent Events. The Company evaluates subsequent events up until the date the condensed consolidated financial statements are issued.
Senior Unsecured Notes Payable
On July 1, 2021 (the “Redemption Date”), the Issuers redeemed all $300.0 million aggregate principal amount of the 2025 Notes at a redemption price equal to 102.625% of the principal amount of the 2025 Notes, plus accrued and unpaid interest thereon up to, but not including, the Redemption Date. During the third quarter of 2021, the Company recorded a loss on the extinguishment of debt of $10.8 million, including a prepayment penalty of approximately $7.9 million and an approximately $2.9 million write-off of deferred financing costs associated with the redemption of the 2025 Notes.
Recent Acquisition and Amended Lease Agreement
In August 2021, the Company acquired two skilled nursing facilities for approximately $32.5 million, which includes estimated capitalized acquisition costs. The facilities were leased to affiliates of Ensign. In conjunction with the acquisition of the two facilities, the Company amended and extended the initial term of an existing triple-net master lease with Ensign to include the two skilled nursing facilities. The Ensign lease, as amended, has a remaining initial term of approximately 17 years, with three five-year renewal options and CPI-based rent escalators. Annual cash rent under the amended lease increased by approximately $2.2 million, with GAAP rent increasing by $2.5 million due to a $5.0 million prepayment of rent made at closing, which will be amortized on a straight-line basis over the remaining lease term. The Operating Partnership drew on the Revolving Facility to fund the acquisition.
Asset Held for Sale
In August 2021, the Company met the held for sale criteria on one assisted living facility operated by affiliates of Noble Senior Services, and is in the process of estimating its fair value, which is expected to be below the net carrying value of $4.9 million. The associated impairment loss is expected to be recorded in the quarter ending September 30, 2021.
18

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Forward-Looking Statements
Certain statements in this report may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Those forward-looking statements include all statements that are not historical statements of fact and those regarding our intent, belief or expectations, including, but not limited to, statements regarding: future financing plans, business strategies, growth prospects and operating and financial performance; expectations regarding the making of distributions and the payment of dividends; and compliance with and changes in governmental regulations.

Words such as “anticipate(s),” “expect(s),” “intend(s),” “plan(s),” “believe(s),” “may,” “will,” “would,” “could,” “should,” “seek(s)” and similar expressions, or the negative of these terms, are intended to identify such forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks and uncertainties that could lead to actual results differing materially from those projected, forecasted or expected. Although we believe that the assumptions underlying the forward-looking statements are reasonable, we can give no assurance that our expectations will be attained. Factors which could have a material adverse effect on our operations and future prospects or which could cause actual results to differ materially from our expectations include, but are not limited to: (i) the COVID-19 pandemic, including the risk of additional surges of COVID-19 infections due to the rate of public acceptance and efficacy of COVID-19 vaccines or to new and more contagious and/or vaccine resistant variants, and the measures taken to prevent the spread of COVID-19 and the related impact on our business or the businesses of our tenants; (ii) the ability and willingness of our tenants to meet and/or perform their obligations under the triple-net leases we have entered into with them, including, without limitation, their respective obligations to indemnify, defend and hold us harmless from and against various claims, litigation and liabilities; (iii) the ability of our tenants to comply with applicable laws, rules and regulations in the operation of the properties we lease to them; (iv) the ability and willingness of our tenants to renew their leases with us upon their expiration, and the ability to reposition our properties on the same or better terms in the event of nonrenewal or in the event we replace an existing tenant, as well as any obligations, including indemnification obligations, we may incur in connection with the replacement of an existing tenant; (v) the availability of and the ability to identify (a) tenants who meet our credit and operating standards, and (b) suitable acquisition opportunities, and the ability to acquire and lease the respective properties to such tenants on favorable terms; (vi) the ability to generate sufficient cash flows to service our outstanding indebtedness; (vii) access to debt and equity capital markets; (viii) fluctuating interest rates; (ix) the ability to retain our key management personnel; (x) the ability to maintain our status as a real estate investment trust (“REIT”); (xi) changes in the U.S. tax law and other state, federal or local laws, whether or not specific to REITs; (xii) other risks inherent in the real estate business, including potential liability relating to environmental matters and illiquidity of real estate investments; and (xiii) any additional factors included under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020, including in the section entitled “Risk Factors” in Item 1A of Part I of such report, as such risk factors may be amended, supplemented or superseded from time to time by other reports we file with the Securities and Exchange Commission (the “SEC”).
Forward-looking statements speak only as of the date of this report. Except in the normal course of our public disclosure obligations, we expressly disclaim any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any statement is based.
Overview
CareTrust REIT is a self-administered, publicly-traded REIT engaged in the ownership, acquisition, development and leasing of seniors housing and healthcare-related properties. As of June 30, 2021, we owned and leased to independent operators, 223 skilled nursing, multi-service campuses, assisted living and independent living facilities consisting of 23,301 operational beds and units located in 28 states with the highest concentration of properties by rental revenues located in California, Texas, Louisiana, Idaho and Arizona. As of June 30, 2021, we also had other real estate investments consisting of one mezzanine loan receivable with a carrying value of $15.2 million.
We generate revenues primarily by leasing healthcare-related properties to healthcare operators in triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property (including property taxes, insurance, maintenance and repair costs and capital expenditures, subject to certain exceptions in the case of properties leased to Ensign and Pennant). We conduct and manage our business as one operating segment for internal reporting and internal decision-making purposes. We expect to grow our portfolio by pursuing opportunities to acquire additional properties that will be leased to a diverse group of local, regional and national healthcare providers, which may include new or existing skilled nursing operators, as well as seniors housing operators and related businesses. We also anticipate diversifying our portfolio over time, including by acquiring properties in different geographic markets, and in different asset classes. In addition, we actively
19

monitor the clinical, regulatory and financial operating results of our tenants, and work to identify opportunities within their operations and markets that could improve their operating results at our facilities. We communicate such observations to our tenants; however, we have no contractual obligation to do so. Moreover, our tenants have sole discretion with respect to the day-to-day operation of the facilities they lease from us, and how and whether to implement any observation we may share with them. We also actively monitor the overall occupancy, skilled mix, and other operating metrics of our tenants on at least a monthly basis including, beginning in the quarter ended June 30, 2020, any stimulus funds received by each tenant. We have replaced tenants in the past, and may elect to replace tenants in the future, if they fail to meet the terms and conditions of their leases with us. The replacement tenants may include tenants with whom we have had no prior landlord-tenant relationship as well as current tenants with whom we are comfortable expanding our relationships. We have also provided select tenants with strategic capital for facility upkeep and modernization, as well as short-term working capital loans when they are awaiting licensure and certification or conducting turnaround work in one or more of our properties, and we may continue to do so in the future. In addition, we periodically reassess the investments we have made and the tenant relationships we have entered into, and have selectively disposed of facilities or investments, or terminated such relationships, and we expect to continue making such reassessments and, where appropriate, taking such actions.

Recent Developments

COVID-19 Update
Tenants of our properties operating pursuant to triple-net master leases have been adversely impacted, and we expect that they will continue to be adversely impacted, by the COVID-19 pandemic. Our tenants are experiencing increased operating costs as a result of actions they are taking to prevent or mitigate the outbreak or spread of COVID-19 at their facilities, including in connection with their implementation of safety protocols and procedures and other regulatory requirements. To help offset these costs as well as occupancy declines, various relief programs have been enacted by federal and state governments, including the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which have provided, and we expect will continue to provide some benefits to our tenants subject to the programs’ respective terms and conditions (the “Provider Relief Funds”). The estimated federal and state relief approved, received and retained to date by our operators, as reported by our operators, is approximately $132.2 million. At June 30, 2021, two of our operators who received Provider Relief Funds have disclosed that they have returned all or a portion of the Provider Relief Funds issued to them.
At a portfolio wide level, occupancy levels at our seniors housing facilities remained relatively stable from the onset of the COVID-19 pandemic until the beginning of the fourth quarter of 2020, during which we began to see a decline, and occupancy levels declined further in the second quarter of 2021. Occupancy levels at our skilled nursing facilities (“SNFs”), which declined at the onset of the COVID-19 pandemic and continued to decline through January 2021, have been on a steady incline since February 2021 and continued to increase through the second quarter of 2021. Beginning in early 2020, the federal government temporarily suspended the three-day hospital stay requirement for a patient’s Medicare benefits to refresh. Providers can now “skill in place,” eliminating the risk of transferring the patient to the hospital. Because of this temporary rule change, overall skilled mix remained slightly elevated in the three months ended June 30, 2021 compared to the pre-pandemic skilled mix during the three months ended March 31, 2020. An increase in skilled mix can, but may not necessarily, offset some or all of the adverse financial impact to the operator of the SNF from a decline in occupancy. However, the skilled mix in our SNFs during the three months ended June 30, 2021 was lower than the peak level seen in December 2020, and we anticipate that skilled mix in our SNFs will continue to decline as cases of COVID-19 decline.
The higher operating costs affecting our tenants, and the impact of lower occupancy levels, have adversely impacted and may continue to adversely impact the ability of our tenants to satisfy their rental obligations to us in full or on a timely basis. Provider Relief Funds not being made available to our seniors housing facilities has also impacted some of our tenants’ ability to continue to meet some of their financial obligations, as they continue to experience lower occupancy levels and higher operating costs. Subsequent to the quarter ended June 30, 2021, one seniors housing operator failed to pay rent for July and proposed a rent deferral for the months of July, August and a portion of September under a plan that would bring all rent deferrals current by the end of 2021. We are currently considering their request. Approximately 100.0% of our contractual rent obligations due for the second quarter of 2021, and approximately 96.2% due for July 2021, have been collected from our tenants before considering any cash deposits on-hand from which we may offset any shortfalls in rent received.
A number of COVID-19 vaccines were issued emergency use authorization by the United States Food and Drug Administration. As of August 5, 2021, based on information provided by operators who have reported such information to us, almost three-quarters of our operators’ residents have been fully vaccinated, while almost half of such operators’ staff have received at least one dose.
20

The duration and extent of the COVID-19 pandemic’s effect on our operational and financial performance, and the operational and financial performance of our tenants, will depend on future developments, which are highly uncertain and cannot be predicted at this time, including the rate of public acceptance and usage of vaccines and the effectiveness of vaccines in limiting the spread of COVID-19 and its variants, resurgences of COVID-19 and, in particular, new and more contagious and/or vaccine resistant variants, actions taken to contain the spread of COVID-19 and how quickly and to what extent normal economic and operating conditions can resume. The adverse impact of the COVID-19 pandemic on our business, results of operations and financial condition could be material.
Senior Notes Issuance and Redemption
On June 17, 2021, our wholly owned subsidiary, CTR Partnership, L.P. (the “Operating Partnership”), and its wholly owned subsidiary, CareTrust Capital Corp. (together with the Operating Partnership, the “Issuers”) completed a private offering of $400.0 million aggregate principal amount of 3.875% Senior Notes due 2028 (the “Notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). See Note 12, Subsequent Events, for additional information. The aggregate net proceeds from the sale of the Notes were approximately $393.8 million after deducting underwriting fees and other offering expenses. We used a portion of the net proceeds from the sale of the Notes to redeem all of the Issuers’ outstanding 5.25% Senior Notes due 2025 (the “2025 Notes”) and the remaining proceeds to repay a portion of the borrowings outstanding under our Revolving Facility (as defined below).
On July 1, 2021 (the “Redemption Date”), the Issuers redeemed all $300.0 million aggregate principal amount of their outstanding 2025 Notes. The 2025 Notes were redeemed at a redemption price equal to 102.625% of the principal amount of the 2025 Notes, plus accrued and unpaid interest thereon up to, but not including, the Redemption Date.

Sale of Real Estate and Asset Held for Sale
On February 1, 2021, we closed on the sale of one skilled nursing facility consisting of 90 beds located in Washington with a carrying value of $7.2 million, for net sales proceeds of $7.0 million. We recorded a loss of $0.2 million in connection with the sale. The facility was classified as held for sale as of December 31, 2020.
In August 2021, we met the held for sale criteria on one assisted living facility operated by affiliates of Noble Senior Services, and are in the process of estimating its fair value, which is expected to be below the net carrying value of $4.9 million. The associated impairment loss is expected to be recorded in the quarter ending September 30, 2021.

Recent Investments
From January 1, 2021 through August 5, 2021, we acquired 4 skilled nursing facilities and 4 multi-service campuses for approximately $183.6 million, which includes capitalized acquisition costs. These acquisitions are expected to generate initial annual cash revenues of approximately $13.1 million and an initial blended yield of approximately 7.3%. See Note 3, Real Estate Investments, Net and Note 12, Subsequent Events in the Notes to condensed consolidated financial statements for additional information.

At-The-Market Offering of Common Stock
On March 10, 2020, we entered into a new equity distribution agreement to issue and sell, from time to time, up to $500.0 million in aggregate offering price of our common stock through an “at-the-market” equity offering program (the “ATM Program”). In connection with the entry into the equity distribution agreement and the commencement of the ATM Program, our “at-the-market” equity offering program pursuant to our prior equity distribution agreement, dated as of March 4, 2019, was terminated (the “Prior ATM Program”).
There was no Prior ATM Program or ATM Program activity for the three and six months ended June 30, 2020. The following table summarizes the ATM Program activity for the three and six months ended June 30, 2021 (in thousands, except
21

per share amounts).
For the Three Months EndedFor the Six Months Ended
June 30, 2021June 30, 2021
Number of shares288 990 
Average sales price per share$24.05 $23.74 
Gross proceeds(1)
$6,926 $23,505 
(1) Total gross proceeds is before $0.1 million and $0.3 million of commissions paid to the sales agents during the three and six months ended June 30, 2021, respectively, under the ATM Program.
As of June 30, 2021, we had $476.5 million available for future issuances under the ATM Program.

Results of Operations
Operating Results
Three Months Ended June 30, 2021 Compared to Three Months Ended June 30, 2020:
 Three Months Ended June 30,Increase
(Decrease)
Percentage
Difference
 20212020
 (dollars in thousands)
Revenues:
Rental income$47,744 $42,507 $5,237 12 %
Independent living facilities— 615 (615)(100)%
Interest and other income514 1,046 (532)(51)%
Expenses:
Depreciation and amortization13,843 13,239 604 %
Interest expense6,534 5,849 685 12 %
Property taxes766 837 (71)(8)%
Independent living facilities — 546 (546)(100)%
General and administrative5,798 4,762 1,036 22 %
    
Rental income. The $5.2 million, or 12%, increase in rental income is primarily due to a $4.4 million increase in rental income from real estate investments made after April 1, 2020, $0.9 million from contractual increases in rental rates for our existing tenants and $0.1 million in cash rents due to lease amendments, partially offset by a $0.1 million decrease in rental income due to the disposal of assets in February 2021 and a $0.1 million decrease in tenant reimbursements.
Independent living facilities. The $0.6 million, or 100%, decrease in revenues from our ILFs was due to the sale of our one remaining ILF to a third party in November 2020. The $0.5 million, or 100%, decrease in expenses was for the same reason indicated for the decrease in revenues.
Interest and other income. The $0.5 million, or 51%, decrease in interest and other income was primarily due to a decrease in interest income of $0.9 million due to the repayment of mortgage loans and other loans receivable primarily by CommuniCare in May 2020 and Cascade in July 2020, partially offset by approximately $0.4 million of interest income related to our mezzanine loan to Next VA Star Realty Holdings, LLC originated in November 2020. See Note 4, Other Real Estate Investments, Net.
Depreciation and amortization. The $0.6 million, or 5%, increase in depreciation and amortization was primarily due to an increase in depreciation and amortization of $1.4 million related to new real estate investments and capital improvements made after April 1, 2020, partially offset by $0.7 million due to assets becoming fully depreciated after April 1, 2020 and $0.1 million of depreciation related to the disposal of assets.
Interest expense. The $0.7 million, or 12%, increase in interest expense was primarily due to a higher weighted average debt balance of approximately $157.5 million for the three months ended June 30, 2021 compared to the three months ended June 30, 2020 due to the issuance of the Notes on June 17, 2021 and the redemption of the 2025 Notes on July 1, 2021, partially offset by lower weighted average interest rates.
22

Property taxes. The $0.1 million, or 8%, decrease in property taxes was primarily due to a $0.2 million decrease due to reassessments and decreased effective tax rates, partially offset by an increase of $0.1 million in property taxes due to the transfer of certain properties to new operators in January 2021 that do not make direct tax payments.
General and administrative expense. The $1.0 million, or 22%, increase in general and administrative expense was primarily related to higher stock compensation expense of $0.8 million, higher cash wages of $0.3 million and $0.1 million of other general and administrative expense, partially offset by a decrease of $0.2 million in state and business taxes compared to the prior period.
Six Months Ended June 30, 2021 Compared to Six Months Ended June 30, 2020:
 Six Months Ended June 30,Increase
(Decrease)
Percentage
Difference
 20212020
 (dollars in thousands)
Revenues:
Rental income$92,990 $84,971 $8,019 %
Independent living facilities— 1,240 (1,240)(100)%
Interest and other income1,019 2,297 (1,278)(56)%
Expenses:
Depreciation and amortization27,316 26,399 917 %
Interest expense12,296 12,563 (267)(2)%
Property taxes1,462 1,322 140 11 %
Independent living facilities — 1,092 (1,092)(100)%
General and administrative10,940 8,816 2,124 24 %
Other loss:
Loss on sale of real estate(192)(56)(136)243 %
    
Rental income. The $8.0 million, or 9%, increase in rental income is primarily due to a $6.7 million increase in rental income from real estate investments made after January 1, 2020, $1.6 million from contractual increases in rental rates for our existing tenants and $0.4 million in cash rents due to lease amendments, partially offset by a $0.6 million decrease in rental income due to the disposal of assets in February 2020 and February 2021 and a $0.1 million decrease in tenant reimbursements.
Independent living facilities. The $1.2 million, or 100%, decrease in revenues from our ILFs was due to the sale of our one remaining ILF to a third party in November 2020. The $1.1 million, or 100%, decrease in expenses was for the same reason indicated for the decrease in revenues.
Interest and other income. The $1.3 million, or 56%, decrease in interest and other income was primarily due to a decrease in interest income of $2.2 million due to the repayment of mortgage loans and other loans receivable primarily by Manteca in May 2020, CommuniCare in May 2020 and Cascade in July 2020, partially offset by approximately $0.9 million of interest income related to our mezzanine loan to Next VA Star Realty Holdings, LLC originated in November 2020. See Note 4, Other Real Estate Investments, Net.
Depreciation and amortization. The $0.9 million, or 3%, increase in depreciation and amortization was primarily due to an increase in depreciation and amortization of $2.3 million related to new real estate investments and capital improvements made after January 1, 2020, partially offset by $1.2 million due to assets becoming fully depreciated after January 1, 2020 and $0.2 million of depreciation related to the disposal of assets.
Interest expense. The $0.3 million, or 2%, decrease in interest expense was primarily due to lower weighted average interest rates, partially offset by a higher weighted average debt balance of approximately $90.9 million for the six months ended June 30, 2021 compared to the six months ended June 30, 2020.
Property taxes. The $0.1 million, or 11%, increase in property taxes was primarily due to a $0.4 million increase in property taxes realized upon the disposition of assets in February 2020 and the transfer of certain properties to new operators in January 2021 that make direct tax payments, partially offset by a decrease of $0.3 million of property taxes due to reassessments and decreased effective tax rates.
23

General and administrative expense. The $2.1 million, or 24%, increase in general and administrative expense was primarily related to higher stock compensation expense of $1.5 million, higher cash wages of $0.5 million, increased professional service fees of $0.2 million and $0.1 million of other general and administrative expense, partially offset by a decrease of $0.2 million in state and business taxes compared to the prior period.
Loss on sale of real estate. During the six months ended June 30, 2021, we recorded a $0.2 million loss on sale of real estate related to the sale of one skilled nursing facility. During the six months ended June 30, 2020, we recorded a $0.1 million loss on sale of real estate related to the sale of six skilled nursing facilities.
Liquidity and Capital Resources
To qualify as a REIT for federal income tax purposes, we are required to distribute at least 90% of our REIT taxable income, determined without regard to the dividends paid deduction and excluding any net capital gains, to our stockholders on an annual basis. Accordingly, we intend to make, but are not contractually bound to make, regular quarterly dividends to common stockholders from cash flow from operating activities. All such dividends are at the discretion of our board of directors.
As of June 30, 2021, we had cash, cash equivalents and restricted cash of $311.0 million. The $309.2 million in restricted cash as of June 30, 2021 related to the cash deposited with the trustee to pay the redemption price of the 2025 Notes. The 2025 Notes were redeemed on July 1, 2021. See above under “Recent Developments” and Note 12, Subsequent Events, for additional information.
During the three and six months ended June 30, 2021, we sold 288,000 and 990,000 shares of common stock under our ATM Program for gross proceeds of $6.9 million and $23.5 million, respectively. As of June 30, 2021, we had $476.5 million available for future issuances under the ATM Program.
As of June 30, 2021, we also had $50.0 million in borrowings outstanding and $550.0 million of availability remaining under the Revolving Facility (as defined below). We believe that our available cash, expected operating cash flows, and the availability under the ATM Program and Amended Credit Facility (as defined below) will provide sufficient funds for our operations, anticipated scheduled debt service payments and projected dividend payments for at least the next twelve months.
We intend to invest in and/or develop additional healthcare properties as suitable opportunities arise and adequate sources of financing are available. We expect that future investments in and/or development of properties, including any improvements or renovations of current or newly-acquired properties, will depend on and will be financed by, in whole or in part, our existing cash, borrowings available to us under the Amended Credit Facility, future borrowings or the proceeds from sales of shares of our common stock pursuant to our ATM Program or additional issuances of common stock or other securities. In addition, we may seek financing from U.S. government agencies, including through Fannie Mae and the U.S. Department of Housing and Urban Development, in appropriate circumstances in connection with acquisitions and refinancing of existing mortgage loans.
We have filed an automatic shelf registration statement with the U.S. Securities and Exchange Commission that expires in March 2023, which will allow us or certain of our subsidiaries, as applicable, to offer and sell shares of common stock, preferred stock, warrants, rights, units and debt securities through underwriters, dealers or agents or directly to purchasers, in one or more offerings on a continuous or delayed basis, in amounts, at prices and on terms we determine at the time of the offering.
Although we are subject to restrictions on our ability to incur indebtedness, we expect that we will be able to refinance existing indebtedness or incur additional indebtedness for acquisitions or other purposes, if needed. However, there can be no assurance that we will be able to refinance our indebtedness, incur additional indebtedness or access additional sources of capital, such as by issuing common stock or other debt or equity securities, on terms that are acceptable to us or at all.
24

Cash Flows
The following table presents selected data from our condensed consolidated statements of cash flows for the periods presented (dollars in thousands):
 For the Six Months Ended June 30,
 20212020
 
Net cash provided by operating activities$70,557 $67,942 
Net cash (used in) provided by investing activities(145,043)25,325 
Net cash provided by (used in) financing activities366,525 (107,796)
Net increase (decrease) in cash, cash equivalents, and restricted cash292,039 (14,529)
Cash, cash equivalents, and restricted cash as of the beginning of period18,919 20,327 
Cash, cash equivalents, and restricted cash as of the end of period$310,958 $5,798 
Net cash provided by operating activities increased $2.6 million for the six months ended June 30, 2021 compared to the six months ended June 30, 2020. Operating cash inflows are derived primarily from the rental payments received under our lease agreements, including as a result of new investments, and interest payments on our other real estate investments. Operating cash outflows consist primarily of interest expense on our borrowings and general and administrative expenses. The net increase of $2.6 million in cash provided by operating activities for the six months ended June 30, 2021 is primarily due to increased rental payments as a result of new investments and a decrease in cash paid for interest on outstanding indebtedness due to lower weighted average interest rates, partially offset by a decrease in interest and other income due to the repayments of our other real estate investments and an increase in cash paid for general and administrative expenses.
Cash used in investing activities for the six months ended June 30, 2021 was primarily comprised of $148.5 million in acquisitions of real estate and investments in other loans and $3.5 million of purchases of equipment, furniture and fixtures and improvements to real estate, partially offset by $6.8 million in net proceeds from real estate sales and $0.1 million of payments received from other loans receivable. Cash provided by investing activities for the six months ended June 30, 2020 was primarily comprised of $69.3 million of payments received from our preferred equity investment and mortgage and other loans receivable and $2.1 million in net proceeds from real estate sales, partially offset by $39.9 million in acquisitions of real estate and investments in real estate mortgage loans and $6.2 million of purchases of furniture, fixtures and equipment and improvements to real estate.
Our cash flows provided by financing activities for the six months ended June 30, 2021 were primarily comprised of $400.0 million of proceeds from the issuance of the Notes, $22.9 million of net proceeds from the issuance of common stock under the ATM Program, partially offset by $49.5 million in dividends paid, $5.6 million in payments of deferred financing costs and a $1.3 million net settlement adjustment on restricted stock. Our cash flows used in financing activities for the six months ended June 30, 2020 were primarily comprised of $45.4 million in dividends paid, a $2.0 million net settlement adjustment on restricted stock, $0.4 million paid for common stock offering related costs and $60.0 million in net repayments under our Amended Credit Facility.
Indebtedness
3.875% Senior Unsecured Notes due 2028
On June 17, 2021, the Issuers completed a private offering of $400.0 million aggregate principal amount of 3.875% Senior Notes due 2028 to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act. The Notes were issued at par, resulting in gross proceeds of $400.0 million and net proceeds of approximately $393.8 million after deducting underwriting fees and other offering expenses. The Notes mature on June 30, 2028. The Notes accrue interest at a rate of 3.875% per annum payable semiannually in arrears on June 30 and December 30 of each year, commencing on December 30, 2021.
The obligations under the Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by the Company and all of CareTrust’s existing and future subsidiaries (other than the Issuers) that guarantee obligations under the Amended Credit Facility (as defined below); provided, however, that such guarantees are subject to automatic release under certain customary circumstances. See above under “Recent Developments” and Note 6, Debt, for additional information.
25

The indenture governing the Notes requires CareTrust REIT and its restricted subsidiaries to maintain a specified ratio of unencumbered assets to unsecured indebtedness. These covenants are subject to a number of important and significant limitations, qualifications and exceptions. The indenture also contains customary events of default.
As of June 30, 2021, we were in compliance with all applicable financial covenants under the indenture governing the Notes.
5.25% Senior Unsecured Notes due 2025 and Issuer and Guarantor Financial Information
On May 10, 2017, the Issuers completed a public offering of $300.0 million aggregate principal amount of the 2025 Notes. The 2025 Notes were issued at par, resulting in gross proceeds of $300.0 million and net proceeds of approximately $294.0 million after deducting underwriting fees and other offering expenses. The 2025 Notes were scheduled to mature on June 1, 2025 and bore interest at a rate of 5.25% per year. Interest on the 2025 Notes was payable on June 1 and December 1 of each year, beginning on December 1, 2017. On July 1, 2021, the Issuers redeemed all $300.0 million aggregate principal amount of the 2025 Notes. See above under “Recent Developments” and Note 12, Subsequent Events, for additional information.
The obligations under the 2025 Notes were fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by CareTrust REIT (the “Parent Guarantor”) and all of CareTrust REIT’s existing and future subsidiaries (other than the Issuers) that guaranteed obligations under the Amended Credit Facility; provided, however, that such guarantees were subject to automatic release under certain customary circumstances, including if the Subsidiary Guarantor was sold or sold all or substantially all of its assets, the Subsidiary Guarantor was designated “unrestricted” for covenant purposes under the indenture governing the 2025 Notes, the Subsidiary Guarantor’s guarantee of other indebtedness which resulted in the creation of the guarantee of the 2025 Notes was terminated or released, or the requirements for legal defeasance or covenant defeasance or to discharge the indenture had been satisfied.
The following provides information regarding the entity structure of the Parent Guarantor, the Issuers and the Subsidiary Guarantors of the 2025 Notes:
CareTrust REIT, Inc. – The Parent Guarantor was formed on October 29, 2013 in connection with the separation of Ensign’s healthcare business and its real estate business into two separate and independent publicly traded companies (the “Spin-Off”). The Parent Guarantor was a wholly owned subsidiary of Ensign prior to the effective date of the Spin-Off on June 1, 2014. The Parent Guarantor has not conducted any operations or had any business since the Spin-Off.
CTR Partnership, L.P. and CareTrust Capital Corp. – The Issuers, each of which is a wholly owned subsidiary of the Parent Guarantor, were formed on May 8, 2014 and May 9, 2014, respectively, in anticipation of the Spin-Off and the related transactions. The Issuers did not conduct any operations or have any business prior to the date of the consummation of the Spin-Off related transactions. The Operating Partnership directly invests in real estate and real estate related assets and therefore does not rely solely on the cash flow generated by the Subsidiary Guarantors and their ability to make cash available to the Issuers, by dividend or otherwise. However, in the event that the earnings or available assets of the Issuers were insufficient, the Issuers’ ability to pay principal and interest on the 2025 Notes could have been dependent on the cash flow generated by the Subsidiary Guarantors and their ability to make such cash available to the Issuers. CareTrust Capital Corp., a co-issuer of the 2025 Notes, has no material assets and conducts no operations. Therefore, it had no independent ability to service the interest and principal obligations under the 2025 Notes.
Subsidiary Guarantors – The Subsidiary Guarantors consisted of all of the subsidiaries of the Parent Guarantor other than the Issuers. The Parent Guarantor conducts a substantial portion of its business operations through the Subsidiary Guarantors.
The assets and liabilities and results of operations of the combined guarantors (the Parent Guarantor and the Subsidiary Guarantors) and the Issuers of the 2025 Notes are not materially different than the corresponding amounts presented in our condensed consolidated financial statements.
The indenture governing the 2025 Notes contained customary covenants such as limiting the ability of CareTrust REIT and its restricted subsidiaries to: incur or guarantee additional indebtedness; incur or guarantee secured indebtedness; make certain investments or other restricted payments; sell assets; enter into transactions with affiliates; merge or consolidate or sell all or substantially all of their assets, and pay dividends or distributions on, or redeem or repurchase, capital stock, including a restriction on the ability of the Issuers and their restricted subsidiaries to pay dividends or other amounts to the Issuers, subject to certain other exceptions, unless: (i) there was no default or event of default under the indenture; (ii) the
26

Issuers were in compliance with specified limitations on indebtedness under the indenture; and (iii) the payments did not exceed a specified restricted payment basket. Dividends or distributions were also permitted if the Parent Guarantor’s board of directors believed in good faith they were necessary to maintain Parent Guarantor’s REIT status or to avoid any excise tax or income tax imposed on Parent Guarantor, provided there was no default or event of default under the indenture. Further, the Issuers and their restricted subsidiaries were not permitted to create or cause to become effective any encumbrance or restriction on the ability of the Issuers to, among other things, pay dividends or make distributions, pay indebtedness, make loans or advances to the Issuers or their restricted subsidiaries or transfer property or assets to the Issuers or their restricted subsidiaries, other than in connection with certain customary exceptions such as in respect of the indenture or the Amended Credit Facility.
As of June 30, 2021, we were in compliance with all applicable financial covenants under the indenture governing the 2025 Notes.
Unsecured Revolving Credit Facility and Term Loan
On February 8, 2019, the Operating Partnership, as the borrower, the Company, as guarantor, CareTrust GP, LLC, and certain of the Operating Partnership’s wholly owned subsidiaries entered into an amended and restated credit and guaranty agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender, and the lenders party thereto (the “Amended Credit Agreement”). The Amended Credit Agreement provides for: (i) an unsecured revolving credit facility (the “Revolving Facility”) with revolving commitments in an aggregate principal amount of $600.0 million, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments and (ii) an unsecured term loan credit facility (the “Term Loan” and, together with the Revolving Facility, the “Amended Credit Facility”) in an aggregate principal amount of $200.0 million. Borrowing availability under the Revolving Facility is subject to no default or event of default under the Amended Credit Agreement having occurred at the time of borrowing. The proceeds of the Term Loan were used, in part, to repay in full all outstanding borrowings under our prior term loan and revolving facility under our prior credit agreement. Future borrowings under the Amended Credit Facility will be used for working capital purposes, for capital expenditures, to fund acquisitions and for general corporate purposes.
The interest rates applicable to loans under the Revolving Facility are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.10% to 0.55% per annum or LIBOR plus a margin ranging from 1.10% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). The interest rates applicable to loans under the Term Loan are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.50% to 1.20% per annum or LIBOR plus a margin ranging from 1.50% to 2.20% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). In addition, the Operating Partnership will pay a facility fee on the revolving commitments under the Revolving Facility ranging from 0.15% to 0.35% per annum, based on the debt to asset value ratio of the Company and its consolidated subsidiaries (unless the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt and the Operating Partnership elects to decrease the applicable margin as described above, in which case the Operating Partnership will pay a facility fee on the revolving commitments ranging from 0.125% to 0.30% per annum based off the credit ratings of the Company’s senior long-term unsecured debt). As of June 30, 2021, we had $200.0 million outstanding under the Term Loan and $50.0 million outstanding under the Revolving Facility. Subsequent to June 30, 2021, we borrowed an additional $50.0 million under our Revolving Facility to fund the acquisition of two SNFs in August 2021. See Note 12, Subsequent Events for additional information.
The Revolving Facility has a maturity date of February 8, 2023, and includes, at our sole discretion, two, six-month extension options. The Term Loan has a maturity date of February 8, 2026.
The Amended Credit Facility is guaranteed, jointly and severally, by the Company and its wholly-owned subsidiaries that are party to the Amended Credit Agreement (other than the Operating Partnership). The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend organizational documents and pay certain dividends and other restricted payments. The Amended Credit Agreement requires the Company to comply with financial maintenance covenants to be tested quarterly, consisting of a maximum debt to asset value ratio, a minimum fixed charge coverage ratio, a minimum tangible net worth, a maximum cash distributions to operating income ratio, a maximum secured debt to asset value ratio, a maximum secured recourse debt to asset value ratio, a maximum unsecured debt to unencumbered properties asset value ratio, a minimum unsecured interest coverage ratio and a minimum rent coverage ratio. The Amended Credit Agreement also contains certain
27

customary events of default, including the failure to make timely payments under the Amended Credit Facility or other material indebtedness, the failure to satisfy certain covenants (including the financial maintenance covenants), the occurrence of change of control and specified events of bankruptcy and insolvency.
As of June 30, 2021, we were in compliance with all applicable financial covenants under the Amended Credit Agreement.
Obligations and Commitments
The following table summarizes our contractual obligations and commitments as of June 30, 2021 (in thousands):
 Payments Due by Period
 TotalLess
than
1 Year
1 Year
to Less
than
3 Years
3 Years
to Less
than
5 Years
More
than
5 years
2028 Senior unsecured notes payable (1)$509,103 $16,103 $31,000 $31,000 $431,000 
2025 Senior unsecured notes payable (2)309,187 309,187 — — — 
Senior unsecured term loan (3)214,930 3,243 6,477 205,210 — 
Unsecured revolving credit facility (4)52,453 1,525 50,928 — — 
Operating leases3,662 265 230 104 3,063 
Total$1,089,335 $330,323 $88,635 $236,314 $434,063 
 
(1)Amounts include interest payments of $109.1 million.
(2)Amount includes the redemption price of the 2025 Notes. The 2025 Notes were redeemed on July 1, 2021. See above under “Recent Developments” and Note 12, Subsequent Events for additional information.
(3)Amounts include interest payments of $14.9 million.
(4)Amounts include payments related to the credit facility fee of $1.5 million and interest payments of $1.0 million. Amounts do not include $50.0 million in additional borrowings under the Revolving Facility made in August 2021. See Note 12, Subsequent Events for additional information.
Capital Expenditures
Capital expenditures for each property leased under our triple-net leases are generally the responsibility of the tenant, except that, for the facilities leased to subsidiaries of Ensign and Pennant, the tenant will have an option to require us to finance certain capital expenditures up to an aggregate of 20% of our initial investment in such property, subject to a corresponding rent increase at the time of funding. For our other triple-net master leases, subject to approval by us, the tenants may request capital expenditure funding that would generally be subject to a corresponding rent increase at the time of funding and which are subject to tenant compliance with the conditions to our approval and funding of their requests. As of June 30, 2021, we had committed to fund certain capital improvements at certain triple-net leased facilities totaling $13.1 million, of which $11.6 million is subject to rent increase at the time of funding. We expect the majority of the funding of these commitments to be completed over the next one to two years.
Critical Accounting Policies and Estimates
Our condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q have been prepared in accordance with GAAP for interim financial information set forth in the Accounting Standards Codification, as published by the Financial Accounting Standards Board. GAAP requires us to make estimates and assumptions regarding future events that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. We base these estimates on our experience and assumptions we believe to be reasonable under the circumstances. However, if our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, we may have applied a different accounting treatment, resulting in a different presentation of our financial statements. We periodically reevaluate our estimates and assumptions, and in the event they prove to be different from actual results, we make adjustments in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Please refer to “Critical Accounting Policies and Estimates” in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC
28

on February 10, 2021, for further information regarding the critical accounting policies that affect our more significant estimates and judgments used in the preparation of our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. There have been no material changes in such critical accounting policies during the six months ended June 30, 2021.
 
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Our primary market risk exposure is interest rate risk with respect to our variable rate indebtedness.
Our Amended Credit Agreement provides for revolving commitments in an aggregate principal amount of $600.0 million from a syndicate of banks and other financial institutions. The interest rates applicable to loans under the Revolving Facility are, at the Company’s option, equal to either a base rate plus a margin ranging from 0.10% to 0.55% per annum or LIBOR plus a margin ranging from 1.10% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). The interest rates applicable to loans under the Term Loan are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.50% to 1.20% per annum or LIBOR plus a margin ranging from 1.50% to 2.20% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). As of June 30, 2021, we had a $200.0 million Term Loan outstanding and had $50.0 million outstanding under the Revolving Facility.
An increase in interest rates could make the financing of any acquisition by us more costly as well as increase the costs of our variable rate debt obligations. Rising interest rates could also limit our ability to refinance our debt when it matures or cause us to pay higher interest rates upon refinancing and increase interest expense on refinanced indebtedness. In addition, the Chief Executive of the U.K. Financial Conduct Authority (the “FCA”), which regulates LIBOR, has announced that the FCA will no longer persuade or compel banks to submit rates for the calculation of LIBOR after 2021. However, for U.S. dollar LIBOR, the relevant date was deferred to June 30, 2023 for certain tenors (including overnight and one, three, six and 12 months), at which time the LIBOR administrator will cease publication of U.S. dollar LIBOR. Despite this deferral, the LIBOR administrator has advised that no new contracts using U.S. dollar LIBOR should be entered into after December 31, 2021. These actions indicate that the continuation of U.S. LIBOR on the current basis cannot and will not be guaranteed after June 30, 2023. Moreover, it is possible that U.S. LIBOR will be discontinued or modified prior to June 30, 2023. When LIBOR ceases to exist, we will need to enter into an amendment to the Amended Credit Agreement and we cannot predict what alternative index would be negotiated with our lenders. If our lenders have increased costs due to changes in LIBOR, we may experience potential increases in interest rates on our variable rate debt, which could adversely impact our interest expense, results of operations and cash flows. Based on our outstanding debt balance as of June 30, 2021 described above and the interest rates applicable to our outstanding debt at June 30, 2021, assuming a 100 basis point increase in the interest rates related to our variable rate debt, interest expense would have increased approximately $1.3 million for the six months ended June 30, 2021.
We may, in the future, manage, or hedge, interest rate risks related to our borrowings by means of interest rate swap agreements. However, the REIT provisions of the Internal Revenue Code of 1986, as amended, substantially limit our ability to hedge our assets and liabilities. See “Risk Factors — Risks Related to Our Status as a REIT — Complying with REIT requirements may limit our ability to hedge effectively and may cause us to incur tax liabilities,” which is included in our Annual Report on Form 10-K for the year ended December 31, 2020. As of June 30, 2021, we had no swap agreements to hedge our interest rate risks. We also expect to manage our exposure to interest rate risk by maintaining a mix of fixed and variable rates for our indebtedness.

Item 4. Controls and Procedures.
Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”)) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is processed, recorded, summarized and reported within the time periods specified in the SEC’s rules and regulations and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the
29

desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
As of June 30, 2021, we carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, regarding the effectiveness of our disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, as of June 30, 2021.
Changes in Internal Control over Financial Reporting
There has been no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended June 30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
30

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.
The Company and its subsidiaries are and may become from time to time a party to various claims and lawsuits arising in the ordinary course of business, but none of the Company or any of its subsidiaries is, and none of their respective properties are, the subject of any material legal proceedings. Claims and lawsuits may include matters involving general or professional liability asserted against its tenants, which are the responsibility of its tenants and for which the Company is entitled to be indemnified by its tenants under the insurance and indemnification provisions in the applicable leases.

Item 1A. Risk Factors.
We have disclosed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 risk factors which materially affect our business, financial condition, or results of operations. There have been no material changes from the risk factors previously disclosed.

31


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
On March 20, 2020, our Board of Directors authorized us to repurchase up to $150.0 million of outstanding shares of our common stock (the “Repurchase Program”). Repurchases under the Repurchase Program, which expires on March 31, 2023, may be made through open market purchases, privately negotiated transactions, structured or derivative transactions, including accelerated share repurchase transactions, or other methods of acquiring shares, in each case subject to market conditions and at such times as shall be permitted by applicable securities laws and determined by management. Repurchases under the Repurchase Program may also be made pursuant to a plan adopted under Rule 10b5-1 promulgated under the Exchange Act. We did not repurchase any shares of our common stock under the Repurchase Program during the three months ended June 30, 2021 and $150.0 million remains available for the repurchase of shares of our common stock under the Repurchase Program as of June 30, 2021. The Repurchase Program may be modified, discontinued or suspended at any time.
32


Item 6. Exhibits.
Exhibit
Number
 Description of the Document
 
 
 
 
 
*101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
*101.SCH XBRL Taxonomy Extension Schema Document
*101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
*101.DEFXBRL Taxonomy Extension Definition Linkbase Document
*101.LAB XBRL Taxonomy Extension Label Linkbase Document
*101.PRE XBRL Taxonomy Extension Presentation Linkbase Document
*104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
* Filed herewith
** Furnished herewith

33

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
CareTrust REIT, Inc.
August 5, 2021By:/s/ Gregory K. Stapley
Gregory K. Stapley
Chief Executive Officer
(duly authorized officer)
August 5, 2021By:/s/ William M. Wagner
William M. Wagner
Chief Financial Officer and Treasurer
(principal financial officer and
principal accounting officer)

34
EX-31.1 2 ctre20210630q2ex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, Gregory K. Stapley, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of CareTrust REIT, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
By:/s/ Gregory K. Stapley
Gregory K. Stapley
Chief Executive Officer
Date: August 5, 2021

EX-31.2 3 ctre20210630q2ex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION
I, William M. Wagner, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of CareTrust REIT, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
By:/s/ William M. Wagner
William M. Wagner
Chief Financial Officer and Treasurer
Date: August 5, 2021

EX-32.1 4 ctre20210630q2ex321.htm EX-32.1 Document

Exhibit 32.1
Certification of Chief Executive Officer and
Chief Financial Officer Pursuant to
18 U.S.C. Section 1350, As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report on Form 10-Q of CareTrust REIT, Inc. (the “Company”) for the quarterly period ended June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Gregory K. Stapley, as Chief Executive Officer of the Company, and William M. Wagner, as Chief Financial Officer and Treasurer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ Gregory K. Stapley
Name:Gregory K. Stapley
Title:Chief Executive Officer
Date:August 5, 2021
/s/ William M. Wagner
Name:William M. Wagner
Title:Chief Financial Officer and Treasurer
Date:August 5, 2021


EX-101.SCH 5 ctre-20210630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Income Statements link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Equity link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2108103 - Disclosure - Real Estate Investments, Net link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - Real Estate Investments, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Real Estate Investments, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Real Estate Investments, Net - Investment in Owned Properties (Details) link:presentationLink link:calculationLink link:definitionLink 2412406 - Disclosure - Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details) link:presentationLink link:calculationLink link:definitionLink 2413407 - Disclosure - Real Estate Investments, Net - Tenant Purchase Options (Details) link:presentationLink link:calculationLink link:definitionLink 2414408 - Disclosure - Real Estate Investments, Net - Rental Income (Details) link:presentationLink link:calculationLink link:definitionLink 2415409 - Disclosure - Real Estate Investments, Net - Recent Real Estate Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2416410 - Disclosure - Real Estate Investments, Net - Asset Sales and Assets Held for Sale Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2417411 - Disclosure - Real Estate Investments, Net - Lease Amendments Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2118104 - Disclosure - Other Real Estate Investments, Net link:presentationLink link:calculationLink link:definitionLink 2419412 - Disclosure - Other Real Estate Investments, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2120105 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2321303 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2422413 - Disclosure - Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2423414 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2424415 - Disclosure - Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2125106 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2326304 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2427416 - Disclosure - Debt - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2428417 - Disclosure - Debt - Senior Unsecured Notes Payable Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2429418 - Disclosure - Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2130107 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2331305 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2432419 - Disclosure - Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2433420 - Disclosure - Equity - At-The-Market Offering (Details) link:presentationLink link:calculationLink link:definitionLink 2434421 - Disclosure - Equity - Dividends on Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2135108 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2336306 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2437422 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2438423 - Disclosure - Stock-Based Compensation - Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2439424 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2140109 - Disclosure - Earnings Per Common Share link:presentationLink link:calculationLink link:definitionLink 2341307 - Disclosure - Earnings Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2442425 - Disclosure - Earnings Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2143110 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2444426 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2145111 - Disclosure - Concentration of Risk link:presentationLink link:calculationLink link:definitionLink 2446427 - Disclosure - Concentration of Risk (Details) link:presentationLink link:calculationLink link:definitionLink 2147112 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2448428 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 ctre-20210630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 ctre-20210630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 ctre-20210630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Share repurchase program authorization Stock Repurchase Program, Authorized Amount Integral equipment, furniture and fixtures Fixtures and Equipment, Gross Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Customer [Domain] Customer [Domain] Letter of credit Letter of Credit [Member] Skilled nursing, multi-service campuses, assisted living and independent living facilities Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities [Member] Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net income Net income Net income (loss) Net Income (Loss) Attributable to Parent Entity Emerging Growth Company Entity Emerging Growth Company Combined principal amount of loan Mortgage Loan, Combined Principal Mortgage Loan, Combined Principal Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Officers and employees Officer And Employee [Member] Officer And Employee Preferred stock, outstanding (shares) Preferred Stock, Shares Outstanding Statistical Measurement [Domain] Statistical Measurement [Domain] Receivable Type [Axis] Receivable Type [Axis] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Schedule of Real Estate Acquisitions Schedule Of Assets Acquisitions [Table Text Block] Schedule Of Assets Acquisitions [Table Text Block] Additional paid-in capital Additional Paid in Capital, Common Stock Entity Filer Category Entity Filer Category Real Estate Properties [Line Items] Real Estate Properties [Line Items] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Investment, Name [Axis] Investment, Name [Axis] Expected dividend yield (assuming full reinvestment) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Net increase (decrease) in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Lease Arrangements [Domain] Lease Arrangements [Domain] Lease Arrangements Redemption price of notes (percent) Debt Instrument, Redemption Price, Percentage Expected stock price volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Rental income Total Operating Lease, Lease Income Schedule of Rental Income Operating Lease, Lease Income [Table Text Block] Amortization of stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Interest income related to preferred equity investments Interest Income, Other Document Fiscal Year Focus Document Fiscal Year Focus Dividends on common stock Dividends, Common Stock [Abstract] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Payments of deferred financing costs Payments of Financing Costs Proceeds from settlement of loan Proceeds from Loans Sale of Stock [Axis] Sale of Stock [Axis] Subsequent Events [Abstract] Subsequent Events [Abstract] Authorized aggregate offering price of common stock Securities Offering, Authorized Amount Securities Offering, Authorized Amount Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Number of states with properties Number of States in which Entity Operates Increased in deferred financing costs payable Increase (Decrease) In Deferred Financing Costs Payable Increase (Decrease) In Deferred Financing Costs Payable Award grant date fair value (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Facility fee on revolving commitment fees (percent) Line of Credit Facility, Commitment Fee Percentage Lessor, Lease, Description [Table] Lessor, Lease, Description [Table] Title of Individual [Domain] Title of Individual [Domain] Disposal Group Name [Axis] Disposal Group Name [Axis] Award Type [Domain] Award Type [Domain] Greater than 90 days past due Financial Asset, Equal to or Greater than 90 Days Past Due [Member] Average sales price per share Shares Issued During Period, Average Price Per Share Shares Issued During Period, Average Price Per Share Credit Facility [Domain] Credit Facility [Domain] Assets: Assets [Abstract] Initial Annual Cash Rent Initial annual cash rents Operating Leases, Anticipated Initial Annual Lease Revenues Operating Leases, Anticipated Initial Annual Lease Revenues Senior unsecured notes Senior Unsecured Notes [Member] Senior Unsecured Notes [Member] Acquisitions of real estate, net of deposits applied Payment to acquire facility Payments to Acquire Commercial Real Estate Number of awards granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Concentration risk (percent) Concentration Risk, Percentage Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued and outstanding as of June 30, 2021 and December 31, 2020 Preferred Stock, Value, Issued Entity Address, City or Town Entity Address, City or Town Debt Instrument [Axis] Debt Instrument [Axis] Prepaid expenses and other assets, net Increase (Decrease) in Prepaid Expense and Other Assets Financial Asset, Aging [Domain] Financial Asset, Aging [Domain] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Number of Properties Number of properties acquired Number Of Properties Acquired Number Of Properties Acquired Financing Receivable, Past Due [Line Items] Financing Receivable, Past Due [Line Items] Interest income distribution from other real estate investment Proceeds from Equity Method Investment, Distribution Loans receivable exit fee (percent) Loans Receivable, Exit Fee, Percent Loans Receivable, Exit Fee, Percent Accounts and other receivables Increase (Decrease) in Accounts Receivable Dividends record date Dividends Payable, Date of Record Right-of-use asset obtained in exchange for new operating lease obligation Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Loan receivable interest rate (percent) Loans Receivable, Fixed Interest Rate Loans Receivable, Fixed Interest Rate Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Other loans receivable Loans Receivable [Member] Entity Interactive Data Current Entity Interactive Data Current Prime Rate Prime Rate [Member] Increase in dividends payable Increase Decrease In Dividends Payable Increase Decrease In Dividends Payable Investment in real estate mortgage and other loans receivable Payments to Acquire Loans Receivable Annual cash rent increase under amended lease Annual Cash Rent Increase Under Amended Lease Annual Cash Rent Increase Under Amended Lease Purchase and sale agreement amount Purchase And Sale Agreement, Amount Purchase And Sale Agreement, Amount Basic (in usd per share) Earnings per common share, basic (in dollars per share) Earnings Per Share, Basic Schedule of Real Estate Properties [Table] Schedule of Real Estate Properties [Table] Unvested stock awards outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Document Type Document Type Lease termination revenue Gain (Loss) on Termination of Lease Lease Expiration October 2034, Next option 2026 Properties With Purchase Option, Lease Expiration October 2034, Next Option 2026 [Member] Properties With Purchase Option, Lease Expiration October 2034, Next Option 2026 Real estate investments Real Estate Investment Property, at Cost Number of Beds/Units Number Of Beds Or Units In Properties Acquired Number Of Beds Or Units In Properties Acquired Fair Value Measurement [Domain] Fair Value Measurement [Domain] Entity Current Reporting Status Entity Current Reporting Status Number of equal annual vesting installments Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting, Number Of Equal Annual Installments Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting, Number of Equal Annual Installments Ensign amended triple-net master lease Ensign Amended Triple-Net Master Lease [Member] Ensign Amended Triple-Net Master Lease Metron skilled nursing facilities Metron Skilled Nursing Facilities [Member] Metron Skilled Nursing Facilities [Member] 2026 Lessor, Operating Lease, Payment to be Received, Year Five Principal Amount Outstanding amounts Long-term Debt, Gross Period prior to March 30 2028 Debt Instrument, Redemption, Period Two [Member] Assets: Assets, Fair Value Disclosure [Abstract] Carrying Value Outstanding borrowings Long-term Debt Repayment of other real estate investment Return of initial investment Proceeds from Equity Method Investment, Distribution, Return of Capital Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Document Transition Report Document Transition Report LIBOR floor for loan (percent) Loans Receivable, LIBOR Floor, Percentage Loans Receivable, LIBOR Floor, Percentage Current Cash Rent Lessor, Annualized Cash Revenue For Contracts In Place Lessor, Annualized Cash Revenue For Contracts In Place Cascadia Development, Boise ID Preferred Equity Investment Cascadia Development Boise ID [Member] Preferred Equity Investment Cascadia Development Boise ID Base Rate Base Rate [Member] Prepaid rent component Asset Acquisition, Consideration Transferred, Other Assets Financial liabilities: Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract] Total liabilities and equity Liabilities and Equity Cascade Capital Group, LLC Cascade Capital Group LLC [Member] Cascade Capital Group LLC Accounts and other receivables Accounts Receivable, after Allowance for Credit Loss Total Lessor, Operating Lease, Payments to be Received Scenario [Axis] Scenario [Axis] Held for sale Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member] Restricted cash Restricted Cash Cumulative Distributions in Excess of Earnings Accumulated Distributions in Excess of Net Income [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Liabilities and Equity: Liabilities and Equity [Abstract] Earnings Per Common Share Earnings Per Share [Text Block] Initial lease term (in years) Lessor, Operating Lease, Term of Contract Expenses: Operating Expenses [Abstract] 5.25% Senior Notes due 2025 2025 Senior unsecured notes payable Five Point Two Five Senior Notes Due 2025 [Member] Five Point Two Five Senior Notes Due 2025 [Member] Minimum Minimum [Member] Summary of Investment in Owned Properties Schedule of Real Estate Properties [Table Text Block] Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Number of days after termination of purchase and sale agreement for maturity Purchase And Sale Agreement, Maturity Date Option, Number Of Days After Termination Purchase And Sale Agreement, Maturity Date Option, Number Of Days After Termination Unsecured revolving credit facility Long-term Line of Credit Schedule of Total Future Contractual Minimum Rental Income Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block] GAAP rent increase under amended lease GAAP Rent Increase Under Amended Lease GAAP Rent Increase Under Amended Lease Summary of the At-The-Market Offering Program Schedule of Stock by Class [Table Text Block] Deferred financing costs, net Debt Issuance Costs, Net Preferred stock, authorized (shares) Preferred Stock, Shares Authorized Noble Noble VA Holdings LLC [Member] Noble VA Holdings LLC Trading Symbol Trading Symbol 2022 Lessor, Operating Lease, Payment to be Received, Year One Receivable [Domain] Receivable [Domain] Issuance of common stock, net Stock Issued During Period, Value, New Issues Ensign and Pennant Ensign And Pennant [Member] Ensign And Pennant General and administrative General and Administrative Expense Debt Debt Disclosure [Text Block] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Unsecured revolving credit facility Revolving Facility Line of Credit [Member] Stock-Based Compensation Share-based Payment Arrangement [Text Block] Senior unsecured notes Senior Notes [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Dividends paid on common stock Payments of Ordinary Dividends, Common Stock Ensign Ensign [Member] Ensign [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Mortgage loan receivable Mortgage Receivable [Member] Sale of real estate settled with note receivable Noncash or Part Noncash Divestiture, Amount of Consideration Received Noble triple-net master lease Noble Triple-Net Master Lease [Member] Noble Triple-Net Master Lease Proceeds from (costs paid for) the issuance of common stock, net Commissions paid on stock issuance Payments of Stock Issuance Costs Issuance of common stock, net, (in shares) Number of shares Stock Issued During Period, Shares, New Issues Mezzanine loan receivable Mezzanine Loan [Member] Mezzanine Loan 2025 Lessor, Operating Lease, Payment to be Received, Year Four Aggregate required financing of capital expenditures as percentage of initial investment in property (percent) Aggregate Required Financing Of Capital Expenditures As Percentage Of Initial Investment In Property Aggregate Required Financing Of Capital Expenditures As Percentage Of Initial Investment In Property Property taxes Real Estate Tax Expense Common stock, $0.01 par value; 500,000,000 shares authorized, 96,296,673 and 95,215,797 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively Common Stock, Value, Issued Weighted average remaining vesting period related to expense recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Customer concentration risk Customer Concentration Risk [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Performance stock award Performance Shares [Member] Commitments and contingencies Commitments and Contingencies Subsequent Event [Table] Subsequent Event [Table] Summary of Face Value, Carrying Amount and Fair Value of Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] SNF Skilled nursing facility Skilled Nursing Facility [Member] Skilled Nursing Facility [Member] Net proceeds from issuance Proceeds from Debt, Net of Issuance Costs Restricted stock award Restricted Stock [Member] Other Commitments [Table] Other Commitments [Table] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Document Period End Date Document Period End Date Schedule of Valuation Assumptions Schedule Of Share-Based Payment Award, Performance Stock Award, Valuation Assumptions [Table Text Block] Schedule Of Share-Based Payment Award, Performance Stock Award, Valuation Assumptions Dilutive market condition stock awards Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Total expenses Costs and Expenses Entity Registrant Name Entity Registrant Name Number of properties sold Number Of Properties Sold Number Of Properties Sold Independent living facilities, cost of services Cost, Product and Service [Extensible Enumeration] Straight-line rental income Straight-line rent Straight Line Rent Number of extension options Loan Receivable, Number Of Extension Options Loan Receivable, Number Of Extension Options Common dividends (in usd per share) Dividends declared per share Common Stock, Dividends, Per Share, Declared Independent living facilities Revenue from Contract with Customer, Excluding Assessed Tax Schedule of Dividends on Common Stock Dividends Declared [Table Text Block] Future Contractual Minimum Rental Income Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract] Issuance of common stock, net Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Equity [Abstract] Equity [Abstract] Carrying Amount Reported Value Measurement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Common Stock Common Stock [Member] Variable Rate [Axis] Variable Rate [Axis] New Revolving Facility New Revolving Facility [Member] New Revolving Facility [Member] Financial Asset, Aging [Axis] Financial Asset, Aging [Axis] Certain capital improvements at triple-net leased facilities Capital Improvements At Triple Net Leased Facilities [Member] Capital Improvements At Triple Net Leased Facilities Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Lease Expiration March 2029, Next option 2022 Properties With Purchase Option, Lease Expiration March 2029, Next Option 2022 [Member] Properties With Purchase Option, Lease Expiration March 2029, Next Option 2022 Assets held for sale, net Assets Held-for-sale, Not Part of Disposal Group Variable Rate [Domain] Variable Rate [Domain] Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Number of facilities in agreement secured by membership interests Loan Receivable, Number Of Facilities In Agreement Secured By Membership Interests Loan Receivable, Number Of Facilities In Agreement Secured By Membership Interests Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Other real estate investments Real Estate Investments, Joint Ventures Loan receivable Financing Receivable, after Allowance for Credit Loss Percentage of principal amount (percent) Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities Award Type [Axis] Award Type [Axis] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Total equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Common stock, issued (shares) Common Stock, Shares, Issued Preferred stock, issued (shares) Preferred Stock, Shares Issued Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Equity: Stockholders' Equity Attributable to Parent [Abstract] Net carrying value Real Estate Held-for-sale Land Land Measurement Frequency [Domain] Measurement Frequency [Domain] Debt instrument face amount Senior unsecured notes payable - face value Debt Instrument, Face Amount Interest expense Interest Expense Lease Expiration October 2034, Next option 2021 Properties With Purchase Option, Lease Expiration October 2034, Next Option 2022 [Member] Properties With Purchase Option, Lease Expiration October 2034, Next Option 2022 City Area Code City Area Code Independent living facilities, revenue services Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Other Real Estate Investments, Net Other Real Estate Investments [Text Block] Other Real Estate Investments Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Business Acquisition [Line Items] Business Acquisition [Line Items] Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Principal payments received on real estate mortgage and other loans receivable Proceeds from Collection of Loans Receivable Preferred equity investment Equity Method Investments Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] Income Statement [Abstract] Income Statement [Abstract] Amendment Flag Amendment Flag Concentration Risk [Table] Concentration Risk [Table] Historical volatility term basis for expected volatility assumption Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Term For Expected Volatility Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Historical Volatility Term For Expected Volatility Interest and other income Interest and Other Income 2028 Senior unsecured notes payable 3.875% Senior Notes due 2028 Three Point Eight Seven Five Senior Notes Due 2028 [Member] Three Point Eight Seven Five Senior Notes Due 2028 Fair Value Estimate of Fair Value Measurement [Member] Prepaid expenses and other assets, net Prepaid Expense and Other Assets ATM Program At-The-Market Offering Program [Member] At-The-Market Offering Program [Member] Senior unsecured notes payable Notes Payable, Fair Value Disclosure Held for sale Discontinued Operations, Held-for-sale [Member] Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Other Commitments [Domain] Other Commitments [Domain] Ensign Master Lease Amended Ensign Master Lease Amended [Member] Ensign Master Lease Amended Equity Components [Axis] Equity Components [Axis] Number of renewal options Lessor, Operating Lease, Number Of Renewal Options Lessor, Operating Lease, Number Of Renewal Options Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Loss on redemption price Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost Concentration Risk Type [Domain] Concentration Risk Type [Domain] Sale of Stock [Domain] Sale of Stock [Domain] Shares forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of states where Ensign leases the highest concentration of properties Concentration Risk, Number Of States Number of states where the entity's major tenants lease the highest concentration of properties. Contractual rent due Operating Lease, Lease Income, Lease Payments Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Ensign employees Ensign Employees [Member] Ensign Employees [Member] Entity File Number Entity File Number Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Less: Net income allocated to participating securities Undistributed Earnings (Loss) Allocated to Participating Securities, Basic Percentage of awards to vest relative To initial grant based on TSR performance Share-Based Compensation Arrangement By Share-Based Payment Award, TSR Performance, Percentage To Vest Relative To Initial Grant Share-Based Compensation Arrangement By Share-Based Payment Award, TSR Performance, Percentage To Vest Relative To Initial Grant Initial rent subject to a fixed escalator in second year Operating Leases, Anticipated Initial Annual Lease Revenues, Subject To Fixed Escalator In Year Two Operating Leases, Anticipated Initial Annual Lease Revenues, Subject To Fixed Escalator In Year Two Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Next VA Star Realty Holdings LLC Next VA Star Realty Holdings LLC [Member] Next VA Star Realty Holdings LLC Proceeds from the issuance of senior unsecured notes payable Gross proceeds from issuance Proceeds from Issuance of Unsecured Debt Portion of funding commitment subject to rent increase at time of funding Portion Of Commitment Subject To Rent Increase At Time Of Funding Portion Of Commitment Subject To Rent Increase At Time Of Funding Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Schedule of Cash, Cash Equivalents and Restricted Cash Schedule of Cash and Cash Equivalents [Table Text Block] Entity Small Business Entity Small Business ALF Assisted living Assisted Living Facility [Member] Assisted Living Facility [Member] Net proceeds from sales of real estate Proceeds from sale Proceeds from Sale of Real Estate Held-for-investment Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Rental income, exclusive of operating expense reimbursements Revenue Benchmark [Member] Equity Component [Domain] Equity Component [Domain] Period after March 30 2028 Debt Instrument, Redemption, Period Three [Member] Disposal Group Name [Domain] Disposal Group Name [Domain] 2021 (six months) Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year Interest income Interest and Fee Income, Loans, Commercial, Real Estate Lease renewal term (in years) Lessor, Operating Lease, Renewal Term Accounts payable and accrued liabilities Accounts Payable and Other Accrued Liabilities SNF / Campus Skilled nursing and campus facilities Skilled Nursing And Campus Facilities [Member] Skilled Nursing And Campus Facilities Deferred Loan Fees Debt Issuance Costs, Gross Statement [Line Items] Statement [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Funding commitment Other Commitment Counterparty Name [Domain] Counterparty Name [Domain] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Transfer of pre-acquisition costs to acquired assets Transfer Of Preacquisition Costs To Acquired Assets Transfer Of Preacquisition Costs To Acquired Assets Entity Address, State or Province Entity Address, State or Province Level 2 Fair Value, Inputs, Level 2 [Member] PMG Priority Management Group LLC [Member] Priority Management Group LLC Senior unsecured notes payable, net Unsecured Long-term Debt, Noncurrent Redemption price, percentage upon change of control (percent) Debt Instrument Redemption Price Upon Change Of Control As Percentage Of Principal Amount Debt instrument redemption price upon change of control as percentage of principal amount. Customer [Axis] Customer [Axis] Accumulated depreciation and amortization Real Estate Investment Property, Accumulated Depreciation Senior unsecured term loan, net Loans Payable, Noncurrent Lease Expiration October 2032, Next option 2023 Properties With Purchase Option, Lease Expiration October 2032, Next Option 2023 [Member] Properties With Purchase Option, Lease Expiration October 2032, Next Option 2023 Reconciliation of Weighted-Average Common Shares Outstanding Used in Calculation of Basic EPS to Diluted EPS Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Entity Shell Company Entity Shell Company Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Local Phone Number Local Phone Number Schedule of Stock-Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Forecast Forecast [Member] Disposed of by sale Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Number of extension options Line Of Credit Facility, Number Of Extension Options Line Of Credit Facility, Number Of Extension Options Proceeds from (costs paid for) the issuance of common stock, net Gross proceeds(1) Proceeds from Issuance of Common Stock Total assets Assets Investment, Name [Domain] Investment, Name [Domain] Board of Directors Director [Member] Common stock, authorized (shares) Common Stock, Shares Authorized Dividends payment date Dividends Payable, Date to be Paid Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Numerator for basic and diluted earnings available to common stockholders Net Income (Loss) Available to Common Stockholders, Diluted Numerator: Net Income (Loss) Attributable to Parent [Abstract] Buildings and improvements Investment Building and Building Improvements Numerator for basic earnings available to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Title of Individual [Axis] Title of Individual [Axis] Swingline loan Swingline Loan [Member] Swingline Loan [Member] Schedule Of Tenant Purchase Options Schedule Of Tenant Purchase Options [Table Text Block] Schedule Of Tenant Purchase Options 2023 Lessor, Operating Lease, Payment to be Received, Year Two Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Interest rate (percent) Debt Instrument, Interest Rate, Stated Percentage Cumulative distributions in excess of earnings Accumulated Distributions in Excess of Net Income Thereafter Lessor, Operating Lease, Payment to be Received, after Year Five Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Revolving credit facility Revolving Credit Facility [Member] MCRC, LLC Manteca Valley Post Acute [Member] Manteca Valley Post Acute [Member] Real Estate [Line Items] Real Estate [Line Items] Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Loss on sale of real estate Loss on sale of real estate Gain (loss) on sale of real estate Gains (Losses) on Sales of Investment Real Estate Remaining offering amount available Securities Offering, Remaining Authorized Amount Securities Offering, Remaining Authorized Amount Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Entity Tax Identification Number Entity Tax Identification Number Facility fee on revolving commitment fee based on investment grade ratings (percent) Line Of Credit, Commitment Fee Based On Investment Grade Rating, Percentage Line Of Credit, Commitment Fee Based On Investment Grade Rating, Percentage Subsequent Event [Line Items] Subsequent Event [Line Items] Lease Contractual Term [Domain] Lease Contractual Term [Domain] Basic (in shares) Weighted-average basic common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in usd per share) Earnings per common share, diluted (in dollars per share) Earnings Per Share, Diluted Payments on unsecured revolving credit facility Repayments of Long-term Lines of Credit Amortization of deferred financing costs Amortization of Debt Issuance Costs and Discounts Subsequent Events Subsequent Events [Text Block] Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Weighted-average number of common shares: Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Number of properties transferred Number Of Properties Transferred Number Of Properties Transferred Lease Arrangements [Axis] Lease Arrangements [Axis] Lease Arrangements Loan receivable Receivables, Fair Value Disclosure Fair Value Measurements Fair Value Disclosures [Text Block] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Purchases of equipment, furniture and fixtures and improvements to real estate Payments To Acquire Equipment, Furniture And Fixtures And Develop Real Estate Assets Payments To Acquire Equipment, Furniture And Fixtures And Develop Real Estate Assets Depreciation and amortization (including below-market ground leases) Depreciation, Depletion and Amortization Preferred equity investment minimum yield Equity Method Investment, Rate Of Return, Floor Equity Method Investment, Rate Of Return, Floor Common dividends Dividends payable as of record date Dividends, Common Stock Schedule of Items Measured at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Borrowings under unsecured revolving credit facility Proceeds from Long-term Lines of Credit Five Oaks Healthcare LLC Five Oaks Healthcare LLC [Member] Five Oaks Healthcare LLC Common stock, outstanding (shares) Common Stock, Shares, Outstanding Dividends payable Dividends Payable Number of operational beds and units in facilities Number Of Operational Beds And Units In Facilities Number Of Operational Beds And Units In Facilities Independent living facilities Cost of Goods and Services Sold Revenues: Revenues [Abstract] Lease Contractual Term [Axis] Lease Contractual Term [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Financing Receivable, Past Due [Table] Financing Receivable, Past Due [Table] Supplemental schedule of noncash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Real estate investments, net Real estate investments, net Real Estate Investment Property, Net Lessor, Lease, Description [Line Items] Lessor, Lease, Description [Line Items] Concentration of Risk Concentration Risk Disclosure [Text Block] Skilled nursing Skilled nursing properties Skilled Nursing Properties [Member] Skilled Nursing Properties [Member] Shares repurchased (in shares) Treasury Stock, Shares, Acquired Schedule of Debt Instruments Schedule of Long-term Debt Instruments [Table Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Earnings per common share: Earnings Per Share [Abstract] Lease Expiration November 2030, Next option 2022 Properties With Purchase Option, Lease Expiration November 2030, Next Option 2022 [Member] Properties With Purchase Option, Lease Expiration November 2030, Next Option 2022 Lease Expiration November 2034, Next option 2024 Properties With Purchase Option, Lease Expiration November 2034, Next Option 2024 [Member] Properties With Purchase Option, Lease Expiration November 2034, Next Option 2024 Senior unsecured term loan New Term Loan Senior Unsecured Term Loan [Member] Senior Unsecured Term Loan [Member] Extension option term (in months) Line Of Credit Facility Extension Option Term Line of credit facility extension option term. Document Quarterly Report Document Quarterly Report Total revenues Revenues Vesting of restricted common stock, net of shares withheld for employee taxes Restricted Stock, Value, Shares Issued Net of Tax Withholdings Line of Credit Facility [Table] Line of Credit Facility [Table] Purchase Price Aggregate purchase price Asset Acquisition, Consideration Transferred Other Commitments [Line Items] Other Commitments [Line Items] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Amortization of stock-based compensation Stock-based compensation expense Share-based Payment Arrangement, Expense Contract purchase price Disposal Group, Including Discontinued Operation, Contract Purchase Price Disposal Group, Including Discontinued Operation, Contract Purchase Price Document Fiscal Period Focus Document Fiscal Period Focus Number of beds and units in facilities Number Of Units And Beds In Facilities Number Of Units And Beds In Facilities Term Loan New Term Loan Feb 2019 [Member] New Term Loan Feb 2019 [Member] Number of properties with right to operate Number Of Properties With Right To Operate Number Of Properties With Right To Operate Counterparty Name [Axis] Counterparty Name [Axis] Cumulative contractual preferred return through acquisition date Equity Method Investment, Cumulative Contractual Preferred Return Equity Method Investment, Cumulative Contractual Preferred Return Cash, cash equivalents, and restricted cash as of the beginning of period Cash, cash equivalents, and restricted cash as of the end of period Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Extension option term (in months) Loan Receivable, Extension Option, Term Loan Receivable, Extension Option, Term Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Period prior to June 30 2024 Debt Instrument, Redemption, Period One [Member] Identified intangible assets Finite-Lived Intangible Assets, Gross Real Estate [Table] Real Estate [Table] Initial lease yield (percent) Initial Lease Yield Initial Lease Yield Entity Central Index Key Entity Central Index Key LIBOR London Interbank Offered Rate (LIBOR) [Member] Security Exchange Name Security Exchange Name Number of beds planned for construction Number Of Beds Planned For Construction Number Of Beds Planned For Construction Vesting of restricted common stock, net of shares withheld for employee taxes (in shares) Restricted Stock, Shares Issued Net of Shares for Tax Withholdings Disposal Group Classification [Domain] Disposal Group Classification [Domain] Diluted (in shares) Weighted-average diluted common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Recurring Fair Value, Recurring [Member] Period of unpaid interest payments due upon prepayment Loan Receivable, Period Of Unpaid Interest Payments Due Upon Prepayment Loan Receivable, Period Of Unpaid Interest Payments Due Upon Prepayment Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Basis spread on variable rate (percent) Debt Instrument, Basis Spread on Variable Rate Real Estate [Abstract] Real Estate [Abstract] Equity Stockholders' Equity Note Disclosure [Text Block] Measurement Basis [Axis] Measurement Basis [Axis] Initial rent subject to a fixed escalator in first twelve months Operating Leases, Anticipated Initial Annual Lease Revenues, Subject To Fixed Escalator In First Twelve Months Operating Leases, Anticipated Initial Annual Lease Revenues, Subject To Fixed Escalator In First Twelve Months Officers Officer [Member] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Other loss: Nonoperating Income (Expense) [Abstract] Class of Stock [Line Items] Class of Stock [Line Items] Mezzanine loan receivable Loans Receivable, Fair Value Disclosure Name of Property [Axis] Name of Property [Axis] Credit Facility [Axis] Credit Facility [Axis] Number of beds in facility used to secure loan Loan Receivable, Number Of Beds In Property Utilized To Secure Loan Loan Receivable, Number Of Beds In Property Utilized To Secure Loan Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Change in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Number of operational beds Number Of Operational Beds Number Of Operational Beds Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Properties Number Of Properties With Tenant Purchase Option Number Of Properties With Tenant Purchase Option Expected service period Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Net-settle adjustment on restricted stock Payment, Tax Withholding, Share-based Payment Arrangement Number of publicly traded healthcare REITs in peer group Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Metric, TSR Performance Peer Group Number Of Companies Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Metric, TSR Performance Peer Group Number Of Companies Credit facility borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Facilities utilized to secure mortgage loan Loan Receivable, Number Of Facilities Utilized To Secure Mortgage Loan Loan Receivable Number Of Facilities Utilized To Secure Mortgage Loan Entity Address, Postal Zip Code Entity Address, Postal Zip Code Mortgage loan receivable Financing Receivable, before Allowance for Credit Loss Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Title of 12(b) Security Title of 12(b) Security CommuniCare CommuniCare [Member] CommuniCare [Member] Statement [Table] Statement [Table] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Other Commitments [Axis] Other Commitments [Axis] Valuation Assumptions Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Unamortized stock-based compensation expense related to unvested awards Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Basis spread of preferred equity investment yield Equity Method Investments, Basis Spread On Variable Rate Equity Method Investments, Basis Spread On Variable Rate Stock awards unvested during spin-off (in shares) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Spin Off In Period Share based compensation arrangement by share based payment award equity instruments other than options nonvested spin off in period. Statistical Measurement [Axis] Statistical Measurement [Axis] Real Estate Investments, Net Real Estate Disclosure [Text Block] Subsequent event Subsequent Event [Member] Cover [Abstract] Cover [Abstract] Redemption of debt Extinguishment of Debt, Amount Number of facilities Number of Real Estate Properties Basis spread on variable rate for loan (percent) Loans Receivable, Basis Spread on Variable Rate Multi-service campuses(3) Multi-Service Campus Properties [Member] Multi-Service Campus Properties [Member] Write off of deferred financing costs Write off of Deferred Debt Issuance Cost 2024 Lessor, Operating Lease, Payment to be Received, Year Three Name of Property [Domain] Name of Property [Domain] Number of properties held for sale Number Of Properties To Be Sold Number Of Properties To Be Sold Scenario [Domain] Scenario [Domain] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Subfacility capacity as percentage of available revolving commitments (percent) Line Of Credit, Subfacility, Capacity As Percentage Of Available Revolving Commitments Line Of Credit, Subfacility, Capacity As Percentage Of Available Revolving Commitments Health Care, Resident Service [Member] EX-101.PRE 9 ctre-20210630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 ctre-20210630_htm.xml IDEA: XBRL DOCUMENT 0001590717 2021-01-01 2021-06-30 0001590717 2021-08-04 0001590717 2021-06-30 0001590717 2020-12-31 0001590717 2021-04-01 2021-06-30 0001590717 2020-04-01 2020-06-30 0001590717 2020-01-01 2020-06-30 0001590717 us-gaap:CommonStockMember 2020-12-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-12-31 0001590717 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001590717 2021-01-01 2021-03-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2021-01-01 2021-03-31 0001590717 us-gaap:CommonStockMember 2021-03-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2021-03-31 0001590717 2021-03-31 0001590717 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001590717 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2021-04-01 2021-06-30 0001590717 us-gaap:CommonStockMember 2021-06-30 0001590717 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2021-06-30 0001590717 us-gaap:CommonStockMember 2019-12-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2019-12-31 0001590717 2019-12-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001590717 2020-01-01 2020-03-31 0001590717 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-01-01 2020-03-31 0001590717 us-gaap:CommonStockMember 2020-03-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-03-31 0001590717 2020-03-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001590717 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-04-01 2020-06-30 0001590717 us-gaap:CommonStockMember 2020-06-30 0001590717 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-06-30 0001590717 2020-06-30 0001590717 ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember 2021-06-30 0001590717 ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember 2021-01-01 2021-06-30 0001590717 ctre:FivePointTwoFiveSeniorNotesDue2025Member ctre:SeniorUnsecuredNotesMember 2021-06-30 0001590717 ctre:AssistedLivingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2034NextOption2022Member 2021-06-30 0001590717 ctre:SkilledNursingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2030NextOption2022Member 2021-06-30 0001590717 ctre:SkilledNursingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationMarch2029NextOption2022Member 2021-06-30 0001590717 ctre:SkilledNursingAndCampusFacilitiesMember ctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2032NextOption2023Member 2021-06-30 0001590717 ctre:SkilledNursingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2034NextOption2024Member 2021-06-30 0001590717 ctre:AssistedLivingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2034NextOption2026Member 2021-06-30 0001590717 ctre:SkilledNursingPropertiesMember 2021-01-01 2021-06-30 0001590717 ctre:MultiServiceCampusPropertiesMember 2021-01-01 2021-06-30 0001590717 ctre:MultiServiceCampusPropertiesMember srt:ScenarioForecastMember 2022-01-01 2022-12-31 0001590717 us-gaap:DiscontinuedOperationsHeldforsaleMember ctre:FiveOaksHealthcareLLCMember 2020-12-31 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ctre:FiveOaksHealthcareLLCMember 2021-02-01 2021-02-01 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ctre:FiveOaksHealthcareLLCMember 2021-02-01 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ctre:FiveOaksHealthcareLLCMember 2021-01-01 2021-06-30 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ctre:MetronSkilledNursingFacilitiesMember 2020-02-14 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ctre:MetronSkilledNursingFacilitiesMember 2020-02-14 2020-02-14 0001590717 ctre:CascadeCapitalGroupLLCMember us-gaap:MortgageReceivablesMember 2020-02-14 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ctre:MetronSkilledNursingFacilitiesMember 2020-01-01 2020-03-31 0001590717 ctre:CascadeCapitalGroupLLCMember us-gaap:MortgageReceivablesMember 2020-04-01 2020-04-30 0001590717 ctre:CascadeCapitalGroupLLCMember us-gaap:MortgageReceivablesMember 2020-04-30 0001590717 ctre:CascadeCapitalGroupLLCMember us-gaap:MortgageReceivablesMember 2020-07-01 2020-07-31 0001590717 ctre:EnsignMember ctre:SkilledNursingFacilityMember 2021-06-01 0001590717 ctre:EnsignAmendedTripleNetMasterLeaseMember 2021-06-01 0001590717 ctre:EnsignAmendedTripleNetMasterLeaseMember 2021-06-01 2021-06-01 0001590717 ctre:NobleVAHoldingsLLCMember ctre:AssistedLivingFacilityMember 2020-12-01 0001590717 ctre:NobleTripleNetMasterLeaseMember 2020-12-01 0001590717 ctre:NobleTripleNetMasterLeaseMember 2020-12-01 2020-12-01 0001590717 ctre:NextVAStarRealtyHoldingsLLCMember ctre:MezzanineLoanMember 2020-11-30 0001590717 ctre:NextVAStarRealtyHoldingsLLCMember srt:MinimumMember ctre:MezzanineLoanMember 2020-11-30 0001590717 ctre:NextVAStarRealtyHoldingsLLCMember srt:MaximumMember ctre:MezzanineLoanMember 2020-11-30 0001590717 ctre:NextVAStarRealtyHoldingsLLCMember ctre:MezzanineLoanMember 2020-11-01 2020-11-30 0001590717 ctre:NextVAStarRealtyHoldingsLLCMember ctre:MezzanineLoanMember 2021-04-01 2021-06-30 0001590717 ctre:NextVAStarRealtyHoldingsLLCMember ctre:MezzanineLoanMember 2021-01-01 2021-06-30 0001590717 ctre:MantecaValleyPostAcuteMember us-gaap:MortgageReceivablesMember 2019-07-01 2019-07-31 0001590717 ctre:MantecaValleyPostAcuteMember us-gaap:MortgageReceivablesMember 2019-07-31 0001590717 ctre:MantecaValleyPostAcuteMember 2019-07-01 2019-07-31 0001590717 ctre:CommuniCareMember us-gaap:MortgageReceivablesMember 2019-09-30 0001590717 ctre:CascadeCapitalGroupLLCMember us-gaap:MortgageReceivablesMember 2020-02-29 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ctre:MetronSkilledNursingFacilitiesMember 2020-02-29 0001590717 ctre:CascadeCapitalGroupLLCMember 2020-04-30 0001590717 ctre:CascadeCapitalGroupLLCMember us-gaap:MortgageReceivablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-04-30 0001590717 us-gaap:MortgageReceivablesMember 2021-06-30 0001590717 us-gaap:MortgageReceivablesMember 2021-01-01 2021-06-30 0001590717 us-gaap:MortgageReceivablesMember 2021-04-01 2021-06-30 0001590717 us-gaap:MortgageReceivablesMember 2020-04-01 2020-06-30 0001590717 us-gaap:MortgageReceivablesMember 2020-01-01 2020-06-30 0001590717 us-gaap:LoansReceivableMember 2021-04-01 2021-06-30 0001590717 us-gaap:LoansReceivableMember 2021-01-01 2021-06-30 0001590717 us-gaap:LoansReceivableMember 2020-04-01 2020-06-30 0001590717 us-gaap:LoansReceivableMember 2020-01-01 2020-06-30 0001590717 ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember 2016-09-30 0001590717 ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember us-gaap:PrimeRateMember 2016-09-01 2016-09-30 0001590717 ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember 2016-09-01 2016-09-30 0001590717 ctre:SkilledNursingPropertiesMember 2020-01-01 2020-01-31 0001590717 ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember 2020-01-01 2020-01-31 0001590717 ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember 2020-01-01 2020-06-30 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001590717 us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember 2021-06-30 0001590717 us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember 2020-12-31 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:SeniorNotesMember 2021-06-30 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2021-06-30 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2021-06-30 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:SeniorNotesMember 2020-12-31 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2020-12-31 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2020-12-31 0001590717 ctre:FivePointTwoFiveSeniorNotesDue2025Member us-gaap:SeniorNotesMember 2021-06-30 0001590717 ctre:FivePointTwoFiveSeniorNotesDue2025Member us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2021-06-30 0001590717 ctre:FivePointTwoFiveSeniorNotesDue2025Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2021-06-30 0001590717 ctre:FivePointTwoFiveSeniorNotesDue2025Member us-gaap:SeniorNotesMember 2020-12-31 0001590717 ctre:FivePointTwoFiveSeniorNotesDue2025Member us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2020-12-31 0001590717 ctre:FivePointTwoFiveSeniorNotesDue2025Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2020-12-31 0001590717 ctre:SeniorUnsecuredTermLoanMember 2021-06-30 0001590717 ctre:SeniorUnsecuredTermLoanMember 2020-12-31 0001590717 us-gaap:LineOfCreditMember 2021-06-30 0001590717 us-gaap:LineOfCreditMember 2020-12-31 0001590717 ctre:FivePointTwoFiveSeniorNotesDue2025Member us-gaap:SeniorNotesMember 2017-05-10 0001590717 ctre:FivePointTwoFiveSeniorNotesDue2025Member us-gaap:SeniorNotesMember 2017-05-10 2017-05-10 0001590717 ctre:FivePointTwoFiveSeniorNotesDue2025Member us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2021-07-01 2021-07-01 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:SeniorNotesMember 2021-06-17 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:SeniorNotesMember 2021-06-17 2021-06-17 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:SeniorNotesMember 2021-06-17 2021-06-17 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:DebtInstrumentRedemptionPeriodThreeMember us-gaap:SeniorNotesMember 2021-06-17 2021-06-17 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:SeniorNotesMember 2021-06-17 2021-06-17 0001590717 us-gaap:RevolvingCreditFacilityMember ctre:NewRevolvingFacilityMember 2019-02-08 0001590717 us-gaap:LetterOfCreditMember 2019-02-08 0001590717 ctre:SwinglineLoanMember 2019-02-08 0001590717 ctre:NewTermLoanFeb2019Member ctre:SeniorUnsecuredTermLoanMember 2019-02-08 0001590717 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ctre:NewRevolvingFacilityMember us-gaap:BaseRateMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ctre:NewRevolvingFacilityMember us-gaap:BaseRateMember 2019-02-08 2019-02-08 0001590717 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ctre:NewRevolvingFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ctre:NewRevolvingFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-02-08 2019-02-08 0001590717 srt:MinimumMember ctre:NewTermLoanFeb2019Member ctre:SeniorUnsecuredTermLoanMember us-gaap:BaseRateMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember ctre:NewTermLoanFeb2019Member ctre:SeniorUnsecuredTermLoanMember us-gaap:BaseRateMember 2019-02-08 2019-02-08 0001590717 srt:MinimumMember ctre:NewTermLoanFeb2019Member ctre:SeniorUnsecuredTermLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember ctre:NewTermLoanFeb2019Member ctre:SeniorUnsecuredTermLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-02-08 2019-02-08 0001590717 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ctre:NewRevolvingFacilityMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ctre:NewRevolvingFacilityMember 2019-02-08 2019-02-08 0001590717 us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2021-07-01 2021-08-05 0001590717 us-gaap:RevolvingCreditFacilityMember ctre:NewRevolvingFacilityMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember ctre:AtTheMarketOfferingProgramMember 2020-03-10 0001590717 ctre:AtTheMarketOfferingProgramMember 2020-01-01 2020-06-30 0001590717 ctre:AtTheMarketOfferingProgramMember 2020-04-01 2020-06-30 0001590717 ctre:AtTheMarketOfferingProgramMember 2021-04-01 2021-06-30 0001590717 ctre:AtTheMarketOfferingProgramMember 2021-01-01 2021-06-30 0001590717 ctre:AtTheMarketOfferingProgramMember 2021-06-30 0001590717 2020-03-20 0001590717 ctre:EnsignEmployeesMember us-gaap:RestrictedStockMember 2014-06-01 2014-06-01 0001590717 ctre:EnsignEmployeesMember us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001590717 ctre:EnsignEmployeesMember us-gaap:RestrictedStockMember 2021-06-30 0001590717 ctre:OfficerAndEmployeeMember us-gaap:RestrictedStockMember 2021-01-01 2021-01-31 0001590717 ctre:OfficerAndEmployeeMember us-gaap:RestrictedStockMember 2021-02-01 2021-02-28 0001590717 ctre:OfficerAndEmployeeMember us-gaap:RestrictedStockMember 2021-01-31 0001590717 ctre:OfficerAndEmployeeMember us-gaap:RestrictedStockMember 2021-02-28 0001590717 srt:OfficerMember us-gaap:PerformanceSharesMember 2021-01-01 2021-01-31 0001590717 srt:MinimumMember srt:OfficerMember us-gaap:PerformanceSharesMember 2021-01-01 2021-01-31 0001590717 srt:MaximumMember srt:OfficerMember us-gaap:PerformanceSharesMember 2021-01-01 2021-01-31 0001590717 srt:OfficerMember us-gaap:PerformanceSharesMember 2021-02-01 2021-02-28 0001590717 srt:MinimumMember srt:OfficerMember us-gaap:PerformanceSharesMember 2021-02-01 2021-02-28 0001590717 srt:MaximumMember srt:OfficerMember us-gaap:PerformanceSharesMember 2021-02-01 2021-02-28 0001590717 us-gaap:PerformanceSharesMember 2021-01-01 2021-02-28 0001590717 srt:DirectorMember us-gaap:RestrictedStockMember 2021-04-01 2021-04-30 0001590717 ctre:EnsignAndPennantMember 2021-06-30 0001590717 ctre:CapitalImprovementsAtTripleNetLeasedFacilitiesMember 2021-06-30 0001590717 ctre:EnsignMember ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember 2021-06-30 0001590717 ctre:EnsignMember 2021-01-01 2021-06-30 0001590717 ctre:EnsignMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001590717 ctre:EnsignMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001590717 ctre:EnsignMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-06-30 0001590717 ctre:EnsignMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-04-01 2020-06-30 0001590717 ctre:PriorityManagementGroupLLCMember ctre:SkilledNursingAndCampusFacilitiesMember 2021-06-30 0001590717 ctre:PriorityManagementGroupLLCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001590717 ctre:PriorityManagementGroupLLCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001590717 ctre:PriorityManagementGroupLLCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-06-30 0001590717 ctre:PriorityManagementGroupLLCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-04-01 2020-06-30 0001590717 srt:ScenarioForecastMember ctre:FivePointTwoFiveSeniorNotesDue2025Member us-gaap:SeniorNotesMember 2021-07-01 2021-09-30 0001590717 ctre:SkilledNursingFacilityMember us-gaap:SubsequentEventMember 2021-08-01 2021-08-05 0001590717 ctre:EnsignMember us-gaap:SubsequentEventMember ctre:EnsignMasterLeaseAmendedMember 2021-08-05 0001590717 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember us-gaap:SubsequentEventMember 2021-08-05 shares iso4217:USD iso4217:USD shares ctre:facility ctre:bed ctre:state pure ctre:property ctre:unit ctre:extension_option ctre:installment ctre:company ctre:unit_bed 0001590717 --12-31 2021 Q2 false http://fasb.org/us-gaap/2021-01-31#HealthCareResidentServiceMember http://fasb.org/us-gaap/2021-01-31#HealthCareResidentServiceMember http://fasb.org/us-gaap/2021-01-31#HealthCareResidentServiceMember http://fasb.org/us-gaap/2021-01-31#HealthCareResidentServiceMember http://fasb.org/us-gaap/2021-01-31#HealthCareResidentServiceMember http://fasb.org/us-gaap/2021-01-31#HealthCareResidentServiceMember http://fasb.org/us-gaap/2021-01-31#HealthCareResidentServiceMember http://fasb.org/us-gaap/2021-01-31#HealthCareResidentServiceMember P5D P1Y 10-Q true 2021-06-30 false 001-36181 CareTrust REIT, Inc. MD 46-3999490 905 Calle Amanecer Suite 300 San Clemente CA 92673 949 542-3130 Common Stock, par value $0.01 per share CTRE NASDAQ Yes Yes Large Accelerated Filer false false false 97035096 1575403000 1448099000 15150000 15000000 0 7226000 1771000 18919000 309187000 0 1786000 1823000 7570000 10450000 1552000 2042000 1912419000 1503559000 690890000 296669000 199031000 198925000 50000000 50000000 16804000 19572000 26085000 24251000 982810000 589417000 0.01 0.01 100000000 100000000 0 0 0 0 0 0 0.01 0.01 500000000 500000000 96296673 96296673 95215797 95215797 963000 952000 1189402000 1164402000 260756000 251212000 929609000 914142000 1912419000 1503559000 47744000 42507000 92990000 84971000 0 615000 0 1240000 514000 1046000 1019000 2297000 48258000 44168000 94009000 88508000 13843000 13239000 27316000 26399000 6534000 5849000 12296000 12563000 766000 837000 1462000 1322000 0 546000 0 1092000 5798000 4762000 10940000 8816000 26941000 25233000 52014000 50192000 0 0 -192000 -56000 21317000 18935000 41803000 38260000 0.22 0.20 0.43 0.40 0.22 0.20 0.43 0.40 96082000 95208000 95732000 95185000 96120000 95208000 95755000 95185000 95215797 952000 1164402000 -251212000 914142000 702000 7000 16184000 16191000 63265 1000 -1331000 -1330000 1585000 1585000 0.265 25633000 25633000 20486000 20486000 95981062 960000 1180840000 -256359000 925441000 288000 3000 6752000 6755000 27611 1810000 1810000 0.265 25714000 25714000 21317000 21317000 96296673 963000 1189402000 -260756000 929609000 95103270 951000 1162990000 -236350000 927591000 90000 90000 93061 1000 -1987000 -1986000 884000 884000 0.25 23931000 23931000 19325000 19325000 95196331 952000 1161797000 -240956000 921793000 314000 314000 17749 963000 963000 0.25 23931000 23931000 18935000 18935000 95214080 952000 1162446000 -245952000 917446000 41803000 38260000 27345000 26428000 1012000 975000 3395000 1847000 20000 48000 -192000 -56000 0 1346000 93000 -806000 -88000 -528000 -3165000 -2256000 70557000 67942000 147807000 25905000 3463000 6234000 700000 13958000 113000 66961000 0 2327000 6814000 2134000 -145043000 25325000 22946000 404000 400000000 0 170000000 15000000 170000000 75000000 5577000 0 1331000 1986000 49513000 45406000 366525000 -107796000 292039000 -14529000 18919000 20327000 310958000 5798000 10664000 11586000 1834000 2456000 0 599000 618000 0 358000 167000 0 32400000 ORGANIZATION<div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of Business—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CareTrust REIT, Inc.’s (“CareTrust REIT” or the “Company”) primary business consists of acquiring, financing, developing and owning real property to be leased to third-party tenants in the healthcare sector. As of June 30, 2021, the Company owned and leased to independent operators, 223 skilled nursing, multi-service campuses, assisted living and independent living facilities consisting of 23,301 operational beds and units located in 28 states with the highest concentration of properties by rental revenues located in California, Texas, Louisiana, Idaho and Arizona. As of June 30, 2021, the Company also had other real estate investments consisting of one mezzanine loan receivable with a carrying value of $15.2 million.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has led governments and other authorities around the world, including federal, state and local authorities in the United States, to impose measures intended to reduce its spread, including restrictions on freedom of movement and business operations such as travel bans, border closings, business limitations and closures (subject to exceptions for essential operations and businesses), quarantines and shelter-in-place orders. Although most of these governmental restrictions have since been lifted or scaled back, resurgences of COVID-19 and the emergence of new variants thereof have resulted in the reimposition of certain restrictions and may lead to other restrictions being reimplemented in response to efforts to reduce the spread of COVID-19. Given the dynamic nature of these circumstances and the related adverse impact these restrictions have had, and may continue to have, on the economy generally, the Company’s business, results of operations and financial condition may be adversely impacted by the COVID-19 pandemic. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration and extent of the COVID-19 pandemic’s effect on the Company’s operational and financial performance, and the operational and financial performance of the Company’s tenants, will depend on future developments, which are highly uncertain and cannot be predicted at this time, including the rate of public acceptance and usage of vaccines and the effectiveness of vaccines in limiting the spread of COVID-19 and its variants, resurgences of COVID-19 and, in particular, new and more contagious and/or vaccine resistant variants, actions taken to contain the spread of COVID-19 and how quickly and to what extent normal economic and operating conditions can resume. The adverse impact of the COVID-19 pandemic on the Company’s business, results of operations and financial condition could be material.</span></div> 223 23301 28 15200000 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. All intercompany transactions and account balances within the Company have been eliminated.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company presents cash and cash equivalents separately from restricted cash within the Company’s condensed consolidated balance sheets. The Company includes restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the condensed consolidated statements of cash flows. The Company provides a reconciliation between the balance sheets and statements of cash flows, as required when the balance includes more than one line item for cash, cash equivalents, and restricted cash. The Company also provides a disclosure of the nature of the restrictions related to material restricted cash balances.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, the Company had $309.2 million in restricted cash related to the cash deposited with the trustee to pay the redemption price of the $300.0 million aggregate principal amount of 5.25% Senior Notes due 2025 (the “2025 Notes”). The 2025 Notes were redeemed on July 1, 2021. See Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further detail.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash consisted of the following as of June 30, 2021 and December 31, 2020 (dollars in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,919 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,958 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,919 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-04, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2020-04”), that provides optional relief to applying reference rate reform to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”). For U.S. Dollar LIBOR, the overnight, one-month, three-month, six-month and one-year LIBOR rates will be discontinued in June 2023, while other U.S. Dollar LIBOR rates will be discontinued at the end of 2021. The amendments in this update are effective immediately and may be applied through December 31, 2022. The Company is still evaluating the impact of ASU 2020-04 and expects to take full advantage of the offered optional expedients and exceptions, but does not expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. All intercompany transactions and account balances within the Company have been eliminated.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company presents cash and cash equivalents separately from restricted cash within the Company’s condensed consolidated balance sheets. The Company includes restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the condensed consolidated statements of cash flows. The Company provides a reconciliation between the balance sheets and statements of cash flows, as required when the balance includes more than one line item for cash, cash equivalents, and restricted cash. The Company also provides a disclosure of the nature of the restrictions related to material restricted cash balances.</span> 309200000 300000000.0 0.0525 <div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash consisted of the following as of June 30, 2021 and December 31, 2020 (dollars in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,919 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,958 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,919 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1771000 18919000 309187000 0 310958000 18919000 <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-04, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2020-04”), that provides optional relief to applying reference rate reform to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”). For U.S. Dollar LIBOR, the overnight, one-month, three-month, six-month and one-year LIBOR rates will be discontinued in June 2023, while other U.S. Dollar LIBOR rates will be discontinued at the end of 2021. The amendments in this update are effective immediately and may be applied through December 31, 2022. The Company is still evaluating the impact of ASU 2020-04 and expects to take full advantage of the offered optional expedients and exceptions, but does not expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements.</span> REAL ESTATE INVESTMENTS, NET<div style="margin-bottom:9pt;margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s investment in owned properties as of June 30, 2021 and December 31, 2020 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,356 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,961 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integral equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identified intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362,397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335,294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,575,403 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448,099 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, all 223 of the Company’s facilities wer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e leased to various operators under triple-net leases. All of these leases contain annual escalators based on the percentage change in the Consumer Price Index (“CPI”) (but not less than zero), some of which are subject to a cap, or fixed rent escalators.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements, were (dollars in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (six months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,091 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,062 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052,270 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant Purchase Options</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Type</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Properties</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Expiration</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Next Option Open Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Type</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Cash Rent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALF</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2034</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/1/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B / C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF / Campus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2032</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/1/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2034</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Option type includes:</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A - Fixed base price plus a specified share on any appreciation.</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B - Fixed base price.</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C - Fixed capitalization rate on lease revenue.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Based on annualized cash revenue for contracts in place as of June 30, 2021.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Purchase option reflects two option types.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rental Income</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes components of the Company’s rental income (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.963%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rental Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual rent due</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,736 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,485 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,923 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease termination revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,744 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,507 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,990 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,971 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) During the six months ended June 30, 2021, in connection with the agreement to terminate its lease agreements with affiliates of Metron Integrated Health Systems (“Metron”) and to sell the facilities to a third-party, the Company received $0.1 million from Metron affiliates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Real Estate Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s acquisitions for the six months ended June 30, 2021 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Property</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Initial Annual Cash Rent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Properties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Beds/Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled nursing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,457 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-service campuses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,165 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,899 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Purchase price includes capitalized acquisition costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The number of beds/units includes operating beds at the acquisition date. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Initial annual cash rent represents the first twelve months of rent upon commencement of the Company’s long-term net leases, which occurred during the three months ended June 30, 2021, upon the tenants’ receipt of licensing approval and increases to $9.4 million in the second year with CPI-based annual escalators thereafter.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Included within initial annual cash rent is approximately $0.8 million of initial rent which is subject to a fixed escalator in the first twelve months and increases to $0.9 million in the second year with CPI-based annual escalators thereafter.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Sales and Assets Held for Sale</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, there were no assets classified as held for sale. During the fourth quarter of 2020, the Company met the criteria to classify one skilled nursing facility operated by affiliates of Five Oaks Healthcare, LLC as held for sale. Assets held for sale include the net book value of property the Company plans to sell within the next year. If the determination is made that the Company no longer expects to sell an asset within the next year, the asset is reclassified out of assets held for sale. On February 1, 2021, the Company closed on the sale of the one skilled nursing facility consisting of 90 beds located in Washington with a carrying value of $7.2 million, for net sales proceeds of $7.0 million. During the six months ended June 30, 2021, the Company recorded a loss of $0.2 million in connection with the sale.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2020, the Company closed on the sale of six skilled nursing facilities formerly operated by affiliates of Metron. In connection with the sale for $36.0 million, the Company received $3.5 million in cash and provided subsidiaries of Cascade Capital Group, LLC (“Cascade”), the purchaser of the properties, with a short-term mortgage loan secured by these properties for $32.4 million. The mortgage loan bore interest at 7.5% and initially had a maturity date of March 31, 2020. In connection with the sale, the Company recognized a loss of approximately $0.1 million during the three months ended March 31, 2020. In April 2020, the mortgage loan was settled with $18.9 million in cash and a new mortgage loan for $13.9 million. In July 2020, the Company received prepayment in full, including accrued interest, for the new $13.9 million mortgage loan. See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Real Estate Investments, Net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further detail on the mortgage loan. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Amendments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Five Oaks Lease Termination and Amended Ensign Master Lease. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2021, operating affiliates of The Ensign Group, Inc. (“Ensign”) acquired certain operations and assets of Five Oaks Healthcare, LLC (“Five Oaks”) under an agreement with Five Oaks. The agreement granted Ensign the right to occupy and operate four of the Company’s skilled nursing facilities in Washington that were previously being operated by Five Oaks. In conjunction with consenting to the transfer, the Company terminated the existing Five Oaks master lease, and amended and extended the term of an existing triple-net master lease with Ensign to include the four skilled nursing facilities. The Ensign lease, as amended, has a remaining term of approximately 15 years, with three five-year renewal options and CPI-based rent escalators. Annual cash rent under the terminated Five Oaks master lease was approximately $2.6 million, and annual cash rent under the amended Ensign lease increased by the same amount. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Twenty/20 Lease Termination and New Noble Master Lease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On December 1, 2020, five assisted living facilities in Virginia operated by Twenty/20 Management, Inc. (“Twenty/20”) were transferred to affiliates of Noble VA Holdings, LLC (“Noble”). In connection with the transfer, the Company entered into a new triple-net master lease with Noble. The new lease has a remaining initial term of approximately 14 years, with two five-year renewal options and CPI-based rent escalators. Initial annual cash rent under the new lease is approximately $3.2 million</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s investment in owned properties as of June 30, 2021 and December 31, 2020 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,356 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,961 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integral equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identified intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362,397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335,294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,575,403 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448,099 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 244740000 205356000 1588961000 1477849000 101441000 97836000 2658000 2352000 1937800000 1783393000 362397000 335294000 1575403000 1448099000 223 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements, were (dollars in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (six months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,091 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,062 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052,270 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 93754000 188644000 188438000 187091000 187062000 187166000 1020115000 2052270000 <div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Type</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Properties</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Expiration</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Next Option Open Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Type</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Cash Rent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALF</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2034</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/1/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B / C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF / Campus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2032</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/1/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2034</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Option type includes:</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A - Fixed base price plus a specified share on any appreciation.</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B - Fixed base price.</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C - Fixed capitalization rate on lease revenue.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Based on annualized cash revenue for contracts in place as of June 30, 2021.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Purchase option reflects two option types.</span></div> 7 3282000 11 4800000 1 779000 2 959000 4 3789000 2 1559000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes components of the Company’s rental income (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.963%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rental Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual rent due</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,736 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,485 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,923 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease termination revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,744 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,507 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,990 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,971 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) During the six months ended June 30, 2021, in connection with the agreement to terminate its lease agreements with affiliates of Metron Integrated Health Systems (“Metron”) and to sell the facilities to a third-party, the Company received $0.1 million from Metron affiliates.</span></div> 47736000 42485000 92907000 84923000 8000 22000 20000 48000 0 0 63000 0 47744000 42507000 92990000 84971000 100000 <div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s acquisitions for the six months ended June 30, 2021 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Property</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Initial Annual Cash Rent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Properties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Beds/Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled nursing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,457 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-service campuses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,165 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,899 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Purchase price includes capitalized acquisition costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The number of beds/units includes operating beds at the acquisition date. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Initial annual cash rent represents the first twelve months of rent upon commencement of the Company’s long-term net leases, which occurred during the three months ended June 30, 2021, upon the tenants’ receipt of licensing approval and increases to $9.4 million in the second year with CPI-based annual escalators thereafter.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Included within initial annual cash rent is approximately $0.8 million of initial rent which is subject to a fixed escalator in the first twelve months and increases to $0.9 million in the second year with CPI-based annual escalators thereafter.</span></div> 25457000 2295000 2 268 125708000 8604000 4 640 151165000 10899000 6 908 9400000 800000 900000 0 1 90 7200000 7000000.0 -200000 6 36000000.0 3500000 32400000 0.075 100000 18900000 13900000 13900000 4 4 P15Y 3 P5Y 2600000 5 P14Y 2 P5Y 3200000 OTHER REAL ESTATE INVESTMENTS, NET<div style="margin-bottom:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mezzanine Loan Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—In November 2020, the Company provided Next VA Star Realty Holdings, LLC a mezzanine loan for nine skilled nursing facilities secured by membership interests in affiliates of Next VA Star Realty Holdings, LLC for approximately $15.0 million, at an annual interest rate of 12%. The loan requires monthly interest payments, is set to mature on November 30, 2025, and may (subject to certain restrictions) be prepaid before the maturity date if paid in full and for an exit fee ranging from 1% to 3% of the loan plus unpaid interest payments equal to 24 months (less the amount of monthly interest payments made by the borrower through the date of prepayment). During the three and six months ended June 30, 2021, the Company recognized $0.4 million and $0.9 million, respectively, of interest income related to its mezzanine loan. </span></div><div style="margin-bottom:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage Loans Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—In July 2019, the Company provided MCRC, LLC a real estate loan secured by a 176-bed skilled nursing facility in Manteca, California for $3.0 million, which bore a fixed interest rate of 8% and required monthly interest payments. Concurrently, the Company entered into a purchase and sale agreement to purchase the Manteca facility from MCRC, LLC for approximately $16.4 million subject to normal diligence and other contingencies. The loan documents provided for a maturity date of the earlier to occur of the closing date of the acquisition, or <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM4MTFmYjU4NTg5YTQ4NWRiYjgxZjEwNTczYTlhMjZmL3NlYzozODExZmI1ODU4OWE0ODVkYmI4MWYxMDU3M2E5YTI2Zl80MC9mcmFnOjFkZmQxNGEyYTA1MzQ0YTA4NTU4MGM3OWI3ZGFhMTZlL3RleHRyZWdpb246MWRmZDE0YTJhMDUzNDRhMDg1NTgwYzc5YjdkYWExNmVfMTM3MA_505e2352-6c86-431b-bae3-bf506a466f67">five</span> business days following the termination of the purchase and sale agreement.  MCRC, LLC breached its obligation to sell the Manteca facility to the Company on the terms outlined in the purchase and sale agreement and to repay the real estate loan upon its stated maturity. As a result, the Company commenced non-judicial foreclosure proceedings with respect to the Manteca facility. In January 2020, the borrower further collateralized the loan by causing one of its affiliates to grant the Company a deed of trust in the real estate and improvements that constitute Palm Gardens Assisted Living Facility in Yolo County, California. During the three months ended June 30, 2020, payment for the loan principal and accrued interest, including default interest, as well as reimbursement for attorney’s fees and certain other costs of suit, were received in full by the Company and, as a result, the Company withdrew all foreclosure-related proceedings related to the Manteca facility loan. </span></div><div style="margin-bottom:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company provided affiliates of CommuniCare Family of Companies (“CommuniCare”) a $26.5 million loan secured by mortgages on the three skilled nursing facilities sold to CommuniCare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which bore a fixed interest rate of 10%. The mortgage loan, which required CommuniCare to make monthly interest payments, was set to mature on February 29, 2020 and included an option to be prepaid before the maturity date. In January 2020, the Company amended the mortgage loan’s maturity date to April 30, 2020. In April 2020, the Company amended the mortgage loan’s maturity date to May 29, 2020. During the three months ended June 30, 2020, payment for the mortgage loan and accrued interest was received in full by the Company.</span></div><div style="margin-bottom:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company provided subsidiaries of Cascade a $32.4 million loan secured by mortgages on the six skilled nursing facilities formerly operated by affiliates of Metron and sold to Cascade in February 2020, as discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate Investments, Net. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mortgage loan bore interest at 7.5% and initially had a maturity date of March 31, 2020. In April 2020, the mortgage loan was settled in connection with a new mortgage loan transaction between the Company and a third-party institutional lender as co-lenders, pursuant to which the Company received $18.9 million in cash and a new mortgage loan for $13.9 million. The new mortgage loan with Cascade was secured by the same six skilled nursing facilities purchased by Cascade and was for a combined principal amount of $33.9 million, with the Company’s $13.9 million portion of the indebtedness initially bearing interest at a variable rate equal to LIBOR plus 4.00%, subject to a LIBOR floor of 1.75%. The </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new mortgage loan had a maturity date of April 29, 2022 and included two six-month extension options. In July 2020, prepayment for the mortgage loan of $13.9 million and accrued interest was received in full by the Company. </span></div><div style="margin-bottom:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, the Company had no mortgage loan receivables.</span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During both the three and six months ended June 30, 2021, the Company recognized no interest income related to mortgage loans. During the three and six months ended June 30, 2020, the Company recognized $0.9 million and $2.0 million of interest income, respectively, related to its mortgage loans. During the three and six months ended June 30, 2021, the Company recognized less than $0.1 million and $0.1 million of interest income, respectively, related to its other loans receivable. During the three and six months ended June 30, 2020, the Company recognized $0.1 million and $0.2 million of interest income, respectively, related to its other loans receivable.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Equity Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—In September 2016, the Company completed a $2.3 million preferred equity investment with an affiliate of Cascadia Development, LLC. The preferred equity investment yielded a return equal to prime plus 9.5% but in no event less than 12.0% calculated on a quarterly basis on the outstanding carrying value of the investment. The investment was used to develop a 99-bed skilled nursing facility in Boise, Idaho. In connection with its investment, the Company obtained an option to purchase the development at a fixed-formula price upon stabilization, with an initial lease yield of at least 9.0%. The project was completed in the first quarter of 2018 and began lease-up during the second quarter of 2018. In January 2020, the Company purchased the skilled nursing facility for approximately $18.7 million, inclusive of transaction costs. The Company paid $15.0 million after receiving back its initial investment of $2.3 million and cumulative contractual preferred return through January 17, 2020, the acquisition date, of $1.4 million, of which less than $0.1 million was recognized as interest income during the six months ended June 30, 2020. The Company did not recognize any interest income during the three months ended June 30, 2020 or the three and six months ended June 30, 2021 related to preferred equity investments. As of June 30, 2021, the Company had no preferred equity investments.</span></div> 9 15000000.0 0.12 0.01 0.03 P24M 400000 900000 176 3000000.0 0.08 16400000 26500000 3 0.10 32400000 6 0.075 18900000 13900000 6 33900000 13900000 0.0400 0.0175 2 P6M 13900000 0 0 0 900000 2000000.0 100000 100000 100000 200000 2300000 0.095 0.120 99 0.090 18700000 15000000.0 2300000 1400000 100000 0 FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loan receivable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,150 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loan receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mezzanine loan receivable:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of the mezzanine loan receivable was estimated using an internal valuation model that considered the expected future cash flows of the investment, the underlying collateral value, market interest rates and other credit enhancements. As such, the Company classifies the instrument as Level 3 due to the significant unobservable inputs used in determining market interest rates for investments with similar terms. Future changes in market interest rates could materially impact the estimated discounted cash flows. As of June 30, 2021 and December 31, 2020, the Company did not have any loans that were 90 days or more past due.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, there were no classification changes in assets and liabilities with Level 3 inputs in the fair value hierarchy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items Disclosed at Fair Value</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Considerable judgment is necessary to estimate the fair value disclosure of financial instruments. The estimates of fair value presented herein are not necessarily indicative of the amounts that could be realized upon disposition of the financial instruments. A summary of the face values, carrying amounts and fair values of the Company’s financial instruments as of June 30, 2021 and December 31, 2020 using Level 2 inputs for the Notes (as defined in Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below), is as follows (dollars in thousands): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.581%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Face<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Face<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 Senior unsecured notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 Senior unsecured notes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307,875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296,669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311,430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The $300.0 million aggregate principal amount of the 2025 Notes were redeemed on July 1, 2021. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further detail.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents, restricted cash, accounts and other receivables, other loans receivable, and accounts payable and accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These balances approximate their fair values due to the short-term nature of these instruments.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unsecured revolving credit facility and senior unsecured term loan:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair values approximate their carrying values as the interest rates are variable and approximate prevailing market interest rates for similar debt arrangements.</span></div> <div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.</span></div> <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loan receivable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,150 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loan receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 15150000 15150000 0 0 15000000 15000000 0 0 A summary of the face values, carrying amounts and fair values of the Company’s financial instruments as of June 30, 2021 and December 31, 2020 using Level 2 inputs for the Notes (as defined in Note 6, <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below), is as follows (dollars in thousands): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.581%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Face<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Face<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 Senior unsecured notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 Senior unsecured notes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307,875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296,669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311,430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The $300.0 million aggregate principal amount of the 2025 Notes were redeemed on July 1, 2021. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further detail.</span></div> 400000000 393842000 410000000 0 0 0 300000000 297048000 307875000 300000000 296669000 311430000 300000000.0 DEBT<div style="margin-top:6pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of the Company’s indebtedness as of June 30, 2021 and December 31, 2020 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.985%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.192%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Loan Fees</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Loan Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Senior unsecured notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,158)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,842 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Senior unsecured notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured term loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(969)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unsecured revolving credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,079)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939,921 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,406)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,594 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes Payable</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On May 10, 2017, the Company’s wholly owned subsidiary, CTR Partnership, L.P. (the “Operating Partnership”), and its wholly owned subsidiary, CareTrust Capital Corp. (together with the Operating Partnership, the “Issuers”), completed an underwritten public offering of $300.0 million aggregate principal amount of 5.25% Senior Notes due 2025. The 2025 Notes were issued at par, resulting in gross proceeds of $300.0 million and net proceeds of approximately $294.0 million after deducting underwriting fees and other offering expenses. The 2025 Notes were scheduled to mature on June 1, 2025 and bore interest at a rate of 5.25% per year. Interest on the 2025 Notes was payable on June 1 and December 1 of each year. On July 1, 2021, the Issuers redeemed all $300.0 million aggregate principal amount of the 2025 Notes. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2028 Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On June 17, 2021, the Issuers completed a private offering of $400.0 million aggregate principal amount of 3.875% Senior Notes due 2028 (the “Notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended. The Notes were issued at par, resulting in gross proceeds of $400.0 million and net proceeds of approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$393.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> after deducting underwriting fees and other offering expenses. The Notes mature on June 30, 2028. The Notes accrue interest at a rate of 3.875% per annum payable semiannually in arrears on June 30 and December 30 of each year, commencing on December 30, 2021.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Issuers may redeem some or all of the Notes at any time prior to March 30, 2028 at a price equal to 100% of the principal amount of the Notes redeemed plus accrued and unpaid interest on the Notes, if any, to, but not including, the redemption date, plus a “make-whole” premium. At any time on or after March 30, 2028, the Issuers may redeem some or all of the Notes at a redemption price equal to 100% of the principal amount of the Notes redeemed plus accrued interest on the Notes, if any, to, but not including, the redemption date. In addition, at any time on or prior to June 30, 2024, up to 40% of the aggregate principal amount of the Notes may be redeemed with the net proceeds of certain equity offerings at a redemption price of 103.875% of the aggregate principal amount of Notes to be redeemed plus accrued and unpaid interest on the Notes, if any, to, but not including, the redemption date. If certain changes of control of the Company occur, the Issuers will be required to make an offer to holders of the Notes to repurchase their Notes at a price of 101% of their principal amount plus accrued and unpaid interest, if any, to, but not including, the repurchase date.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations under the Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by the Company and all of CareTrust’s existing and future subsidiaries (other than the Issuers) that guarantee obligations under the Amended Credit Facility (as defined below); provided, however, that such guarantees are subject to automatic release under certain customary circumstances.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture governing the Notes contains customary covenants such as limiting the ability of the Company and its restricted subsidiaries to: incur or guarantee additional indebtedness; incur or guarantee secured indebtedness; pay dividends or distributions on, or redeem or repurchase, capital stock; make certain investments or other restricted payments; sell assets; enter into transactions with affiliates; merge or consolidate or sell all or substantially all of their assets; and create restrictions on the ability of the Issuers and their restricted subsidiaries to pay dividends or other amounts to the Issuers. The indenture governing the Notes also requires the Company and its restricted subsidiaries to maintain a specified ratio of unencumbered </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets to unsecured indebtedness. These covenants are subject to a number of important and significant limitations, qualifications and exceptions. The indenture governing the Notes also contains customary events of default.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, the Company was in compliance with all applicable financial covenants under the indenture governing the 2025 Notes and the indenture governing the Notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unsecured Revolving Credit Facility and Term Loan</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2019, the Operating Partnership, as the borrower, the Company, as guarantor, CareTrust GP, LLC, and certain of the Operating Partnership’s wholly owned subsidiaries entered into an amended and restated credit and guaranty agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender, and the lenders party thereto (the “Amended Credit Agreement”). The Amended Credit Agreement provides for: (i) an unsecured revolving credit facility (the “Revolving Facility”) with revolving commitments in an aggregate principal amount of $600.0 million, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments and (ii) an unsecured term loan credit facility (the “Term Loan” and, together with the Revolving Facility, the “Amended Credit Facility”) in an aggregate principal amount of $200.0 million. Borrowing availability under the Revolving Facility is subject to no default or event of default under the Amended Credit Agreement having occurred at the time of borrowing. The proceeds of the Term Loan were used, in part, to repay in full all outstanding borrowings under the Company’s prior term loan and revolving facility under its prior credit agreement. Future borrowings under the Amended Credit Facility will be used for working capital purposes, for capital expenditures, to fund acquisitions and for general corporate purposes. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rates applicable to loans under the Revolving Facility are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.10% to 0.55% per annum or LIBOR plus a margin ranging from 1.10% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). The interest rates applicable to loans under the Term Loan are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.50% to 1.20% per annum or LIBOR plus a margin ranging from 1.50% to 2.20% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). In addition, the Operating Partnership will pay a facility fee on the revolving commitments under the Revolving Facility ranging from 0.15% to 0.35% per annum, based on the debt to asset value ratio of the Company and its consolidated subsidiaries (unless the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt and the Operating Partnership elects to decrease the applicable margin as described above, in which case the Operating Partnership will pay a facility fee on the revolving commitments ranging from 0.125% to 0.30% per annum based on the credit ratings of the Company’s senior long-term unsecured debt). As of June 30, 2021, the Operating Partnership had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$200.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outstanding under the Term Loan and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$50.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of borrowings outstanding under the Revolving Facility. Subsequent to June 30, 2021, the Operating Partnership borrowed an additional $50.0 million under the Revolving Facility. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Facility has a maturity date of February 8, 2023, and includes, at the sole discretion of the Operating Partnership, two, six-month extension options. The Term Loan has a maturity date of February 8, 2026.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Facility is guaranteed, jointly and severally, by the Company and its wholly owned subsidiaries that are party to the Amended Credit Agreement (other than the Operating Partnership). The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend organizational documents and pay certain dividends and other restricted payments. The Amended Credit Agreement requires the Company to comply with financial maintenance covenants to be tested quarterly, consisting of a maximum debt to asset value ratio, a minimum fixed charge coverage ratio, a minimum tangible net worth, a maximum cash distributions to operating income ratio, a maximum secured debt to asset value ratio, a maximum secured recourse debt to asset value ratio, a maximum unsecured debt to unencumbered properties asset value ratio, a minimum unsecured interest coverage ratio and a minimum rent coverage ratio. The Amended Credit Agreement also contains certain customary events of default, including the failure to make timely payments under the Amended Credit Facility or other material indebtedness, the failure to satisfy certain covenants (including the financial maintenance covenants), the occurrence of change of control and specified events of bankruptcy and insolvency.</span></div>As of June 30, 2021, the Company was in compliance with all applicable financial covenants under the Amended Credit Agreement. <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of the Company’s indebtedness as of June 30, 2021 and December 31, 2020 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.985%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.192%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Loan Fees</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Loan Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Senior unsecured notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,158)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,842 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Senior unsecured notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured term loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(969)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unsecured revolving credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,079)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939,921 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,406)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,594 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 400000000 6158000 393842000 0 0 0 300000000 2952000 297048000 300000000 3331000 296669000 200000000 969000 199031000 200000000 1075000 198925000 50000000 0 50000000 50000000 0 50000000 950000000 10079000 939921000 550000000 4406000 545594000 300000000.0 0.0525 300000000.0 294000000.0 0.0525 300000000.0 400000000.0 0.03875 400000000.0 393800000 0.03875 1 1 0.40 1.03875 1.01 600000000.0 0.10 0.10 200000000.0 0.0010 0.0055 0.0110 0.0155 0.0050 0.0120 0.0150 0.0220 0.0015 0.0035 0.00125 0.0030 200000000.0 50000000.0 50000000.0 2 P6M EQUITY<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-The-Market Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—On March 10, 2020, the Company entered into a new equity distribution agreement to issue and sell, from time to time, up to $500.0 million in aggregate offering price of its common stock through an “at-the-market” equity offering program (the “ATM Program”). In connection with the entry into the equity distribution agreement and the commencement of the ATM Program, the Company’s “at-the-market” equity offering program pursuant to the Company’s prior equity distribution agreement, dated as of March 4, 2019, was terminated (the “Prior ATM Program”).</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no Prior ATM Program or ATM Program activity for the three and six months ended June 30, 2020. The following table summarizes the ATM Program activity for the three and six months ended June 30, 2021 (in thousands, except per share amounts).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.855%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average sales price per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross proceeds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,926 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,505 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Total gross proceeds is before $0.1 million and $0.3 million of commissions paid to the sales agents during the three and six months ended June 30, 2021, respectively, under the ATM Program. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, the Company had $476.5 million available for future issuances under the ATM Program. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Share Repurchase Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">—On March 20, 2020, the Company’s Board of Directors authorized a share repurchase program to repurchase up to $150.0 million of outstanding shares of the Company’s common stock (the “Repurchase Program”). </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Repurchases under the Repurchase Program, which expires on March 31, 2023, may be made through open market purchases, privately negotiated transactions, structured or derivative transactions, including accelerated share repurchase transactions, or other methods of acquiring shares, in each case subject to market conditions and at such times as shall be permitted by applicable securities laws and determined by management. Repurchases under the Repurchase Program may also be made pursuant to a plan adopted under Rule 10b5-1 promulgated under the Exchange Act. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company expects to finance any share repurchases under the Repurchase Program using available cash and may also use short-term borrowings under the Revolving Facility. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company did not repurchase any shares of common stock under the Repurchase Program during the three and six months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 30, 2021 and 2020</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Repurchase Program may be modified, discontinued or suspended at any time.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends on Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The following table summarizes the cash dividends on the Company’s common stock declared by the Company’s Board of Directors for the first six months of 2021 (dollars in thousands, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.265 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.265 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payment date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 15, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 15, 2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable as of record date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,714 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends record date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="display:none"/></tr></table></div> 500000000.0 0 0 The following table summarizes the ATM Program activity for the three and six months ended June 30, 2021 (in thousands, except per share amounts).<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.855%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average sales price per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross proceeds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,926 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,505 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table>(1) Total gross proceeds is before $0.1 million and $0.3 million of commissions paid to the sales agents during the three and six months ended June 30, 2021, respectively, under the ATM Program. 288000 990000 24.05 23.74 6926000 23505000 100000 300000 476500000 150000000.0 0 0 0 0 The following table summarizes the cash dividends on the Company’s common stock declared by the Company’s Board of Directors for the first six months of 2021 (dollars in thousands, except per share amounts):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.265 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.265 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payment date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 15, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 15, 2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable as of record date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,714 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends record date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="display:none"/></tr></table> 0.265 0.265 2021-04-15 2021-07-15 25633000 25714000 2021-03-31 2021-06-30 STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based awards are subject to the terms of the CareTrust REIT, Inc. and CTR Partnership, L.P. Incentive Award Plan (the “Plan”). The Plan provides for the granting of stock-based compensation, including stock options, restricted stock, performance awards, restricted stock units and other incentive awards to officers, employees and directors in connection with their employment with or services provided to the Company.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—In connection with the separation of the healthcare business and real estate business of Ensign into two separate and independent publicly traded companies (the “Spin-Off”) on June 1, 2014, employees of Ensign </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">who had unvested shares of restricted stock were given one share of CareTrust REIT unvested restricted stock totaling 207,580 shares at the Spin-Off. These restricted shares were subject to a time vesting provision only and the Company did not recognize any stock compensation expense associated with these awards. During the year ended December 31, 2020, 1,760 shares were forfeited. At June 30, 2021, there were no unvested restricted stock awards outstanding.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021 and February 2021, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted 140,514 and 99,189 shares of restricted stock, respectively, to officers and employees. Each share had a fair market value on the date of grant of $22.48 and $22.18 per share, respectively, based on the closing market price of the Company’s common stock on that date, and the shares vest in three equal annual installments beginning on the first anniversary of the grant date. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Compensation Committee granted 108,414 performance stock awards to officers. Each share had a fair market value on the date of grant of $22.48 per share, based on the closing market price of the Company’s common stock on that date. Performance stock awards are subject to both time and performance based conditions and vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM4MTFmYjU4NTg5YTQ4NWRiYjgxZjEwNTczYTlhMjZmL3NlYzozODExZmI1ODU4OWE0ODVkYmI4MWYxMDU3M2E5YTI2Zl81Mi9mcmFnOmY3OWI1NWYwZGU5ODQ1YTJhNzdjNzUxYzFlNDk1ZDllL3RleHRyZWdpb246Zjc5YjU1ZjBkZTk4NDVhMmE3N2M3NTFjMWU0OTVkOWVfMjAyMQ_25b66830-47cb-4267-b4e2-9b7638e10db8">one</span>-to three-year period. The amount of such performance awards that will ultimately vest is dependent on the Company’s Normalized Funds from Operations per share, as defined by the Compensation Committee, meeting or exceeding a specified per share amount for the applicable vesting period. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in February 2021, the Compensation Committee granted 99,189 performance stock awards to officers. Each share had an estimated fair market value on the date of grant of $27.98 per share. Performance stock awards are subject to both time and performance based conditions and cliff vest after a three-year period. The amount of such performance awards that will ultimately vest is dependent on the Company’s total shareholder return (“TSR”) performance relative to a custom TSR peer group consisting of 16 other publicly traded healthcare REITs and will range from 0% to 200% of the TSR awards initially granted. Compensation expense for awards with performance-based vesting conditions is recognized based upon the grant date fair value per share multiplied by the estimated number of performance stock awards to be earned after considering the Company’s expectation of future performance and is recognized provided that the requisite service is rendered, regardless of when, if ever, the market condition is satisfied. Forfeitures of stock-based awards are recognized as they occur.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the TSR-based performance stock awards is estimated on the date of the grant using a Monte Carlo valuation model. The risk-free rate is based on the U.S. Treasury yield curve in effect at the grant date for the expected performance period. Expected volatility is based on historical volatility for the most recent 2.84 year period ending on the grant date for the Company and the selected TSR peer group, and is calculated on a daily basis. The following are the key assumptions used in this valuation:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.298%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected service period</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield (assuming full reinvestment)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Compensation Committee granted 20,266 shares of restricted stock to non-employee members of the Board of Directors. Each share had a fair market value on the date of grant of $24.18 per share, based on the closing market price of the Company’s common stock on that date, and the shares vest in full on the earlier to occur of April 30, 2022 or the Company’s 2022 Annual Meeting of Stockholders.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized during the periods presented (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,810 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,395 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, ther</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e was $13.2 million of unamortized stock-based compensation expense related to unvested awards and the weighted-average remaining vesting period of such awards was 2.2 years.</span> 207580 1760 0 140514 99189 22.48 22.18 3 3 108414 22.48 P3Y 99189 27.98 P3Y 16 0 2 P2Y10M2D The following are the key assumptions used in this valuation:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.298%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected service period</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield (assuming full reinvestment)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 0.0027 0.5293 P2Y10M2D 0 20266 24.18 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized during the periods presented (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,810 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,395 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1810000 963000 3395000 1847000 13200000 P2Y2M12D EARNINGS PER COMMON SHARE<div style="margin-top:6pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted earnings per common share (“EPS”) for the Company’s common stock for the three and six months ended June 30, 2021 and 2020, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (amounts in thousands, except per share amounts):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income allocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for basic and diluted earnings available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,201 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,860 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,569 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,112 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,732 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive market condition stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,120 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,208 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,755 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,185 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share, diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.40 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unvest</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed restricted shares associated with its incentive award plan and unvested restricted shares issued to employees of Ensign at the Spin-Off ha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ve been excluded from the above calculation of earnings per diluted share for the three and six months ended June 30, 2021 and 2020, as applicable, when their inclusion would have been anti-dilutive.</span></div> <div style="margin-top:6pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted earnings per common share (“EPS”) for the Company’s common stock for the three and six months ended June 30, 2021 and 2020, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (amounts in thousands, except per share amounts):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income allocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for basic and diluted earnings available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,201 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,860 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,569 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,112 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,732 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive market condition stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,120 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,208 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,755 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,185 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share, diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.40 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 21317000 18935000 41803000 38260000 116000 75000 234000 148000 21201000 21201000 18860000 18860000 41569000 41569000 38112000 38112000 96082000 95208000 95732000 95185000 38000 0 23000 0 96120000 95208000 95755000 95185000 0.22 0.20 0.43 0.40 0.22 0.20 0.43 0.40 COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are and may become from time to time a party to various claims and lawsuits arising in the ordinary course of business, which are not individually or in the aggregate anticipated to have a material adverse effect on the Company’s results of operations, financial condition or cash flows. Claims and lawsuits may include matters involving general or professional liability asserted against the Company’s tenants, which are the responsibility of the Company’s tenants and for which the Company is entitled to be indemnified by its tenants under the insurance and indemnification provisions in the applicable leases.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures for each property leased under the Company’s triple-net leases are generally the responsibility of the tenant, except that, for the facilities leased to subsidiaries of Ensign and The Pennant Group, Inc. (“Pennant”), the tenant will have an option to require the Company to finance certain capital expenditures up to an aggregate of 20% of the Company’s initial investment in such property, subject to a corresponding rent increase at the time of funding. For the Company’s other triple-net master leases, subject to approval by the Company, the tenants may request capital expenditure funding that would generally be subject to a corresponding rent increase at the time of funding and which are subject to tenant compliance with the conditions to the Company’s approval and funding of their requests. As of June 30, 2021, the Company had committed to fund certain capital improvements at certain triple-net leased facilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> totaling $13.1 million, of which $11.6 million is su</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bject to rent increase at the time of funding.</span></div> 0.20 13100000 11600000 CONCENTRATION OF RISK<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Major operator concentrations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – As of June 30, 2021, Ensign leased 93 skilled nursing, multi-service campuses, assisted living and independent living facilities which had a total of 9,907 beds and units and are located in Arizona, California, Colorado, Idaho, Iowa, Nebraska, Nevada, Texas, Utah and Washington. The four states in which Ensign leases the highest concentration of properties by rental revenues as of June 30, 2021 are Texas, California, Arizona and Utah. During the three and six months ended June 30, 2021, Ensign represented 31% and 32%, respectively, of the Company’s rental income, </span><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exclusive of operating expense reimbursements. During both the three and six months ended June 30, 2020, Ensign represented 32% of the Company’s rental income, exclusive of operating expense reimbursements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensign is subject to the registration and reporting requirements of the SEC and is required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. Ensign’s financial statements, as filed with the SEC, can be found at http://www.sec.gov. The Company has not verified this information through an independent investigation or otherwise. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, Priority Management Group (“PMG”) leased 15 skilled nursing and campus facilities which had a total of 2,144 beds and units, and are located in Louisiana and Texas. During both the three and six months ended June 30, 2021, PMG represented 15% of the Company’s rental income, exclusive of operating expense reimbursements. During both the three and six months ended June 30, 2020, PMG represented 17% of the Company’s rental income, exclusive of operating expense reimbursements.</span></div> 93 9907 4 0.31 0.32 0.32 0.32 15 2144 0.15 0.15 0.17 0.17 SUBSEQUENT EVENTS<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates subsequent events in accordance with ASC 855, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company evaluates subsequent events up until the date the condensed consolidated financial statements are issued.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes Payable</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021 (the “Redemption Date”), the Issuers redeemed all $300.0 million aggregate principal amount of the 2025 Notes at a redemption price equal to 102.625% of the principal amount of the 2025 Notes, plus accrued and unpaid interest thereon up to, but not including, the Redemption Date. During the third quarter of 2021, the Company recorded a loss on the extinguishment of debt of $10.8 million, including a prepayment penalty of approximately $7.9 million and an approximately $2.9 million write-off of deferred financing costs associated with the redemption of the 2025 Notes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Acquisition and Amended Lease Agreement</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company acquired two skilled nursing facilities for approximately $32.5 million, which includes estimated capitalized acquisition costs. The facilities were leased to affiliates of Ensign. In conjunction with the acquisition of the two facilities, the Company amended and extended the initial term of an existing triple-net master lease with Ensign to include the two skilled nursing facilities. The Ensign lease, as amended, has a remaining initial term of approximately 17 years, with three five-year renewal options and CPI-based rent escalators. Annual cash rent under the amended lease increased by approximately $2.2 million, with GAAP rent increasing by $2.5 million due to a $5.0 million prepayment of rent made at closing, which will be amortized on a straight-line basis over the remaining lease term. The Operating Partnership drew on the Revolving Facility to fund the acquisition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Held for Sale</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company met the held for sale criteria on one assisted living facility operated by affiliates of Noble Senior Services, and is in the process of estimating its fair value, which is expected to be below the net carrying value of $4.9 million. The associated impairment loss is expected to be recorded in the quarter ending September 30, 2021.</span></div> 300000000.0 1.02625 -10800000 -7900000 2900000 2 32500000 2 2 P17Y 3 P5Y 2200000 2500000 5000000.0 1 4900000 XML 11 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover - shares
6 Months Ended
Jun. 30, 2021
Aug. 04, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2021  
Document Transition Report false  
Entity File Number 001-36181  
Entity Registrant Name CareTrust REIT, Inc.  
Entity Central Index Key 0001590717  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Entity Incorporation, State or Country Code MD  
Entity Tax Identification Number 46-3999490  
Entity Address, Address Line One 905 Calle Amanecer  
Entity Address, Address Line Two Suite 300  
Entity Address, City or Town San Clemente  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92673  
City Area Code 949  
Local Phone Number 542-3130  
Title of 12(b) Security Common Stock, par value $0.01 per share  
Trading Symbol CTRE  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   97,035,096
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Assets:    
Real estate investments, net $ 1,575,403 $ 1,448,099
Other real estate investments 15,150 15,000
Assets held for sale, net 0 7,226
Cash and cash equivalents 1,771 18,919
Restricted cash 309,187 0
Accounts and other receivables 1,786 1,823
Prepaid expenses and other assets, net 7,570 10,450
Deferred financing costs, net 1,552 2,042
Total assets 1,912,419 1,503,559
Liabilities and Equity:    
Senior unsecured notes payable, net 690,890 296,669
Senior unsecured term loan, net 199,031 198,925
Unsecured revolving credit facility 50,000 50,000
Accounts payable and accrued liabilities 16,804 19,572
Dividends payable 26,085 24,251
Total liabilities 982,810 589,417
Commitments and contingencies
Equity:    
Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued and outstanding as of June 30, 2021 and December 31, 2020 0 0
Common stock, $0.01 par value; 500,000,000 shares authorized, 96,296,673 and 95,215,797 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively 963 952
Additional paid-in capital 1,189,402 1,164,402
Cumulative distributions in excess of earnings (260,756) (251,212)
Total equity 929,609 914,142
Total liabilities and equity $ 1,912,419 $ 1,503,559
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, par value (in usd per share) $ 0.01 $ 0.01
Preferred stock, authorized (shares) 100,000,000 100,000,000
Preferred stock, issued (shares) 0 0
Preferred stock, outstanding (shares) 0 0
Common stock, par value (in usd per share) $ 0.01 $ 0.01
Common stock, authorized (shares) 500,000,000 500,000,000
Common stock, issued (shares) 96,296,673 95,215,797
Common stock, outstanding (shares) 96,296,673 95,215,797
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Income Statements - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenues:        
Rental income $ 47,744 $ 42,507 $ 92,990 $ 84,971
Independent living facilities $ 0 $ 615 $ 0 $ 1,240
Independent living facilities, revenue services us-gaap:HealthCareResidentServiceMember us-gaap:HealthCareResidentServiceMember us-gaap:HealthCareResidentServiceMember us-gaap:HealthCareResidentServiceMember
Interest and other income $ 514 $ 1,046 $ 1,019 $ 2,297
Total revenues 48,258 44,168 94,009 88,508
Expenses:        
Depreciation and amortization 13,843 13,239 27,316 26,399
Interest expense 6,534 5,849 12,296 12,563
Property taxes 766 837 1,462 1,322
Independent living facilities $ 0 $ 546 $ 0 $ 1,092
Independent living facilities, cost of services us-gaap:HealthCareResidentServiceMember us-gaap:HealthCareResidentServiceMember us-gaap:HealthCareResidentServiceMember us-gaap:HealthCareResidentServiceMember
General and administrative $ 5,798 $ 4,762 $ 10,940 $ 8,816
Total expenses 26,941 25,233 52,014 50,192
Other loss:        
Loss on sale of real estate 0 0 (192) (56)
Net income $ 21,317 $ 18,935 $ 41,803 $ 38,260
Earnings per common share:        
Basic (in usd per share) $ 0.22 $ 0.20 $ 0.43 $ 0.40
Diluted (in usd per share) $ 0.22 $ 0.20 $ 0.43 $ 0.40
Weighted-average number of common shares:        
Basic (in shares) 96,082 95,208 95,732 95,185
Diluted (in shares) 96,120 95,208 95,755 95,185
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Cumulative Distributions in Excess of Earnings
Beginning balance at Dec. 31, 2019 $ 927,591 $ 951 $ 1,162,990 $ (236,350)
Beginning balance (in shares) at Dec. 31, 2019   95,103,270    
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock, net (90)   (90)  
Vesting of restricted common stock, net of shares withheld for employee taxes (1,986) $ 1 (1,987)  
Vesting of restricted common stock, net of shares withheld for employee taxes (in shares)   93,061    
Amortization of stock-based compensation 884   884  
Common dividends (23,931)     (23,931)
Net income 19,325     19,325
Ending balance at Mar. 31, 2020 921,793 $ 952 1,161,797 (240,956)
Ending balance (in shares) at Mar. 31, 2020   95,196,331    
Beginning balance at Dec. 31, 2019 927,591 $ 951 1,162,990 (236,350)
Beginning balance (in shares) at Dec. 31, 2019   95,103,270    
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 38,260      
Ending balance at Jun. 30, 2020 917,446 $ 952 1,162,446 (245,952)
Ending balance (in shares) at Jun. 30, 2020   95,214,080    
Beginning balance at Mar. 31, 2020 921,793 $ 952 1,161,797 (240,956)
Beginning balance (in shares) at Mar. 31, 2020   95,196,331    
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock, net (314)   (314)  
Vesting of restricted common stock, net of shares withheld for employee taxes (in shares)   17,749    
Amortization of stock-based compensation 963   963  
Common dividends (23,931)     (23,931)
Net income 18,935     18,935
Ending balance at Jun. 30, 2020 917,446 $ 952 1,162,446 (245,952)
Ending balance (in shares) at Jun. 30, 2020   95,214,080    
Beginning balance at Dec. 31, 2020 914,142 $ 952 1,164,402 (251,212)
Beginning balance (in shares) at Dec. 31, 2020   95,215,797    
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock, net 16,191 $ 7 16,184  
Issuance of common stock, net, (in shares)   702,000    
Vesting of restricted common stock, net of shares withheld for employee taxes (1,330) $ 1 (1,331)  
Vesting of restricted common stock, net of shares withheld for employee taxes (in shares)   63,265    
Amortization of stock-based compensation 1,585   1,585  
Common dividends (25,633)     (25,633)
Net income 20,486     20,486
Ending balance at Mar. 31, 2021 925,441 $ 960 1,180,840 (256,359)
Ending balance (in shares) at Mar. 31, 2021   95,981,062    
Beginning balance at Dec. 31, 2020 914,142 $ 952 1,164,402 (251,212)
Beginning balance (in shares) at Dec. 31, 2020   95,215,797    
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 41,803      
Ending balance at Jun. 30, 2021 929,609 $ 963 1,189,402 (260,756)
Ending balance (in shares) at Jun. 30, 2021   96,296,673    
Beginning balance at Mar. 31, 2021 925,441 $ 960 1,180,840 (256,359)
Beginning balance (in shares) at Mar. 31, 2021   95,981,062    
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock, net 6,755 $ 3 6,752  
Issuance of common stock, net, (in shares)   288,000    
Vesting of restricted common stock, net of shares withheld for employee taxes (in shares)   27,611    
Amortization of stock-based compensation 1,810   1,810  
Common dividends (25,714)     (25,714)
Net income 21,317     21,317
Ending balance at Jun. 30, 2021 $ 929,609 $ 963 $ 1,189,402 $ (260,756)
Ending balance (in shares) at Jun. 30, 2021   96,296,673    
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Equity (Parenthetical) - $ / shares
3 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Mar. 31, 2020
Statement of Stockholders' Equity [Abstract]        
Common dividends (in usd per share) $ 0.265 $ 0.265 $ 0.25 $ 0.25
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Cash flows from operating activities:    
Net income $ 41,803 $ 38,260
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization (including below-market ground leases) 27,345 26,428
Amortization of deferred financing costs 1,012 975
Amortization of stock-based compensation 3,395 1,847
Straight-line rental income (20) (48)
Loss on sale of real estate 192 56
Interest income distribution from other real estate investment 0 1,346
Change in operating assets and liabilities:    
Accounts and other receivables (93) 806
Prepaid expenses and other assets, net 88 528
Accounts payable and accrued liabilities (3,165) (2,256)
Net cash provided by operating activities 70,557 67,942
Cash flows from investing activities:    
Acquisitions of real estate, net of deposits applied (147,807) (25,905)
Purchases of equipment, furniture and fixtures and improvements to real estate (3,463) (6,234)
Investment in real estate mortgage and other loans receivable (700) (13,958)
Principal payments received on real estate mortgage and other loans receivable 113 66,961
Repayment of other real estate investment 0 2,327
Net proceeds from sales of real estate 6,814 2,134
Net cash (used in) provided by investing activities (145,043) 25,325
Cash flows from financing activities:    
Proceeds from (costs paid for) the issuance of common stock, net 22,946  
Proceeds from (costs paid for) the issuance of common stock, net   (404)
Proceeds from the issuance of senior unsecured notes payable 400,000 0
Borrowings under unsecured revolving credit facility 170,000 15,000
Payments on unsecured revolving credit facility (170,000) (75,000)
Payments of deferred financing costs (5,577) 0
Net-settle adjustment on restricted stock (1,331) (1,986)
Dividends paid on common stock (49,513) (45,406)
Net cash provided by (used in) financing activities 366,525 (107,796)
Net increase (decrease) in cash, cash equivalents, and restricted cash 292,039 (14,529)
Cash, cash equivalents, and restricted cash as of the beginning of period 18,919 20,327
Cash, cash equivalents, and restricted cash as of the end of period 310,958 5,798
Supplemental disclosures of cash flow information:    
Interest paid 10,664 11,586
Supplemental schedule of noncash investing and financing activities:    
Increase in dividends payable 1,834 2,456
Right-of-use asset obtained in exchange for new operating lease obligation 0 599
Increased in deferred financing costs payable 618 0
Transfer of pre-acquisition costs to acquired assets 358 167
Sale of real estate settled with note receivable $ 0 $ 32,400
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Organization
6 Months Ended
Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization ORGANIZATION
Description of Business—CareTrust REIT, Inc.’s (“CareTrust REIT” or the “Company”) primary business consists of acquiring, financing, developing and owning real property to be leased to third-party tenants in the healthcare sector. As of June 30, 2021, the Company owned and leased to independent operators, 223 skilled nursing, multi-service campuses, assisted living and independent living facilities consisting of 23,301 operational beds and units located in 28 states with the highest concentration of properties by rental revenues located in California, Texas, Louisiana, Idaho and Arizona. As of June 30, 2021, the Company also had other real estate investments consisting of one mezzanine loan receivable with a carrying value of $15.2 million.
COVID-19—The COVID-19 pandemic has led governments and other authorities around the world, including federal, state and local authorities in the United States, to impose measures intended to reduce its spread, including restrictions on freedom of movement and business operations such as travel bans, border closings, business limitations and closures (subject to exceptions for essential operations and businesses), quarantines and shelter-in-place orders. Although most of these governmental restrictions have since been lifted or scaled back, resurgences of COVID-19 and the emergence of new variants thereof have resulted in the reimposition of certain restrictions and may lead to other restrictions being reimplemented in response to efforts to reduce the spread of COVID-19. Given the dynamic nature of these circumstances and the related adverse impact these restrictions have had, and may continue to have, on the economy generally, the Company’s business, results of operations and financial condition may be adversely impacted by the COVID-19 pandemic.
The duration and extent of the COVID-19 pandemic’s effect on the Company’s operational and financial performance, and the operational and financial performance of the Company’s tenants, will depend on future developments, which are highly uncertain and cannot be predicted at this time, including the rate of public acceptance and usage of vaccines and the effectiveness of vaccines in limiting the spread of COVID-19 and its variants, resurgences of COVID-19 and, in particular, new and more contagious and/or vaccine resistant variants, actions taken to contain the spread of COVID-19 and how quickly and to what extent normal economic and operating conditions can resume. The adverse impact of the COVID-19 pandemic on the Company’s business, results of operations and financial condition could be material.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. All intercompany transactions and account balances within the Company have been eliminated.
Restricted Cash—The Company presents cash and cash equivalents separately from restricted cash within the Company’s condensed consolidated balance sheets. The Company includes restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the condensed consolidated statements of cash flows. The Company provides a reconciliation between the balance sheets and statements of cash flows, as required when the balance includes more than one line item for cash, cash equivalents, and restricted cash. The Company also provides a disclosure of the nature of the restrictions related to material restricted cash balances.
As of June 30, 2021, the Company had $309.2 million in restricted cash related to the cash deposited with the trustee to pay the redemption price of the $300.0 million aggregate principal amount of 5.25% Senior Notes due 2025 (the “2025 Notes”). The 2025 Notes were redeemed on July 1, 2021. See Note 6, Debt, and Note 12, Subsequent Events, for further detail.
Cash, cash equivalents and restricted cash consisted of the following as of June 30, 2021 and December 31, 2020 (dollars in thousands):
June 30, 2021December 31, 2020
Cash and cash equivalents$1,771 $18,919 
Restricted cash309,187 — 
Cash, cash equivalents and restricted cash$310,958 $18,919 
 Recent Accounting Pronouncements— In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), that provides optional relief to applying reference rate reform to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”). For U.S. Dollar LIBOR, the overnight, one-month, three-month, six-month and one-year LIBOR rates will be discontinued in June 2023, while other U.S. Dollar LIBOR rates will be discontinued at the end of 2021. The amendments in this update are effective immediately and may be applied through December 31, 2022. The Company is still evaluating the impact of ASU 2020-04 and expects to take full advantage of the offered optional expedients and exceptions, but does not expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Real Estate Investments, Net
6 Months Ended
Jun. 30, 2021
Real Estate [Abstract]  
Real Estate Investments, Net REAL ESTATE INVESTMENTS, NET
The following table summarizes the Company’s investment in owned properties as of June 30, 2021 and December 31, 2020 (dollars in thousands):
June 30, 2021December 31, 2020
Land$244,740 $205,356 
Buildings and improvements1,588,961 1,477,849 
Integral equipment, furniture and fixtures101,441 97,836 
Identified intangible assets2,658 2,352 
Real estate investments1,937,800 1,783,393 
Accumulated depreciation and amortization(362,397)(335,294)
Real estate investments, net$1,575,403 $1,448,099 
As of June 30, 2021, all 223 of the Company’s facilities were leased to various operators under triple-net leases. All of these leases contain annual escalators based on the percentage change in the Consumer Price Index (“CPI”) (but not less than zero), some of which are subject to a cap, or fixed rent escalators.
As of June 30, 2021, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements, were (dollars in thousands):
YearAmount
2021 (six months)$93,754 
2022188,644 
2023188,438 
2024187,091 
2025187,062 
2026187,166 
Thereafter1,020,115 
Total$2,052,270 
Tenant Purchase Options
Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):
Asset TypePropertiesLease ExpirationNext Option Open Date
Option Type(1)
Current Cash Rent(2)
ALF7October 20341/1/2022A$3,282 
SNF11November 20301/1/2022C4,800 
SNF1March 20294/1/2022
B / C(3)
779 
SNF / Campus2October 20321/1/2023B959 
SNF4November 203412/1/2024B3,789 
ALF2October 20341/1/2026A1,559 
(1) Option type includes:
A - Fixed base price plus a specified share on any appreciation.
B - Fixed base price.
C - Fixed capitalization rate on lease revenue.
(2) Based on annualized cash revenue for contracts in place as of June 30, 2021.
(3) Purchase option reflects two option types.
Rental Income
The following table summarizes components of the Company’s rental income (dollars in thousands):
For the Three Months Ended June 30,
For the Six Months Ended June 30,
Rental Income2021202020212020
Contractual rent due(1)
$47,736 $42,485 $92,907 $84,923 
Straight-line rent22 20 48 
Lease termination revenue(2)
— — 63 — 
Total$47,744 $42,507 $92,990 $84,971 
(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received.
(2) During the six months ended June 30, 2021, in connection with the agreement to terminate its lease agreements with affiliates of Metron Integrated Health Systems (“Metron”) and to sell the facilities to a third-party, the Company received $0.1 million from Metron affiliates.
Recent Real Estate Acquisitions
The following table summarizes the Company’s acquisitions for the six months ended June 30, 2021 (dollars in thousands):
Type of Property
Purchase Price(1)
Initial Annual Cash RentNumber of Properties
Number of Beds/Units(2)
Skilled nursing$25,457 $2,295 (4)268 
Multi-service campuses(3)
125,708 8,604 640 
Total$151,165 $10,899 908 
(1) Purchase price includes capitalized acquisition costs.
(2) The number of beds/units includes operating beds at the acquisition date.
(3) Initial annual cash rent represents the first twelve months of rent upon commencement of the Company’s long-term net leases, which occurred during the three months ended June 30, 2021, upon the tenants’ receipt of licensing approval and increases to $9.4 million in the second year with CPI-based annual escalators thereafter.
(4) Included within initial annual cash rent is approximately $0.8 million of initial rent which is subject to a fixed escalator in the first twelve months and increases to $0.9 million in the second year with CPI-based annual escalators thereafter.

Asset Sales and Assets Held for Sale
As of June 30, 2021, there were no assets classified as held for sale. During the fourth quarter of 2020, the Company met the criteria to classify one skilled nursing facility operated by affiliates of Five Oaks Healthcare, LLC as held for sale. Assets held for sale include the net book value of property the Company plans to sell within the next year. If the determination is made that the Company no longer expects to sell an asset within the next year, the asset is reclassified out of assets held for sale. On February 1, 2021, the Company closed on the sale of the one skilled nursing facility consisting of 90 beds located in Washington with a carrying value of $7.2 million, for net sales proceeds of $7.0 million. During the six months ended June 30, 2021, the Company recorded a loss of $0.2 million in connection with the sale.
On February 14, 2020, the Company closed on the sale of six skilled nursing facilities formerly operated by affiliates of Metron. In connection with the sale for $36.0 million, the Company received $3.5 million in cash and provided subsidiaries of Cascade Capital Group, LLC (“Cascade”), the purchaser of the properties, with a short-term mortgage loan secured by these properties for $32.4 million. The mortgage loan bore interest at 7.5% and initially had a maturity date of March 31, 2020. In connection with the sale, the Company recognized a loss of approximately $0.1 million during the three months ended March 31, 2020. In April 2020, the mortgage loan was settled with $18.9 million in cash and a new mortgage loan for $13.9 million. In July 2020, the Company received prepayment in full, including accrued interest, for the new $13.9 million mortgage loan. See Note 4, Other Real Estate Investments, Net, for further detail on the mortgage loan.
Lease Amendments
Five Oaks Lease Termination and Amended Ensign Master Lease. On June 1, 2021, operating affiliates of The Ensign Group, Inc. (“Ensign”) acquired certain operations and assets of Five Oaks Healthcare, LLC (“Five Oaks”) under an agreement with Five Oaks. The agreement granted Ensign the right to occupy and operate four of the Company’s skilled nursing facilities in Washington that were previously being operated by Five Oaks. In conjunction with consenting to the transfer, the Company terminated the existing Five Oaks master lease, and amended and extended the term of an existing triple-net master lease with Ensign to include the four skilled nursing facilities. The Ensign lease, as amended, has a remaining term of approximately 15 years, with three five-year renewal options and CPI-based rent escalators. Annual cash rent under the terminated Five Oaks master lease was approximately $2.6 million, and annual cash rent under the amended Ensign lease increased by the same amount.
Twenty/20 Lease Termination and New Noble Master Lease. On December 1, 2020, five assisted living facilities in Virginia operated by Twenty/20 Management, Inc. (“Twenty/20”) were transferred to affiliates of Noble VA Holdings, LLC (“Noble”). In connection with the transfer, the Company entered into a new triple-net master lease with Noble. The new lease has a remaining initial term of approximately 14 years, with two five-year renewal options and CPI-based rent escalators. Initial annual cash rent under the new lease is approximately $3.2 million.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Other Real Estate Investments, Net
6 Months Ended
Jun. 30, 2021
Real Estate [Abstract]  
Other Real Estate Investments, Net OTHER REAL ESTATE INVESTMENTS, NET
Mezzanine Loan Receivable—In November 2020, the Company provided Next VA Star Realty Holdings, LLC a mezzanine loan for nine skilled nursing facilities secured by membership interests in affiliates of Next VA Star Realty Holdings, LLC for approximately $15.0 million, at an annual interest rate of 12%. The loan requires monthly interest payments, is set to mature on November 30, 2025, and may (subject to certain restrictions) be prepaid before the maturity date if paid in full and for an exit fee ranging from 1% to 3% of the loan plus unpaid interest payments equal to 24 months (less the amount of monthly interest payments made by the borrower through the date of prepayment). During the three and six months ended June 30, 2021, the Company recognized $0.4 million and $0.9 million, respectively, of interest income related to its mezzanine loan.
Mortgage Loans Receivable—In July 2019, the Company provided MCRC, LLC a real estate loan secured by a 176-bed skilled nursing facility in Manteca, California for $3.0 million, which bore a fixed interest rate of 8% and required monthly interest payments. Concurrently, the Company entered into a purchase and sale agreement to purchase the Manteca facility from MCRC, LLC for approximately $16.4 million subject to normal diligence and other contingencies. The loan documents provided for a maturity date of the earlier to occur of the closing date of the acquisition, or five business days following the termination of the purchase and sale agreement.  MCRC, LLC breached its obligation to sell the Manteca facility to the Company on the terms outlined in the purchase and sale agreement and to repay the real estate loan upon its stated maturity. As a result, the Company commenced non-judicial foreclosure proceedings with respect to the Manteca facility. In January 2020, the borrower further collateralized the loan by causing one of its affiliates to grant the Company a deed of trust in the real estate and improvements that constitute Palm Gardens Assisted Living Facility in Yolo County, California. During the three months ended June 30, 2020, payment for the loan principal and accrued interest, including default interest, as well as reimbursement for attorney’s fees and certain other costs of suit, were received in full by the Company and, as a result, the Company withdrew all foreclosure-related proceedings related to the Manteca facility loan.
In September 2019, the Company provided affiliates of CommuniCare Family of Companies (“CommuniCare”) a $26.5 million loan secured by mortgages on the three skilled nursing facilities sold to CommuniCare, which bore a fixed interest rate of 10%. The mortgage loan, which required CommuniCare to make monthly interest payments, was set to mature on February 29, 2020 and included an option to be prepaid before the maturity date. In January 2020, the Company amended the mortgage loan’s maturity date to April 30, 2020. In April 2020, the Company amended the mortgage loan’s maturity date to May 29, 2020. During the three months ended June 30, 2020, payment for the mortgage loan and accrued interest was received in full by the Company.
In February 2020, the Company provided subsidiaries of Cascade a $32.4 million loan secured by mortgages on the six skilled nursing facilities formerly operated by affiliates of Metron and sold to Cascade in February 2020, as discussed in Note 3, Real Estate Investments, Net. The mortgage loan bore interest at 7.5% and initially had a maturity date of March 31, 2020. In April 2020, the mortgage loan was settled in connection with a new mortgage loan transaction between the Company and a third-party institutional lender as co-lenders, pursuant to which the Company received $18.9 million in cash and a new mortgage loan for $13.9 million. The new mortgage loan with Cascade was secured by the same six skilled nursing facilities purchased by Cascade and was for a combined principal amount of $33.9 million, with the Company’s $13.9 million portion of the indebtedness initially bearing interest at a variable rate equal to LIBOR plus 4.00%, subject to a LIBOR floor of 1.75%. The
new mortgage loan had a maturity date of April 29, 2022 and included two six-month extension options. In July 2020, prepayment for the mortgage loan of $13.9 million and accrued interest was received in full by the Company.
As of June 30, 2021, the Company had no mortgage loan receivables.
During both the three and six months ended June 30, 2021, the Company recognized no interest income related to mortgage loans. During the three and six months ended June 30, 2020, the Company recognized $0.9 million and $2.0 million of interest income, respectively, related to its mortgage loans. During the three and six months ended June 30, 2021, the Company recognized less than $0.1 million and $0.1 million of interest income, respectively, related to its other loans receivable. During the three and six months ended June 30, 2020, the Company recognized $0.1 million and $0.2 million of interest income, respectively, related to its other loans receivable.
Preferred Equity Investments—In September 2016, the Company completed a $2.3 million preferred equity investment with an affiliate of Cascadia Development, LLC. The preferred equity investment yielded a return equal to prime plus 9.5% but in no event less than 12.0% calculated on a quarterly basis on the outstanding carrying value of the investment. The investment was used to develop a 99-bed skilled nursing facility in Boise, Idaho. In connection with its investment, the Company obtained an option to purchase the development at a fixed-formula price upon stabilization, with an initial lease yield of at least 9.0%. The project was completed in the first quarter of 2018 and began lease-up during the second quarter of 2018. In January 2020, the Company purchased the skilled nursing facility for approximately $18.7 million, inclusive of transaction costs. The Company paid $15.0 million after receiving back its initial investment of $2.3 million and cumulative contractual preferred return through January 17, 2020, the acquisition date, of $1.4 million, of which less than $0.1 million was recognized as interest income during the six months ended June 30, 2020. The Company did not recognize any interest income during the three months ended June 30, 2020 or the three and six months ended June 30, 2021 related to preferred equity investments. As of June 30, 2021, the Company had no preferred equity investments.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements
6 Months Ended
Jun. 30, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements FAIR VALUE MEASUREMENTS
The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.

Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.

The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.
Items Measured at Fair Value on a Recurring Basis
The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):
Level 1Level 2Level 3
Balance as of June 30, 2021
Assets:
Mezzanine loan receivable$— $— $15,150 $15,150 
Level 1Level 2Level 3
Balance as of December 31, 2020
Assets:
Mezzanine loan receivable$— $— $15,000 $15,000 

Mezzanine loan receivable: The fair value of the mezzanine loan receivable was estimated using an internal valuation model that considered the expected future cash flows of the investment, the underlying collateral value, market interest rates and other credit enhancements. As such, the Company classifies the instrument as Level 3 due to the significant unobservable inputs used in determining market interest rates for investments with similar terms. Future changes in market interest rates could materially impact the estimated discounted cash flows. As of June 30, 2021 and December 31, 2020, the Company did not have any loans that were 90 days or more past due.
For the three and six months ended June 30, 2021, there were no classification changes in assets and liabilities with Level 3 inputs in the fair value hierarchy.

Items Disclosed at Fair Value

Considerable judgment is necessary to estimate the fair value disclosure of financial instruments. The estimates of fair value presented herein are not necessarily indicative of the amounts that could be realized upon disposition of the financial instruments. A summary of the face values, carrying amounts and fair values of the Company’s financial instruments as of June 30, 2021 and December 31, 2020 using Level 2 inputs for the Notes (as defined in Note 6, Debt, below), is as follows (dollars in thousands):  
 June 30, 2021December 31, 2020
 LevelFace
Value
Carrying
Amount
Fair
Value
Face
Value
Carrying
Amount
Fair
Value
Financial liabilities:
2028 Senior unsecured notes payable2$400,000 $393,842 $410,000 $— $— $— 
2025 Senior unsecured notes payable(1)
2300,000 297,048 307,875 300,000 296,669 311,430 
(1) The $300.0 million aggregate principal amount of the 2025 Notes were redeemed on July 1, 2021. See Note 12, Subsequent Events, for further detail.

Cash and cash equivalents, restricted cash, accounts and other receivables, other loans receivable, and accounts payable and accrued liabilities: These balances approximate their fair values due to the short-term nature of these instruments.

Unsecured revolving credit facility and senior unsecured term loan: The fair values approximate their carrying values as the interest rates are variable and approximate prevailing market interest rates for similar debt arrangements.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Debt
6 Months Ended
Jun. 30, 2021
Debt Disclosure [Abstract]  
Debt DEBT
The following table summarizes the balance of the Company’s indebtedness as of June 30, 2021 and December 31, 2020 (dollars in thousands):
June 30, 2021December 31, 2020
Principal AmountDeferred Loan FeesCarrying ValuePrincipal AmountDeferred Loan FeesCarrying Value
2028 Senior unsecured notes payable$400,000 $(6,158)$393,842 $— $— $— 
2025 Senior unsecured notes payable300,000 (2,952)297,048 300,000 (3,331)296,669 
Senior unsecured term loan200,000 (969)199,031 200,000 (1,075)198,925 
Unsecured revolving credit facility50,000 — 50,000 50,000 — 50,000 
$950,000 $(10,079)$939,921 $550,000 $(4,406)$545,594 

Senior Unsecured Notes Payable
2025 Senior Notes. On May 10, 2017, the Company’s wholly owned subsidiary, CTR Partnership, L.P. (the “Operating Partnership”), and its wholly owned subsidiary, CareTrust Capital Corp. (together with the Operating Partnership, the “Issuers”), completed an underwritten public offering of $300.0 million aggregate principal amount of 5.25% Senior Notes due 2025. The 2025 Notes were issued at par, resulting in gross proceeds of $300.0 million and net proceeds of approximately $294.0 million after deducting underwriting fees and other offering expenses. The 2025 Notes were scheduled to mature on June 1, 2025 and bore interest at a rate of 5.25% per year. Interest on the 2025 Notes was payable on June 1 and December 1 of each year. On July 1, 2021, the Issuers redeemed all $300.0 million aggregate principal amount of the 2025 Notes. See Note 12, Subsequent Events, for additional information.
2028 Senior Notes. On June 17, 2021, the Issuers completed a private offering of $400.0 million aggregate principal amount of 3.875% Senior Notes due 2028 (the “Notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended. The Notes were issued at par, resulting in gross proceeds of $400.0 million and net proceeds of approximately $393.8 million after deducting underwriting fees and other offering expenses. The Notes mature on June 30, 2028. The Notes accrue interest at a rate of 3.875% per annum payable semiannually in arrears on June 30 and December 30 of each year, commencing on December 30, 2021.
The Issuers may redeem some or all of the Notes at any time prior to March 30, 2028 at a price equal to 100% of the principal amount of the Notes redeemed plus accrued and unpaid interest on the Notes, if any, to, but not including, the redemption date, plus a “make-whole” premium. At any time on or after March 30, 2028, the Issuers may redeem some or all of the Notes at a redemption price equal to 100% of the principal amount of the Notes redeemed plus accrued interest on the Notes, if any, to, but not including, the redemption date. In addition, at any time on or prior to June 30, 2024, up to 40% of the aggregate principal amount of the Notes may be redeemed with the net proceeds of certain equity offerings at a redemption price of 103.875% of the aggregate principal amount of Notes to be redeemed plus accrued and unpaid interest on the Notes, if any, to, but not including, the redemption date. If certain changes of control of the Company occur, the Issuers will be required to make an offer to holders of the Notes to repurchase their Notes at a price of 101% of their principal amount plus accrued and unpaid interest, if any, to, but not including, the repurchase date.
The obligations under the Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by the Company and all of CareTrust’s existing and future subsidiaries (other than the Issuers) that guarantee obligations under the Amended Credit Facility (as defined below); provided, however, that such guarantees are subject to automatic release under certain customary circumstances.
The indenture governing the Notes contains customary covenants such as limiting the ability of the Company and its restricted subsidiaries to: incur or guarantee additional indebtedness; incur or guarantee secured indebtedness; pay dividends or distributions on, or redeem or repurchase, capital stock; make certain investments or other restricted payments; sell assets; enter into transactions with affiliates; merge or consolidate or sell all or substantially all of their assets; and create restrictions on the ability of the Issuers and their restricted subsidiaries to pay dividends or other amounts to the Issuers. The indenture governing the Notes also requires the Company and its restricted subsidiaries to maintain a specified ratio of unencumbered
assets to unsecured indebtedness. These covenants are subject to a number of important and significant limitations, qualifications and exceptions. The indenture governing the Notes also contains customary events of default.
As of June 30, 2021, the Company was in compliance with all applicable financial covenants under the indenture governing the 2025 Notes and the indenture governing the Notes.

Unsecured Revolving Credit Facility and Term Loan
On February 8, 2019, the Operating Partnership, as the borrower, the Company, as guarantor, CareTrust GP, LLC, and certain of the Operating Partnership’s wholly owned subsidiaries entered into an amended and restated credit and guaranty agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender, and the lenders party thereto (the “Amended Credit Agreement”). The Amended Credit Agreement provides for: (i) an unsecured revolving credit facility (the “Revolving Facility”) with revolving commitments in an aggregate principal amount of $600.0 million, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments and (ii) an unsecured term loan credit facility (the “Term Loan” and, together with the Revolving Facility, the “Amended Credit Facility”) in an aggregate principal amount of $200.0 million. Borrowing availability under the Revolving Facility is subject to no default or event of default under the Amended Credit Agreement having occurred at the time of borrowing. The proceeds of the Term Loan were used, in part, to repay in full all outstanding borrowings under the Company’s prior term loan and revolving facility under its prior credit agreement. Future borrowings under the Amended Credit Facility will be used for working capital purposes, for capital expenditures, to fund acquisitions and for general corporate purposes.
The interest rates applicable to loans under the Revolving Facility are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.10% to 0.55% per annum or LIBOR plus a margin ranging from 1.10% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). The interest rates applicable to loans under the Term Loan are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.50% to 1.20% per annum or LIBOR plus a margin ranging from 1.50% to 2.20% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). In addition, the Operating Partnership will pay a facility fee on the revolving commitments under the Revolving Facility ranging from 0.15% to 0.35% per annum, based on the debt to asset value ratio of the Company and its consolidated subsidiaries (unless the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt and the Operating Partnership elects to decrease the applicable margin as described above, in which case the Operating Partnership will pay a facility fee on the revolving commitments ranging from 0.125% to 0.30% per annum based on the credit ratings of the Company’s senior long-term unsecured debt). As of June 30, 2021, the Operating Partnership had $200.0 million outstanding under the Term Loan and $50.0 million of borrowings outstanding under the Revolving Facility. Subsequent to June 30, 2021, the Operating Partnership borrowed an additional $50.0 million under the Revolving Facility. See Note 12, Subsequent Events for additional information.
The Revolving Facility has a maturity date of February 8, 2023, and includes, at the sole discretion of the Operating Partnership, two, six-month extension options. The Term Loan has a maturity date of February 8, 2026.
The Amended Credit Facility is guaranteed, jointly and severally, by the Company and its wholly owned subsidiaries that are party to the Amended Credit Agreement (other than the Operating Partnership). The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend organizational documents and pay certain dividends and other restricted payments. The Amended Credit Agreement requires the Company to comply with financial maintenance covenants to be tested quarterly, consisting of a maximum debt to asset value ratio, a minimum fixed charge coverage ratio, a minimum tangible net worth, a maximum cash distributions to operating income ratio, a maximum secured debt to asset value ratio, a maximum secured recourse debt to asset value ratio, a maximum unsecured debt to unencumbered properties asset value ratio, a minimum unsecured interest coverage ratio and a minimum rent coverage ratio. The Amended Credit Agreement also contains certain customary events of default, including the failure to make timely payments under the Amended Credit Facility or other material indebtedness, the failure to satisfy certain covenants (including the financial maintenance covenants), the occurrence of change of control and specified events of bankruptcy and insolvency.
As of June 30, 2021, the Company was in compliance with all applicable financial covenants under the Amended Credit Agreement.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Equity
6 Months Ended
Jun. 30, 2021
Equity [Abstract]  
Equity EQUITY
Common Stock
At-The-Market Offering—On March 10, 2020, the Company entered into a new equity distribution agreement to issue and sell, from time to time, up to $500.0 million in aggregate offering price of its common stock through an “at-the-market” equity offering program (the “ATM Program”). In connection with the entry into the equity distribution agreement and the commencement of the ATM Program, the Company’s “at-the-market” equity offering program pursuant to the Company’s prior equity distribution agreement, dated as of March 4, 2019, was terminated (the “Prior ATM Program”).
There was no Prior ATM Program or ATM Program activity for the three and six months ended June 30, 2020. The following table summarizes the ATM Program activity for the three and six months ended June 30, 2021 (in thousands, except per share amounts).
For the Three Months EndedFor the Six Months Ended
June 30, 2021June 30, 2021
Number of shares288 990 
Average sales price per share$24.05 $23.74 
Gross proceeds(1)
$6,926 $23,505 
(1) Total gross proceeds is before $0.1 million and $0.3 million of commissions paid to the sales agents during the three and six months ended June 30, 2021, respectively, under the ATM Program.
As of June 30, 2021, the Company had $476.5 million available for future issuances under the ATM Program.
Share Repurchase Program—On March 20, 2020, the Company’s Board of Directors authorized a share repurchase program to repurchase up to $150.0 million of outstanding shares of the Company’s common stock (the “Repurchase Program”). Repurchases under the Repurchase Program, which expires on March 31, 2023, may be made through open market purchases, privately negotiated transactions, structured or derivative transactions, including accelerated share repurchase transactions, or other methods of acquiring shares, in each case subject to market conditions and at such times as shall be permitted by applicable securities laws and determined by management. Repurchases under the Repurchase Program may also be made pursuant to a plan adopted under Rule 10b5-1 promulgated under the Exchange Act. The Company expects to finance any share repurchases under the Repurchase Program using available cash and may also use short-term borrowings under the Revolving Facility. The Company did not repurchase any shares of common stock under the Repurchase Program during the three and six months ended June 30, 2021 and 2020. The Repurchase Program may be modified, discontinued or suspended at any time.
Dividends on Common Stock—The following table summarizes the cash dividends on the Company’s common stock declared by the Company’s Board of Directors for the first six months of 2021 (dollars in thousands, except per share amounts):
For the Three Months Ended
March 31, 2021June 30, 2021
Dividends declared per share$0.265 $0.265 
Dividends payment dateApril 15, 2021July 15, 2021
Dividends payable as of record date$25,633 $25,714 
Dividends record dateMarch 31, 2021June 30, 2021
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation
6 Months Ended
Jun. 30, 2021
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation STOCK-BASED COMPENSATION
All stock-based awards are subject to the terms of the CareTrust REIT, Inc. and CTR Partnership, L.P. Incentive Award Plan (the “Plan”). The Plan provides for the granting of stock-based compensation, including stock options, restricted stock, performance awards, restricted stock units and other incentive awards to officers, employees and directors in connection with their employment with or services provided to the Company.
Restricted Stock Awards—In connection with the separation of the healthcare business and real estate business of Ensign into two separate and independent publicly traded companies (the “Spin-Off”) on June 1, 2014, employees of Ensign
who had unvested shares of restricted stock were given one share of CareTrust REIT unvested restricted stock totaling 207,580 shares at the Spin-Off. These restricted shares were subject to a time vesting provision only and the Company did not recognize any stock compensation expense associated with these awards. During the year ended December 31, 2020, 1,760 shares were forfeited. At June 30, 2021, there were no unvested restricted stock awards outstanding.
In January 2021 and February 2021, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted 140,514 and 99,189 shares of restricted stock, respectively, to officers and employees. Each share had a fair market value on the date of grant of $22.48 and $22.18 per share, respectively, based on the closing market price of the Company’s common stock on that date, and the shares vest in three equal annual installments beginning on the first anniversary of the grant date.
In January 2021, the Compensation Committee granted 108,414 performance stock awards to officers. Each share had a fair market value on the date of grant of $22.48 per share, based on the closing market price of the Company’s common stock on that date. Performance stock awards are subject to both time and performance based conditions and vest over a one-to three-year period. The amount of such performance awards that will ultimately vest is dependent on the Company’s Normalized Funds from Operations per share, as defined by the Compensation Committee, meeting or exceeding a specified per share amount for the applicable vesting period.
Additionally, in February 2021, the Compensation Committee granted 99,189 performance stock awards to officers. Each share had an estimated fair market value on the date of grant of $27.98 per share. Performance stock awards are subject to both time and performance based conditions and cliff vest after a three-year period. The amount of such performance awards that will ultimately vest is dependent on the Company’s total shareholder return (“TSR”) performance relative to a custom TSR peer group consisting of 16 other publicly traded healthcare REITs and will range from 0% to 200% of the TSR awards initially granted. Compensation expense for awards with performance-based vesting conditions is recognized based upon the grant date fair value per share multiplied by the estimated number of performance stock awards to be earned after considering the Company’s expectation of future performance and is recognized provided that the requisite service is rendered, regardless of when, if ever, the market condition is satisfied. Forfeitures of stock-based awards are recognized as they occur.
The fair value of the TSR-based performance stock awards is estimated on the date of the grant using a Monte Carlo valuation model. The risk-free rate is based on the U.S. Treasury yield curve in effect at the grant date for the expected performance period. Expected volatility is based on historical volatility for the most recent 2.84 year period ending on the grant date for the Company and the selected TSR peer group, and is calculated on a daily basis. The following are the key assumptions used in this valuation:
Risk-free interest rate0.27 %
Expected stock price volatility52.93 %
Expected service period2.84 years
Expected dividend yield (assuming full reinvestment)— %
In April 2021, the Compensation Committee granted 20,266 shares of restricted stock to non-employee members of the Board of Directors. Each share had a fair market value on the date of grant of $24.18 per share, based on the closing market price of the Company’s common stock on that date, and the shares vest in full on the earlier to occur of April 30, 2022 or the Company’s 2022 Annual Meeting of Stockholders.
The following table summarizes the stock-based compensation expense recognized during the periods presented (dollars in thousands):
 For the Three Months Ended June 30,For the Six Months Ended June 30,
 2021202020212020
Stock-based compensation expense$1,810 $963 $3,395 $1,847 
As of June 30, 2021, there was $13.2 million of unamortized stock-based compensation expense related to unvested awards and the weighted-average remaining vesting period of such awards was 2.2 years.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings Per Common Share
6 Months Ended
Jun. 30, 2021
Earnings Per Share [Abstract]  
Earnings Per Common Share EARNINGS PER COMMON SHARE
The following table presents the calculation of basic and diluted earnings per common share (“EPS”) for the Company’s common stock for the three and six months ended June 30, 2021 and 2020, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (amounts in thousands, except per share amounts):
 
 For the Three Months Ended June 30,For the Six Months Ended June 30,
 2021202020212020
Numerator:
Net income$21,317 $18,935 $41,803 $38,260 
Less: Net income allocated to participating securities(116)(75)(234)(148)
Numerator for basic and diluted earnings available to common stockholders$21,201 $18,860 $41,569 $38,112 
Denominator:
Weighted-average basic common shares outstanding96,082 95,208 95,732 95,185 
Dilutive market condition stock awards38 — 23 — 
Weighted-average diluted common shares outstanding96,120 95,208 95,755 95,185 
Earnings per common share, basic$0.22 $0.20 $0.43 $0.40 
Earnings per common share, diluted$0.22 $0.20 $0.43 $0.40 
The Company’s unvested restricted shares associated with its incentive award plan and unvested restricted shares issued to employees of Ensign at the Spin-Off have been excluded from the above calculation of earnings per diluted share for the three and six months ended June 30, 2021 and 2020, as applicable, when their inclusion would have been anti-dilutive.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies COMMITMENTS AND CONTINGENCIES
The Company and its subsidiaries are and may become from time to time a party to various claims and lawsuits arising in the ordinary course of business, which are not individually or in the aggregate anticipated to have a material adverse effect on the Company’s results of operations, financial condition or cash flows. Claims and lawsuits may include matters involving general or professional liability asserted against the Company’s tenants, which are the responsibility of the Company’s tenants and for which the Company is entitled to be indemnified by its tenants under the insurance and indemnification provisions in the applicable leases.
Capital expenditures for each property leased under the Company’s triple-net leases are generally the responsibility of the tenant, except that, for the facilities leased to subsidiaries of Ensign and The Pennant Group, Inc. (“Pennant”), the tenant will have an option to require the Company to finance certain capital expenditures up to an aggregate of 20% of the Company’s initial investment in such property, subject to a corresponding rent increase at the time of funding. For the Company’s other triple-net master leases, subject to approval by the Company, the tenants may request capital expenditure funding that would generally be subject to a corresponding rent increase at the time of funding and which are subject to tenant compliance with the conditions to the Company’s approval and funding of their requests. As of June 30, 2021, the Company had committed to fund certain capital improvements at certain triple-net leased facilities totaling $13.1 million, of which $11.6 million is subject to rent increase at the time of funding.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Concentration of Risk
6 Months Ended
Jun. 30, 2021
Risks and Uncertainties [Abstract]  
Concentration of Risk CONCENTRATION OF RISKMajor operator concentrations – As of June 30, 2021, Ensign leased 93 skilled nursing, multi-service campuses, assisted living and independent living facilities which had a total of 9,907 beds and units and are located in Arizona, California, Colorado, Idaho, Iowa, Nebraska, Nevada, Texas, Utah and Washington. The four states in which Ensign leases the highest concentration of properties by rental revenues as of June 30, 2021 are Texas, California, Arizona and Utah. During the three and six months ended June 30, 2021, Ensign represented 31% and 32%, respectively, of the Company’s rental income,
exclusive of operating expense reimbursements. During both the three and six months ended June 30, 2020, Ensign represented 32% of the Company’s rental income, exclusive of operating expense reimbursements.
Ensign is subject to the registration and reporting requirements of the SEC and is required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. Ensign’s financial statements, as filed with the SEC, can be found at http://www.sec.gov. The Company has not verified this information through an independent investigation or otherwise.
As of June 30, 2021, Priority Management Group (“PMG”) leased 15 skilled nursing and campus facilities which had a total of 2,144 beds and units, and are located in Louisiana and Texas. During both the three and six months ended June 30, 2021, PMG represented 15% of the Company’s rental income, exclusive of operating expense reimbursements. During both the three and six months ended June 30, 2020, PMG represented 17% of the Company’s rental income, exclusive of operating expense reimbursements.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events
6 Months Ended
Jun. 30, 2021
Subsequent Events [Abstract]  
Subsequent Events SUBSEQUENT EVENTS
The Company evaluates subsequent events in accordance with ASC 855, Subsequent Events. The Company evaluates subsequent events up until the date the condensed consolidated financial statements are issued.
Senior Unsecured Notes Payable
On July 1, 2021 (the “Redemption Date”), the Issuers redeemed all $300.0 million aggregate principal amount of the 2025 Notes at a redemption price equal to 102.625% of the principal amount of the 2025 Notes, plus accrued and unpaid interest thereon up to, but not including, the Redemption Date. During the third quarter of 2021, the Company recorded a loss on the extinguishment of debt of $10.8 million, including a prepayment penalty of approximately $7.9 million and an approximately $2.9 million write-off of deferred financing costs associated with the redemption of the 2025 Notes.
Recent Acquisition and Amended Lease Agreement
In August 2021, the Company acquired two skilled nursing facilities for approximately $32.5 million, which includes estimated capitalized acquisition costs. The facilities were leased to affiliates of Ensign. In conjunction with the acquisition of the two facilities, the Company amended and extended the initial term of an existing triple-net master lease with Ensign to include the two skilled nursing facilities. The Ensign lease, as amended, has a remaining initial term of approximately 17 years, with three five-year renewal options and CPI-based rent escalators. Annual cash rent under the amended lease increased by approximately $2.2 million, with GAAP rent increasing by $2.5 million due to a $5.0 million prepayment of rent made at closing, which will be amortized on a straight-line basis over the remaining lease term. The Operating Partnership drew on the Revolving Facility to fund the acquisition.
Asset Held for Sale
In August 2021, the Company met the held for sale criteria on one assisted living facility operated by affiliates of Noble Senior Services, and is in the process of estimating its fair value, which is expected to be below the net carrying value of $4.9 million. The associated impairment loss is expected to be recorded in the quarter ending September 30, 2021.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. All intercompany transactions and account balances within the Company have been eliminated.
Restricted Cash Restricted Cash—The Company presents cash and cash equivalents separately from restricted cash within the Company’s condensed consolidated balance sheets. The Company includes restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the condensed consolidated statements of cash flows. The Company provides a reconciliation between the balance sheets and statements of cash flows, as required when the balance includes more than one line item for cash, cash equivalents, and restricted cash. The Company also provides a disclosure of the nature of the restrictions related to material restricted cash balances.
Recent Accounting Pronouncements Recent Accounting Pronouncements— In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), that provides optional relief to applying reference rate reform to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”). For U.S. Dollar LIBOR, the overnight, one-month, three-month, six-month and one-year LIBOR rates will be discontinued in June 2023, while other U.S. Dollar LIBOR rates will be discontinued at the end of 2021. The amendments in this update are effective immediately and may be applied through December 31, 2022. The Company is still evaluating the impact of ASU 2020-04 and expects to take full advantage of the offered optional expedients and exceptions, but does not expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements.
Fair Value Measurements
The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.

Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.

The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Schedule of Cash, Cash Equivalents and Restricted Cash
Cash, cash equivalents and restricted cash consisted of the following as of June 30, 2021 and December 31, 2020 (dollars in thousands):
June 30, 2021December 31, 2020
Cash and cash equivalents$1,771 $18,919 
Restricted cash309,187 — 
Cash, cash equivalents and restricted cash$310,958 $18,919 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Real Estate Investments, Net (Tables)
6 Months Ended
Jun. 30, 2021
Real Estate [Abstract]  
Summary of Investment in Owned Properties The following table summarizes the Company’s investment in owned properties as of June 30, 2021 and December 31, 2020 (dollars in thousands):
June 30, 2021December 31, 2020
Land$244,740 $205,356 
Buildings and improvements1,588,961 1,477,849 
Integral equipment, furniture and fixtures101,441 97,836 
Identified intangible assets2,658 2,352 
Real estate investments1,937,800 1,783,393 
Accumulated depreciation and amortization(362,397)(335,294)
Real estate investments, net$1,575,403 $1,448,099 
Schedule of Total Future Contractual Minimum Rental Income As of June 30, 2021, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements, were (dollars in thousands):
YearAmount
2021 (six months)$93,754 
2022188,644 
2023188,438 
2024187,091 
2025187,062 
2026187,166 
Thereafter1,020,115 
Total$2,052,270 
Schedule Of Tenant Purchase Options
Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):
Asset TypePropertiesLease ExpirationNext Option Open Date
Option Type(1)
Current Cash Rent(2)
ALF7October 20341/1/2022A$3,282 
SNF11November 20301/1/2022C4,800 
SNF1March 20294/1/2022
B / C(3)
779 
SNF / Campus2October 20321/1/2023B959 
SNF4November 203412/1/2024B3,789 
ALF2October 20341/1/2026A1,559 
(1) Option type includes:
A - Fixed base price plus a specified share on any appreciation.
B - Fixed base price.
C - Fixed capitalization rate on lease revenue.
(2) Based on annualized cash revenue for contracts in place as of June 30, 2021.
(3) Purchase option reflects two option types.
Schedule of Rental Income
The following table summarizes components of the Company’s rental income (dollars in thousands):
For the Three Months Ended June 30,
For the Six Months Ended June 30,
Rental Income2021202020212020
Contractual rent due(1)
$47,736 $42,485 $92,907 $84,923 
Straight-line rent22 20 48 
Lease termination revenue(2)
— — 63 — 
Total$47,744 $42,507 $92,990 $84,971 
(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received.
(2) During the six months ended June 30, 2021, in connection with the agreement to terminate its lease agreements with affiliates of Metron Integrated Health Systems (“Metron”) and to sell the facilities to a third-party, the Company received $0.1 million from Metron affiliates.
Schedule of Real Estate Acquisitions
The following table summarizes the Company’s acquisitions for the six months ended June 30, 2021 (dollars in thousands):
Type of Property
Purchase Price(1)
Initial Annual Cash RentNumber of Properties
Number of Beds/Units(2)
Skilled nursing$25,457 $2,295 (4)268 
Multi-service campuses(3)
125,708 8,604 640 
Total$151,165 $10,899 908 
(1) Purchase price includes capitalized acquisition costs.
(2) The number of beds/units includes operating beds at the acquisition date.
(3) Initial annual cash rent represents the first twelve months of rent upon commencement of the Company’s long-term net leases, which occurred during the three months ended June 30, 2021, upon the tenants’ receipt of licensing approval and increases to $9.4 million in the second year with CPI-based annual escalators thereafter.
(4) Included within initial annual cash rent is approximately $0.8 million of initial rent which is subject to a fixed escalator in the first twelve months and increases to $0.9 million in the second year with CPI-based annual escalators thereafter.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2021
Fair Value Disclosures [Abstract]  
Schedule of Items Measured at Fair Value on a Recurring Basis
The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):
Level 1Level 2Level 3
Balance as of June 30, 2021
Assets:
Mezzanine loan receivable$— $— $15,150 $15,150 
Level 1Level 2Level 3
Balance as of December 31, 2020
Assets:
Mezzanine loan receivable$— $— $15,000 $15,000 
Summary of Face Value, Carrying Amount and Fair Value of Financial Instruments A summary of the face values, carrying amounts and fair values of the Company’s financial instruments as of June 30, 2021 and December 31, 2020 using Level 2 inputs for the Notes (as defined in Note 6, Debt, below), is as follows (dollars in thousands):  
 June 30, 2021December 31, 2020
 LevelFace
Value
Carrying
Amount
Fair
Value
Face
Value
Carrying
Amount
Fair
Value
Financial liabilities:
2028 Senior unsecured notes payable2$400,000 $393,842 $410,000 $— $— $— 
2025 Senior unsecured notes payable(1)
2300,000 297,048 307,875 300,000 296,669 311,430 
(1) The $300.0 million aggregate principal amount of the 2025 Notes were redeemed on July 1, 2021. See Note 12, Subsequent Events, for further detail.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Debt (Tables)
6 Months Ended
Jun. 30, 2021
Debt Disclosure [Abstract]  
Schedule of Debt Instruments The following table summarizes the balance of the Company’s indebtedness as of June 30, 2021 and December 31, 2020 (dollars in thousands):
June 30, 2021December 31, 2020
Principal AmountDeferred Loan FeesCarrying ValuePrincipal AmountDeferred Loan FeesCarrying Value
2028 Senior unsecured notes payable$400,000 $(6,158)$393,842 $— $— $— 
2025 Senior unsecured notes payable300,000 (2,952)297,048 300,000 (3,331)296,669 
Senior unsecured term loan200,000 (969)199,031 200,000 (1,075)198,925 
Unsecured revolving credit facility50,000 — 50,000 50,000 — 50,000 
$950,000 $(10,079)$939,921 $550,000 $(4,406)$545,594 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Equity (Tables)
6 Months Ended
Jun. 30, 2021
Equity [Abstract]  
Summary of the At-The-Market Offering Program The following table summarizes the ATM Program activity for the three and six months ended June 30, 2021 (in thousands, except per share amounts).
For the Three Months EndedFor the Six Months Ended
June 30, 2021June 30, 2021
Number of shares288 990 
Average sales price per share$24.05 $23.74 
Gross proceeds(1)
$6,926 $23,505 
(1) Total gross proceeds is before $0.1 million and $0.3 million of commissions paid to the sales agents during the three and six months ended June 30, 2021, respectively, under the ATM Program.
Schedule of Dividends on Common Stock The following table summarizes the cash dividends on the Company’s common stock declared by the Company’s Board of Directors for the first six months of 2021 (dollars in thousands, except per share amounts):
For the Three Months Ended
March 31, 2021June 30, 2021
Dividends declared per share$0.265 $0.265 
Dividends payment dateApril 15, 2021July 15, 2021
Dividends payable as of record date$25,633 $25,714 
Dividends record dateMarch 31, 2021June 30, 2021
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Valuation Assumptions The following are the key assumptions used in this valuation:
Risk-free interest rate0.27 %
Expected stock price volatility52.93 %
Expected service period2.84 years
Expected dividend yield (assuming full reinvestment)— %
Schedule of Stock-Based Compensation Expense The following table summarizes the stock-based compensation expense recognized during the periods presented (dollars in thousands):
 For the Three Months Ended June 30,For the Six Months Ended June 30,
 2021202020212020
Stock-based compensation expense$1,810 $963 $3,395 $1,847 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings Per Common Share (Tables)
6 Months Ended
Jun. 30, 2021
Earnings Per Share [Abstract]  
Reconciliation of Weighted-Average Common Shares Outstanding Used in Calculation of Basic EPS to Diluted EPS
The following table presents the calculation of basic and diluted earnings per common share (“EPS”) for the Company’s common stock for the three and six months ended June 30, 2021 and 2020, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (amounts in thousands, except per share amounts):
 
 For the Three Months Ended June 30,For the Six Months Ended June 30,
 2021202020212020
Numerator:
Net income$21,317 $18,935 $41,803 $38,260 
Less: Net income allocated to participating securities(116)(75)(234)(148)
Numerator for basic and diluted earnings available to common stockholders$21,201 $18,860 $41,569 $38,112 
Denominator:
Weighted-average basic common shares outstanding96,082 95,208 95,732 95,185 
Dilutive market condition stock awards38 — 23 — 
Weighted-average diluted common shares outstanding96,120 95,208 95,755 95,185 
Earnings per common share, basic$0.22 $0.20 $0.43 $0.40 
Earnings per common share, diluted$0.22 $0.20 $0.43 $0.40 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Organization (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2021
USD ($)
bed
state
facility
Dec. 31, 2020
USD ($)
Real Estate Properties [Line Items]    
Number of states with properties | state 28  
Other real estate investments | $ $ 15,150 $ 15,000
Skilled nursing, multi-service campuses, assisted living and independent living facilities    
Real Estate Properties [Line Items]    
Number of facilities | facility 223  
Number of operational beds and units in facilities | bed 23,301  
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Accounting Policies [Abstract]    
Restricted cash $ 309,187,000 $ 0
5.25% Senior Notes due 2025 | Senior unsecured notes    
Debt Instrument [Line Items]    
Debt instrument face amount $ 300,000,000.0  
Interest rate (percent) 5.25%  
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Jun. 30, 2020
Dec. 31, 2019
Cash, Cash Equivalents and Restricted Cash        
Cash and cash equivalents $ 1,771 $ 18,919    
Restricted cash 309,187 0    
Cash, cash equivalents and restricted cash $ 310,958 $ 18,919 $ 5,798 $ 20,327
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Real Estate Investments, Net - Narrative (Details)
Jun. 30, 2021
facility
Skilled nursing, multi-service campuses, assisted living and independent living facilities  
Real Estate [Line Items]  
Number of facilities 223
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Real Estate Investments, Net - Investment in Owned Properties (Details) - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Real Estate [Abstract]    
Land $ 244,740 $ 205,356
Buildings and improvements 1,588,961 1,477,849
Integral equipment, furniture and fixtures 101,441 97,836
Identified intangible assets 2,658 2,352
Real estate investments 1,937,800 1,783,393
Accumulated depreciation and amortization (362,397) (335,294)
Real estate investments, net $ 1,575,403 $ 1,448,099
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details)
$ in Thousands
Jun. 30, 2021
USD ($)
Future Contractual Minimum Rental Income  
2021 (six months) $ 93,754
2022 188,644
2023 188,438
2024 187,091
2025 187,062
2026 187,166
Thereafter 1,020,115
Total $ 2,052,270
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Real Estate Investments, Net - Tenant Purchase Options (Details)
$ in Thousands
Jun. 30, 2021
USD ($)
property
ALF | Lease Expiration October 2034, Next option 2021  
Lessor, Lease, Description [Line Items]  
Properties | property 7
Current Cash Rent | $ $ 3,282
ALF | Lease Expiration October 2034, Next option 2026  
Lessor, Lease, Description [Line Items]  
Properties | property 2
Current Cash Rent | $ $ 1,559
SNF | Lease Expiration November 2030, Next option 2022  
Lessor, Lease, Description [Line Items]  
Properties | property 11
Current Cash Rent | $ $ 4,800
SNF | Lease Expiration March 2029, Next option 2022  
Lessor, Lease, Description [Line Items]  
Properties | property 1
Current Cash Rent | $ $ 779
SNF | Lease Expiration November 2034, Next option 2024  
Lessor, Lease, Description [Line Items]  
Properties | property 4
Current Cash Rent | $ $ 3,789
SNF / Campus | Lease Expiration October 2032, Next option 2023  
Lessor, Lease, Description [Line Items]  
Properties | property 2
Current Cash Rent | $ $ 959
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Real Estate Investments, Net - Rental Income (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Real Estate [Abstract]        
Contractual rent due $ 47,736 $ 42,485 $ 92,907 $ 84,923
Straight-line rent 8 22 20 48
Lease termination revenue 0 0 63 0
Total $ 47,744 $ 42,507 $ 92,990 $ 84,971
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Real Estate Investments, Net - Recent Real Estate Acquisitions (Details)
$ in Thousands
1 Months Ended 6 Months Ended 12 Months Ended
Jan. 31, 2020
USD ($)
Jun. 30, 2021
USD ($)
unit
property
Dec. 31, 2022
USD ($)
Business Acquisition [Line Items]      
Purchase Price   $ 151,165  
Initial Annual Cash Rent   $ 10,899  
Number of Properties | property   6  
Number of Beds/Units | unit   908  
Skilled nursing      
Business Acquisition [Line Items]      
Purchase Price $ 18,700 $ 25,457  
Initial Annual Cash Rent   $ 2,295  
Number of Properties | property   2  
Number of Beds/Units | unit   268  
Initial rent subject to a fixed escalator in first twelve months   $ 800  
Initial rent subject to a fixed escalator in second year   900  
Multi-service campuses(3)      
Business Acquisition [Line Items]      
Purchase Price   125,708  
Initial Annual Cash Rent   $ 8,604  
Number of Properties | property   4  
Number of Beds/Units | unit   640  
Multi-service campuses(3) | Forecast      
Business Acquisition [Line Items]      
Initial Annual Cash Rent     $ 9,400
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Real Estate Investments, Net - Asset Sales and Assets Held for Sale Narrative (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 01, 2021
USD ($)
bed
Feb. 14, 2020
USD ($)
facility
Jul. 31, 2020
USD ($)
Apr. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
property
Feb. 29, 2020
USD ($)
facility
Real Estate [Line Items]                      
Assets held for sale, net         $ 0     $ 0   $ 7,226,000  
Real estate investments, net         1,575,403,000     1,575,403,000   $ 1,448,099,000  
Proceeds from sale               6,814,000 $ 2,134,000    
Gain (loss) on sale of real estate         0 $ 0   (192,000) $ (56,000)    
Mortgage loan receivable                      
Real Estate [Line Items]                      
Loan receivable         $ 0     0      
Mortgage loan receivable | Cascade Capital Group, LLC                      
Real Estate [Line Items]                      
Loan receivable   $ 32,400,000                 $ 32,400,000
Loan receivable interest rate (percent)   7.50%                 7.50%
Proceeds from settlement of loan     $ 13,900,000 $ 18,900,000              
Loan receivable       $ 13,900,000              
Held for sale | Five Oaks Healthcare LLC                      
Real Estate [Line Items]                      
Number of properties held for sale | property                   1  
Disposed of by sale | Five Oaks Healthcare LLC                      
Real Estate [Line Items]                      
Number of operational beds | bed 90                    
Real estate investments, net $ 7,200,000                    
Proceeds from sale $ 7,000,000.0                    
Gain (loss) on sale of real estate               $ (200,000)      
Disposed of by sale | Metron skilled nursing facilities                      
Real Estate [Line Items]                      
Number of properties sold | facility   6                 6
Proceeds from sale   $ 3,500,000                  
Gain (loss) on sale of real estate             $ 100,000        
Contract purchase price   $ 36,000,000.0                  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Real Estate Investments, Net - Lease Amendments Narrative (Details)
$ in Thousands
6 Months Ended
Jun. 01, 2021
USD ($)
facility
extension_option
Dec. 01, 2020
USD ($)
facility
extension_option
Jun. 30, 2021
USD ($)
Real Estate [Line Items]      
Initial annual cash rents     $ 10,899
Ensign amended triple-net master lease      
Real Estate [Line Items]      
Initial lease term (in years) 15 years    
Number of renewal options | extension_option 3    
Lease renewal term (in years) 5 years    
Initial annual cash rents $ 2,600    
Noble triple-net master lease      
Real Estate [Line Items]      
Initial lease term (in years)   14 years  
Number of renewal options | extension_option   2  
Lease renewal term (in years)   5 years  
Initial annual cash rents   $ 3,200  
Ensign | Skilled nursing facility      
Real Estate [Line Items]      
Number of properties with right to operate | facility 4    
Noble | Assisted living      
Real Estate [Line Items]      
Number of properties transferred | facility   5  
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Other Real Estate Investments, Net (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Nov. 30, 2020
USD ($)
facility
Jul. 31, 2020
USD ($)
Apr. 30, 2020
USD ($)
extension_option
property
Jan. 31, 2020
USD ($)
Jul. 31, 2019
USD ($)
bed
Sep. 30, 2016
USD ($)
bed
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Feb. 29, 2020
USD ($)
facility
Feb. 14, 2020
USD ($)
facility
Sep. 30, 2019
USD ($)
facility
Real Estate Properties [Line Items]                          
Preferred equity investment             $ 0   $ 0        
Aggregate purchase price                 151,165,000        
Payment to acquire facility                 147,807,000 $ 25,905,000      
Return of initial investment                 0 2,327,000      
Metron skilled nursing facilities | Disposed of by sale                          
Real Estate Properties [Line Items]                          
Number of properties sold | facility                     6 6  
Mortgage loan receivable                          
Real Estate Properties [Line Items]                          
Loan receivable             0   0        
Interest income             0 $ 900,000 0 2,000,000.0      
Other loans receivable                          
Real Estate Properties [Line Items]                          
Interest income             100,000 $ 100,000 100,000 200,000      
Next VA Star Realty Holdings LLC | Mezzanine loan receivable                          
Real Estate Properties [Line Items]                          
Number of facilities in agreement secured by membership interests | facility 9                        
Loan receivable $ 15,000,000.0                        
Loan receivable interest rate (percent) 12.00%                        
Period of unpaid interest payments due upon prepayment 24 months                        
Interest income             $ 400,000   900,000        
Next VA Star Realty Holdings LLC | Mezzanine loan receivable | Minimum                          
Real Estate Properties [Line Items]                          
Loans receivable exit fee (percent) 1.00%                        
Next VA Star Realty Holdings LLC | Mezzanine loan receivable | Maximum                          
Real Estate Properties [Line Items]                          
Loans receivable exit fee (percent) 3.00%                        
MCRC, LLC                          
Real Estate Properties [Line Items]                          
Purchase and sale agreement amount         $ 16,400,000                
Number of days after termination of purchase and sale agreement for maturity         5 days                
MCRC, LLC | Mortgage loan receivable                          
Real Estate Properties [Line Items]                          
Loan receivable         $ 3,000,000.0                
Loan receivable interest rate (percent)         8.00%                
Number of beds in facility used to secure loan | bed         176                
CommuniCare | Mortgage loan receivable                          
Real Estate Properties [Line Items]                          
Loan receivable                         $ 26,500,000
Loan receivable interest rate (percent)                         10.00%
Facilities utilized to secure mortgage loan | facility                         3
Cascade Capital Group, LLC                          
Real Estate Properties [Line Items]                          
Combined principal amount of loan     $ 33,900,000                    
Cascade Capital Group, LLC | Mortgage loan receivable                          
Real Estate Properties [Line Items]                          
Loan receivable                     $ 32,400,000 $ 32,400,000  
Loan receivable interest rate (percent)                     7.50% 7.50%  
Facilities utilized to secure mortgage loan | property     6                    
Proceeds from settlement of loan   $ 13,900,000 $ 18,900,000                    
Loan receivable     $ 13,900,000                    
LIBOR floor for loan (percent)     1.75%                    
Number of extension options | extension_option     2                    
Extension option term (in months)     6 months                    
Cascade Capital Group, LLC | Mortgage loan receivable | LIBOR                          
Real Estate Properties [Line Items]                          
Basis spread on variable rate for loan (percent)     4.00%                    
Cascadia Development, Boise ID                          
Real Estate Properties [Line Items]                          
Preferred equity investment           $ 2,300,000              
Preferred equity investment minimum yield           12.00%              
Number of beds planned for construction | bed           99              
Initial lease yield (percent)           9.00%              
Return of initial investment       $ 2,300,000                  
Cumulative contractual preferred return through acquisition date       1,400,000                  
Interest income related to preferred equity investments                   $ 100,000      
Cascadia Development, Boise ID | Prime Rate                          
Real Estate Properties [Line Items]                          
Basis spread of preferred equity investment yield           9.50%              
Skilled nursing properties                          
Real Estate Properties [Line Items]                          
Aggregate purchase price       18,700,000         $ 25,457,000        
Payment to acquire facility       $ 15,000,000.0                  
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details) - Recurring - Mezzanine loan receivable - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Assets:    
Mezzanine loan receivable $ 15,150 $ 15,000
Level 1    
Assets:    
Mezzanine loan receivable 0 0
Level 2    
Assets:    
Mezzanine loan receivable 0 0
Level 3    
Assets:    
Mezzanine loan receivable $ 15,150 $ 15,000
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements - Narrative (Details) - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Greater than 90 days past due    
Financing Receivable, Past Due [Line Items]    
Mortgage loan receivable $ 0 $ 0
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details) - Senior unsecured notes - USD ($)
Jun. 30, 2021
Jun. 17, 2021
Dec. 31, 2020
May 10, 2017
2028 Senior unsecured notes payable        
Financial liabilities:        
Senior unsecured notes payable - face value $ 400,000,000 $ 400,000,000.0 $ 0  
2025 Senior unsecured notes payable        
Financial liabilities:        
Senior unsecured notes payable - face value 300,000,000.0   300,000,000 $ 300,000,000.0
Carrying Amount | Level 2 | 2028 Senior unsecured notes payable        
Financial liabilities:        
Senior unsecured notes payable 393,842,000   0  
Carrying Amount | Level 2 | 2025 Senior unsecured notes payable        
Financial liabilities:        
Senior unsecured notes payable 297,048,000   296,669,000  
Fair Value | Level 2 | 2028 Senior unsecured notes payable        
Financial liabilities:        
Senior unsecured notes payable 410,000,000   0  
Fair Value | Level 2 | 2025 Senior unsecured notes payable        
Financial liabilities:        
Senior unsecured notes payable $ 307,875,000   $ 311,430,000  
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Debt - Schedule of Debt (Details) - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Debt Instrument [Line Items]    
Principal Amount $ 950,000 $ 550,000
Deferred Loan Fees (10,079) (4,406)
Carrying Value 939,921 545,594
Senior unsecured notes | 2028 Senior unsecured notes payable    
Debt Instrument [Line Items]    
Principal Amount 400,000 0
Deferred Loan Fees (6,158) 0
Carrying Value 393,842 0
Senior unsecured notes | 2025 Senior unsecured notes payable    
Debt Instrument [Line Items]    
Principal Amount 300,000 300,000
Deferred Loan Fees (2,952) (3,331)
Carrying Value 297,048 296,669
Senior unsecured term loan    
Debt Instrument [Line Items]    
Principal Amount 200,000 200,000
Deferred Loan Fees (969) (1,075)
Carrying Value 199,031 198,925
Unsecured revolving credit facility    
Debt Instrument [Line Items]    
Principal Amount 50,000 50,000
Deferred Loan Fees 0 0
Carrying Value $ 50,000 $ 50,000
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Debt - Senior Unsecured Notes Payable Narrative (Details) - USD ($)
6 Months Ended
Jul. 01, 2021
Jun. 17, 2021
May 10, 2017
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Debt Instrument [Line Items]            
Gross proceeds from issuance       $ 400,000,000 $ 0  
Senior unsecured notes | 5.25% Senior Notes due 2025            
Debt Instrument [Line Items]            
Debt instrument face amount     $ 300,000,000.0 300,000,000.0   $ 300,000,000
Interest rate (percent)     5.25%      
Gross proceeds from issuance     $ 300,000,000.0      
Net proceeds from issuance     $ 294,000,000.0      
Senior unsecured notes | 5.25% Senior Notes due 2025 | Subsequent event            
Debt Instrument [Line Items]            
Redemption of debt $ 300,000,000.0          
Redemption price of notes (percent) 102.625%          
Senior unsecured notes | 3.875% Senior Notes due 2028            
Debt Instrument [Line Items]            
Debt instrument face amount   $ 400,000,000.0   $ 400,000,000   $ 0
Interest rate (percent)   3.875%        
Gross proceeds from issuance   $ 400,000,000.0        
Net proceeds from issuance   $ 393,800,000        
Redemption price, percentage upon change of control (percent)   101.00%        
Senior unsecured notes | 3.875% Senior Notes due 2028 | Period prior to March 30 2028            
Debt Instrument [Line Items]            
Redemption price of notes (percent)   100.00%        
Senior unsecured notes | 3.875% Senior Notes due 2028 | Period after March 30 2028            
Debt Instrument [Line Items]            
Redemption price of notes (percent)   100.00%        
Senior unsecured notes | 3.875% Senior Notes due 2028 | Period prior to June 30 2024            
Debt Instrument [Line Items]            
Redemption price of notes (percent)   103.875%        
Percentage of principal amount (percent)   40.00%        
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details)
1 Months Ended 6 Months Ended
Feb. 08, 2019
USD ($)
extension_option
Aug. 05, 2021
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Line of Credit Facility [Line Items]          
Outstanding amounts     $ 950,000,000   $ 550,000,000
Outstanding borrowings     939,921,000   545,594,000
Borrowings under unsecured revolving credit facility     170,000,000 $ 15,000,000  
Revolving credit facility | New Revolving Facility          
Line of Credit Facility [Line Items]          
Credit facility borrowing capacity $ 600,000,000.0        
Number of extension options | extension_option 2        
Extension option term (in months) 6 months        
Revolving credit facility | New Revolving Facility | Minimum          
Line of Credit Facility [Line Items]          
Facility fee on revolving commitment fees (percent) 0.15%        
Facility fee on revolving commitment fee based on investment grade ratings (percent) 0.125%        
Revolving credit facility | New Revolving Facility | Minimum | Base Rate          
Line of Credit Facility [Line Items]          
Basis spread on variable rate (percent) 0.10%        
Revolving credit facility | New Revolving Facility | Minimum | LIBOR          
Line of Credit Facility [Line Items]          
Basis spread on variable rate (percent) 1.10%        
Revolving credit facility | New Revolving Facility | Maximum          
Line of Credit Facility [Line Items]          
Facility fee on revolving commitment fees (percent) 0.35%        
Facility fee on revolving commitment fee based on investment grade ratings (percent) 0.30%        
Revolving credit facility | New Revolving Facility | Maximum | Base Rate          
Line of Credit Facility [Line Items]          
Basis spread on variable rate (percent) 0.55%        
Revolving credit facility | New Revolving Facility | Maximum | LIBOR          
Line of Credit Facility [Line Items]          
Basis spread on variable rate (percent) 1.55%        
Letter of credit          
Line of Credit Facility [Line Items]          
Subfacility capacity as percentage of available revolving commitments (percent) 10.00%        
Swingline loan          
Line of Credit Facility [Line Items]          
Subfacility capacity as percentage of available revolving commitments (percent) 10.00%        
Revolving Facility          
Line of Credit Facility [Line Items]          
Outstanding amounts     50,000,000   50,000,000
Outstanding borrowings     50,000,000   50,000,000
Revolving Facility | Subsequent event          
Line of Credit Facility [Line Items]          
Borrowings under unsecured revolving credit facility   $ 50,000,000.0      
New Term Loan          
Line of Credit Facility [Line Items]          
Outstanding amounts     200,000,000   200,000,000
Outstanding borrowings     $ 199,031,000   $ 198,925,000
New Term Loan | Term Loan          
Line of Credit Facility [Line Items]          
Debt instrument face amount $ 200,000,000.0        
New Term Loan | Term Loan | Minimum | Base Rate          
Line of Credit Facility [Line Items]          
Basis spread on variable rate (percent) 0.50%        
New Term Loan | Term Loan | Minimum | LIBOR          
Line of Credit Facility [Line Items]          
Basis spread on variable rate (percent) 1.50%        
New Term Loan | Term Loan | Maximum | Base Rate          
Line of Credit Facility [Line Items]          
Basis spread on variable rate (percent) 1.20%        
New Term Loan | Term Loan | Maximum | LIBOR          
Line of Credit Facility [Line Items]          
Basis spread on variable rate (percent) 2.20%        
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Equity - Narrative (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Mar. 20, 2020
Mar. 10, 2020
Class of Stock [Line Items]            
Share repurchase program authorization         $ 150,000,000.0  
Shares repurchased (in shares) 0 0 0 0    
ATM Program            
Class of Stock [Line Items]            
Issuance of common stock, net, (in shares) 288,000 0 990,000 0    
Remaining offering amount available $ 476,500,000   $ 476,500,000      
ATM Program | Maximum            
Class of Stock [Line Items]            
Authorized aggregate offering price of common stock           $ 500,000,000.0
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Equity - At-The-Market Offering (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Class of Stock [Line Items]        
Gross proceeds(1)     $ 22,946  
Commissions paid on stock issuance       $ 404
ATM Program        
Class of Stock [Line Items]        
Number of shares 288,000 0 990,000 0
Average sales price per share $ 24.05   $ 23.74  
Gross proceeds(1) $ 6,926   $ 23,505  
Commissions paid on stock issuance $ 100   $ 300  
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Equity - Dividends on Common Stock (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Mar. 31, 2020
Dividends on common stock        
Dividends declared per share $ 0.265 $ 0.265 $ 0.25 $ 0.25
Dividends payment date Jul. 15, 2021 Apr. 15, 2021    
Dividends payable as of record date $ 25,714 $ 25,633 $ 23,931 $ 23,931
Dividends record date Jun. 30, 2021 Mar. 31, 2021    
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation - Narrative (Details)
$ / shares in Units, $ in Millions
1 Months Ended 2 Months Ended 6 Months Ended 12 Months Ended
Jun. 01, 2014
shares
Apr. 30, 2021
$ / shares
shares
Feb. 28, 2021
installment
company
$ / shares
shares
Jan. 31, 2021
installment
$ / shares
shares
Feb. 28, 2021
installment
Jun. 30, 2021
USD ($)
shares
Dec. 31, 2020
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Unamortized stock-based compensation expense related to unvested awards | $           $ 13.2  
Weighted average remaining vesting period related to expense recognition           2 years 2 months 12 days  
Restricted stock award | Ensign employees              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock awards unvested during spin-off (in shares) 207,580            
Shares forfeited (shares)             1,760
Unvested stock awards outstanding (in shares)           0  
Restricted stock award | Officers and employees              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of awards granted (in shares)     99,189 140,514      
Award grant date fair value (in usd per share) | $ / shares     $ 22.18 $ 22.48      
Number of equal annual vesting installments | installment     3 3 3    
Restricted stock award | Board of Directors              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of awards granted (in shares)   20,266          
Award grant date fair value (in usd per share) | $ / shares   $ 24.18          
Performance stock award              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Historical volatility term basis for expected volatility assumption         2 years 10 months 2 days    
Performance stock award | Officers              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of awards granted (in shares)     99,189 108,414      
Award grant date fair value (in usd per share) | $ / shares     $ 27.98 $ 22.48      
Vesting period (in years)     3 years        
Number of publicly traded healthcare REITs in peer group | company     16        
Performance stock award | Minimum | Officers              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period (in years)       1 year      
Percentage of awards to vest relative To initial grant based on TSR performance     0.00%        
Performance stock award | Maximum | Officers              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period (in years)       3 years      
Percentage of awards to vest relative To initial grant based on TSR performance     200.00%        
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation - Valuation Assumptions (Details) - Performance stock award
2 Months Ended
Feb. 28, 2021
Valuation Assumptions  
Risk-free interest rate 0.27%
Expected stock price volatility 52.93%
Expected service period 2 years 10 months 2 days
Expected dividend yield (assuming full reinvestment) 0.00%
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Share-based Payment Arrangement [Abstract]        
Stock-based compensation expense $ 1,810 $ 963 $ 3,395 $ 1,847
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Numerator:            
Net income (loss) $ 21,317 $ 20,486 $ 18,935 $ 19,325 $ 41,803 $ 38,260
Less: Net income allocated to participating securities (116)   (75)   (234) (148)
Numerator for basic earnings available to common stockholders 21,201   18,860   41,569 38,112
Numerator for basic and diluted earnings available to common stockholders $ 21,201   $ 18,860   $ 41,569 $ 38,112
Denominator:            
Weighted-average basic common shares outstanding (in shares) 96,082   95,208   95,732 95,185
Dilutive market condition stock awards 38   0   23 0
Weighted-average diluted common shares outstanding (in shares) 96,120   95,208   95,755 95,185
Earnings per common share, basic (in dollars per share) $ 0.22   $ 0.20   $ 0.43 $ 0.40
Earnings per common share, diluted (in dollars per share) $ 0.22   $ 0.20   $ 0.43 $ 0.40
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies (Details)
$ in Millions
Jun. 30, 2021
USD ($)
Ensign and Pennant  
Other Commitments [Line Items]  
Aggregate required financing of capital expenditures as percentage of initial investment in property (percent) 20.00%
Certain capital improvements at triple-net leased facilities  
Other Commitments [Line Items]  
Funding commitment $ 13.1
Portion of funding commitment subject to rent increase at time of funding $ 11.6
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.21.2
Concentration of Risk (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2021
unit_bed
facility
Jun. 30, 2020
Jun. 30, 2021
unit_bed
facility
state
Jun. 30, 2020
Skilled nursing, multi-service campuses, assisted living and independent living facilities        
Concentration Risk [Line Items]        
Number of facilities 223   223  
Ensign        
Concentration Risk [Line Items]        
Number of states where Ensign leases the highest concentration of properties | state     4  
Ensign | Customer concentration risk | Rental income, exclusive of operating expense reimbursements        
Concentration Risk [Line Items]        
Concentration risk (percent) 31.00% 32.00% 32.00% 32.00%
PMG | Customer concentration risk | Rental income, exclusive of operating expense reimbursements        
Concentration Risk [Line Items]        
Concentration risk (percent) 15.00% 17.00% 15.00% 17.00%
Ensign | Skilled nursing, multi-service campuses, assisted living and independent living facilities        
Concentration Risk [Line Items]        
Number of facilities 93   93  
Number of beds and units in facilities | unit_bed 9,907   9,907  
PMG | Skilled nursing and campus facilities        
Concentration Risk [Line Items]        
Number of facilities 15   15  
Number of beds and units in facilities 2,144   2,144  
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Aug. 05, 2021
USD ($)
facility
extension_option
Jul. 01, 2021
USD ($)
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
property
Subsequent Event [Line Items]        
Number of properties acquired | property       6
Aggregate purchase price       $ 151,165
Subsequent event | Held for sale        
Subsequent Event [Line Items]        
Number of facilities | facility 1      
Net carrying value $ 4,900      
Subsequent event | Ensign Master Lease Amended | Ensign        
Subsequent Event [Line Items]        
Initial lease term (in years) 17 years      
Number of renewal options | extension_option 3      
Lease renewal term (in years) 5 years      
Annual cash rent increase under amended lease $ 2,200      
GAAP rent increase under amended lease $ 2,500      
Subsequent event | Skilled nursing facility        
Subsequent Event [Line Items]        
Number of properties acquired | facility 2      
Aggregate purchase price $ 32,500      
Prepaid rent component $ 5,000      
Subsequent event | 2025 Senior unsecured notes payable | Senior unsecured notes        
Subsequent Event [Line Items]        
Redemption of debt   $ 300,000    
Redemption price of notes (percent)   102.625%    
Forecast | 2025 Senior unsecured notes payable | Senior unsecured notes        
Subsequent Event [Line Items]        
Loss on extinguishment of debt     $ 10,800  
Loss on redemption price     7,900  
Write off of deferred financing costs     $ 2,900  
EXCEL 66 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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end XML 67 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 68 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 69 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 190 336 1 false 75 0 false 13 false false R1.htm 0001001 - Document - Cover Sheet http://www.caretrustreit.com/role/Cover Cover Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Income Statements Sheet http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements Condensed Consolidated Income Statements Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Equity Sheet http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity Condensed Consolidated Statements of Equity Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Equity (Parenthetical) Sheet http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquityParenthetical Condensed Consolidated Statements of Equity (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101101 - Disclosure - Organization Sheet http://www.caretrustreit.com/role/Organization Organization Notes 8 false false R9.htm 2103102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.caretrustreit.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2108103 - Disclosure - Real Estate Investments, Net Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNet Real Estate Investments, Net Notes 10 false false R11.htm 2118104 - Disclosure - Other Real Estate Investments, Net Sheet http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNet Other Real Estate Investments, Net Notes 11 false false R12.htm 2120105 - Disclosure - Fair Value Measurements Sheet http://www.caretrustreit.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 2125106 - Disclosure - Debt Sheet http://www.caretrustreit.com/role/Debt Debt Notes 13 false false R14.htm 2130107 - Disclosure - Equity Sheet http://www.caretrustreit.com/role/Equity Equity Notes 14 false false R15.htm 2135108 - Disclosure - Stock-Based Compensation Sheet http://www.caretrustreit.com/role/StockBasedCompensation Stock-Based Compensation Notes 15 false false R16.htm 2140109 - Disclosure - Earnings Per Common Share Sheet http://www.caretrustreit.com/role/EarningsPerCommonShare Earnings Per Common Share Notes 16 false false R17.htm 2143110 - Disclosure - Commitments and Contingencies Sheet http://www.caretrustreit.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 17 false false R18.htm 2145111 - Disclosure - Concentration of Risk Sheet http://www.caretrustreit.com/role/ConcentrationofRisk Concentration of Risk Notes 18 false false R19.htm 2147112 - Disclosure - Subsequent Events Sheet http://www.caretrustreit.com/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.caretrustreit.com/role/SummaryofSignificantAccountingPolicies 20 false false R21.htm 2305301 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.caretrustreit.com/role/SummaryofSignificantAccountingPolicies 21 false false R22.htm 2309302 - Disclosure - Real Estate Investments, Net (Tables) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables Real Estate Investments, Net (Tables) Tables http://www.caretrustreit.com/role/RealEstateInvestmentsNet 22 false false R23.htm 2321303 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.caretrustreit.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.caretrustreit.com/role/FairValueMeasurements 23 false false R24.htm 2326304 - Disclosure - Debt (Tables) Sheet http://www.caretrustreit.com/role/DebtTables Debt (Tables) Tables http://www.caretrustreit.com/role/Debt 24 false false R25.htm 2331305 - Disclosure - Equity (Tables) Sheet http://www.caretrustreit.com/role/EquityTables Equity (Tables) Tables http://www.caretrustreit.com/role/Equity 25 false false R26.htm 2336306 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.caretrustreit.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.caretrustreit.com/role/StockBasedCompensation 26 false false R27.htm 2341307 - Disclosure - Earnings Per Common Share (Tables) Sheet http://www.caretrustreit.com/role/EarningsPerCommonShareTables Earnings Per Common Share (Tables) Tables http://www.caretrustreit.com/role/EarningsPerCommonShare 27 false false R28.htm 2402401 - Disclosure - Organization (Details) Sheet http://www.caretrustreit.com/role/OrganizationDetails Organization (Details) Details http://www.caretrustreit.com/role/Organization 28 false false R29.htm 2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 29 false false R30.htm 2407403 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) Details 30 false false R31.htm 2410404 - Disclosure - Real Estate Investments, Net - Narrative (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails Real Estate Investments, Net - Narrative (Details) Details 31 false false R32.htm 2411405 - Disclosure - Real Estate Investments, Net - Investment in Owned Properties (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails Real Estate Investments, Net - Investment in Owned Properties (Details) Details 32 false false R33.htm 2412406 - Disclosure - Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details) Details 33 false false R34.htm 2413407 - Disclosure - Real Estate Investments, Net - Tenant Purchase Options (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails Real Estate Investments, Net - Tenant Purchase Options (Details) Details 34 false false R35.htm 2414408 - Disclosure - Real Estate Investments, Net - Rental Income (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails Real Estate Investments, Net - Rental Income (Details) Details 35 false false R36.htm 2415409 - Disclosure - Real Estate Investments, Net - Recent Real Estate Acquisitions (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails Real Estate Investments, Net - Recent Real Estate Acquisitions (Details) Details 36 false false R37.htm 2416410 - Disclosure - Real Estate Investments, Net - Asset Sales and Assets Held for Sale Narrative (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails Real Estate Investments, Net - Asset Sales and Assets Held for Sale Narrative (Details) Details 37 false false R38.htm 2417411 - Disclosure - Real Estate Investments, Net - Lease Amendments Narrative (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails Real Estate Investments, Net - Lease Amendments Narrative (Details) Details 38 false false R39.htm 2419412 - Disclosure - Other Real Estate Investments, Net (Details) Sheet http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails Other Real Estate Investments, Net (Details) Details http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNet 39 false false R40.htm 2422413 - Disclosure - Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details) Sheet http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details) Details 40 false false R41.htm 2423414 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 41 false false R42.htm 2424415 - Disclosure - Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details) Sheet http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details) Details 42 false false R43.htm 2427416 - Disclosure - Debt - Schedule of Debt (Details) Sheet http://www.caretrustreit.com/role/DebtScheduleofDebtDetails Debt - Schedule of Debt (Details) Details 43 false false R44.htm 2428417 - Disclosure - Debt - Senior Unsecured Notes Payable Narrative (Details) Notes http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails Debt - Senior Unsecured Notes Payable Narrative (Details) Details 44 false false R45.htm 2429418 - Disclosure - Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details) Sheet http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details) Details 45 false false R46.htm 2432419 - Disclosure - Equity - Narrative (Details) Sheet http://www.caretrustreit.com/role/EquityNarrativeDetails Equity - Narrative (Details) Details 46 false false R47.htm 2433420 - Disclosure - Equity - At-The-Market Offering (Details) Sheet http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails Equity - At-The-Market Offering (Details) Details 47 false false R48.htm 2434421 - Disclosure - Equity - Dividends on Common Stock (Details) Sheet http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails Equity - Dividends on Common Stock (Details) Details 48 false false R49.htm 2437422 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 49 false false R50.htm 2438423 - Disclosure - Stock-Based Compensation - Valuation Assumptions (Details) Sheet http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails Stock-Based Compensation - Valuation Assumptions (Details) Details 50 false false R51.htm 2439424 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) Sheet http://www.caretrustreit.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails Stock-Based Compensation - Stock-Based Compensation Expense (Details) Details 51 false false R52.htm 2442425 - Disclosure - Earnings Per Common Share (Details) Sheet http://www.caretrustreit.com/role/EarningsPerCommonShareDetails Earnings Per Common Share (Details) Details http://www.caretrustreit.com/role/EarningsPerCommonShareTables 52 false false R53.htm 2444426 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.caretrustreit.com/role/CommitmentsandContingencies 53 false false R54.htm 2446427 - Disclosure - Concentration of Risk (Details) Sheet http://www.caretrustreit.com/role/ConcentrationofRiskDetails Concentration of Risk (Details) Details http://www.caretrustreit.com/role/ConcentrationofRisk 54 false false R55.htm 2448428 - Disclosure - Subsequent Events (Details) Sheet http://www.caretrustreit.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.caretrustreit.com/role/SubsequentEvents 55 false false All Reports Book All Reports ctre-20210630.htm ctre-20210630.xsd ctre-20210630_cal.xml ctre-20210630_def.xml ctre-20210630_lab.xml ctre-20210630_pre.xml ctre20210630q2ex311.htm ctre20210630q2ex312.htm ctre20210630q2ex321.htm http://xbrl.sec.gov/dei/2021 http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 true true JSON 72 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ctre-20210630.htm": { "axisCustom": 1, "axisStandard": 27, "contextCount": 190, "dts": { "calculationLink": { "local": [ "ctre-20210630_cal.xml" ] }, "definitionLink": { "local": [ "ctre-20210630_def.xml" ] }, "inline": { "local": [ "ctre-20210630.htm" ] }, "labelLink": { "local": [ "ctre-20210630_lab.xml" ], "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml" ] }, "presentationLink": { "local": [ "ctre-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml" ] }, "schema": { "local": [ "ctre-20210630.xsd" ], "remote": [ "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 468, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 9, "http://www.caretrustreit.com/20210630": 1, "http://xbrl.sec.gov/dei/2021": 5, "total": 15 }, "keyCustom": 59, "keyStandard": 277, "memberCustom": 38, "memberStandard": 35, "nsprefix": "ctre", "nsuri": "http://www.caretrustreit.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.caretrustreit.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RealEstateDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108103 - Disclosure - Real Estate Investments, Net", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNet", "shortName": "Real Estate Investments, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RealEstateDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "ctre:OtherRealEstateInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118104 - Disclosure - Other Real Estate Investments, Net", "role": "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNet", "shortName": "Other Real Estate Investments, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "ctre:OtherRealEstateInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120105 - Disclosure - Fair Value Measurements", "role": "http://www.caretrustreit.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125106 - Disclosure - Debt", "role": "http://www.caretrustreit.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130107 - Disclosure - Equity", "role": "http://www.caretrustreit.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135108 - Disclosure - Stock-Based Compensation", "role": "http://www.caretrustreit.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140109 - Disclosure - Earnings Per Common Share", "role": "http://www.caretrustreit.com/role/EarningsPerCommonShare", "shortName": "Earnings Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2143110 - Disclosure - Commitments and Contingencies", "role": "http://www.caretrustreit.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2145111 - Disclosure - Concentration of Risk", "role": "http://www.caretrustreit.com/role/ConcentrationofRisk", "shortName": "Concentration of Risk", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2147112 - Disclosure - Subsequent Events", "role": "http://www.caretrustreit.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RealEstateInvestmentPropertyNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AccountsReceivableNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Real Estate Investments, Net (Tables)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables", "shortName": "Real Estate Investments, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321303 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.caretrustreit.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2326304 - Disclosure - Debt (Tables)", "role": "http://www.caretrustreit.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331305 - Disclosure - Equity (Tables)", "role": "http://www.caretrustreit.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "ctre:ScheduleOfShareBasedPaymentAwardPerformanceStockAwardValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2336306 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.caretrustreit.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "ctre:ScheduleOfShareBasedPaymentAwardPerformanceStockAwardValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2341307 - Disclosure - Earnings Per Common Share (Tables)", "role": "http://www.caretrustreit.com/role/EarningsPerCommonShareTables", "shortName": "Earnings Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Organization (Details)", "role": "http://www.caretrustreit.com/role/OrganizationDetails", "shortName": "Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "role": "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i12fad9d9a69c4d32903094fc3516ca15_I20210630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)", "role": "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails", "shortName": "Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i040ec37a146143c092de14b016146d02_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Real Estate Investments, Net - Narrative (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails", "shortName": "Real Estate Investments, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - Real Estate Investments, Net - Investment in Owned Properties (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails", "shortName": "Real Estate Investments, Net - Investment in Owned Properties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412406 - Disclosure - Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails", "shortName": "Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfTenantPurchaseOptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ia224faafd7a2467ab35b250501f390d8_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:NumberOfPropertiesWithTenantPurchaseOption", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413407 - Disclosure - Real Estate Investments, Net - Tenant Purchase Options (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails", "shortName": "Real Estate Investments, Net - Tenant Purchase Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfTenantPurchaseOptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ia224faafd7a2467ab35b250501f390d8_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:NumberOfPropertiesWithTenantPurchaseOption", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i52c60bcf0bca4abe8bb6d9690b905449_D20210401-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414408 - Disclosure - Real Estate Investments, Net - Rental Income (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails", "shortName": "Real Estate Investments, Net - Rental Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i52c60bcf0bca4abe8bb6d9690b905449_D20210401-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfAssetsAcquisitionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415409 - Disclosure - Real Estate Investments, Net - Recent Real Estate Acquisitions (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "shortName": "Real Estate Investments, Net - Recent Real Estate Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfAssetsAcquisitionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": "INF", "lang": "en-US", "name": "ctre:NumberOfBedsOrUnitsInPropertiesAcquired", "reportCount": 1, "unique": true, "unitRef": "unit", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416410 - Disclosure - Real Estate Investments, Net - Asset Sales and Assets Held for Sale Narrative (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails", "shortName": "Real Estate Investments, Net - Asset Sales and Assets Held for Sale Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i5da9e554fce049eab3ff59febbedb09a_I20201231", "decimals": "INF", "lang": "en-US", "name": "ctre:NumberOfPropertiesToBeSold", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfAssetsAcquisitionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "ctre:OperatingLeasesAnticipatedInitialAnnualLeaseRevenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417411 - Disclosure - Real Estate Investments, Net - Lease Amendments Narrative (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "shortName": "Real Estate Investments, Net - Lease Amendments Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i8661a81652914d598453f11b274831a3_I20210601", "decimals": null, "lang": "en-US", "name": "us-gaap:LessorOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419412 - Disclosure - Other Real Estate Investments, Net (Details)", "role": "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "shortName": "Other Real Estate Investments, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:InterestAndFeeIncomeLoansCommercialRealEstate", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i63fa0139ae914f6ea9800c0313d93c36_D20210401-20210630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:InterestAndFeeIncomeLoansCommercialRealEstate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i52c60bcf0bca4abe8bb6d9690b905449_D20210401-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Income Statements", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "shortName": "Condensed Consolidated Income Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i52c60bcf0bca4abe8bb6d9690b905449_D20210401-20210630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ib9b2025d7a554bc5a03e471ba1478090_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LoansReceivableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422413 - Disclosure - Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails", "shortName": "Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ib9b2025d7a554bc5a03e471ba1478090_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LoansReceivableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i5c9401e05b4241cd80f09e9c8b9fc45f_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423414 - Disclosure - Fair Value Measurements - Narrative (Details)", "role": "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails", "shortName": "Fair Value Measurements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i5c9401e05b4241cd80f09e9c8b9fc45f_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "id081502a30c244e893bb80a6f79da8b3_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424415 - Disclosure - Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details)", "role": "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "shortName": "Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "id32bf1722fb14d6582c66ece122e60d6_I20210630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NotesPayableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427416 - Disclosure - Debt - Schedule of Debt (Details)", "role": "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "shortName": "Debt - Schedule of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOfUnsecuredDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428417 - Disclosure - Debt - Senior Unsecured Notes Payable Narrative (Details)", "role": "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "shortName": "Debt - Senior Unsecured Notes Payable Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i6f71554afbe64499915ab088655c6178_I20170510", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429418 - Disclosure - Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details)", "role": "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "shortName": "Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i40e7211da4e24202aed1c0430a089c0d_I20190208", "decimals": "-5", "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i4ae1a227f7994c3b8b61d8aa140dc5a8_I20200320", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432419 - Disclosure - Equity - Narrative (Details)", "role": "http://www.caretrustreit.com/role/EquityNarrativeDetails", "shortName": "Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i4ae1a227f7994c3b8b61d8aa140dc5a8_I20200320", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433420 - Disclosure - Equity - At-The-Market Offering (Details)", "role": "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "shortName": "Equity - At-The-Market Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i9bfcfadf9cd64720aeefbfa00db28063_D20210401-20210630", "decimals": "2", "lang": "en-US", "name": "ctre:SharesIssuedDuringPeriodAveragePricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i52c60bcf0bca4abe8bb6d9690b905449_D20210401-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434421 - Disclosure - Equity - Dividends on Common Stock (Details)", "role": "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails", "shortName": "Equity - Dividends on Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i52c60bcf0bca4abe8bb6d9690b905449_D20210401-20210630", "decimals": null, "lang": "en-US", "name": "us-gaap:DividendPayableDateToBePaidDayMonthAndYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437422 - Disclosure - Stock-Based Compensation - Narrative (Details)", "role": "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "shortName": "Stock-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ibd7399f69ec5431383a887bef804c6e1_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i00d624d4c9de4b25aaf6195aceb3811d_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Equity", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity", "shortName": "Condensed Consolidated Statements of Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i7267d3e75b8a4f01944c3f1423e62907_D20200101-20200331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "if3161dd5340848c4873412ece48630d4_D20210101-20210228", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438423 - Disclosure - Stock-Based Compensation - Valuation Assumptions (Details)", "role": "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails", "shortName": "Stock-Based Compensation - Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "if3161dd5340848c4873412ece48630d4_D20210101-20210228", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i52c60bcf0bca4abe8bb6d9690b905449_D20210401-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439424 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)", "role": "http://www.caretrustreit.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i52c60bcf0bca4abe8bb6d9690b905449_D20210401-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i52c60bcf0bca4abe8bb6d9690b905449_D20210401-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442425 - Disclosure - Earnings Per Common Share (Details)", "role": "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails", "shortName": "Earnings Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i52c60bcf0bca4abe8bb6d9690b905449_D20210401-20210630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ied85faa473b1428da79d51e5fc0efbc7_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:AggregateRequiredFinancingOfCapitalExpendituresAsPercentageOfInitialInvestmentInProperty", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444426 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ied85faa473b1428da79d51e5fc0efbc7_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:AggregateRequiredFinancingOfCapitalExpendituresAsPercentageOfInitialInvestmentInProperty", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i040ec37a146143c092de14b016146d02_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446427 - Disclosure - Concentration of Risk (Details)", "role": "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "shortName": "Concentration of Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "id94ec219c2394a0aac24ff4944d8ae79_D20210101-20210630", "decimals": "INF", "lang": "en-US", "name": "ctre:ConcentrationRiskNumberOfStates", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfAssetsAcquisitionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:NumberOfPropertiesAcquired", "reportCount": 1, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448428 - Disclosure - Subsequent Events (Details)", "role": "http://www.caretrustreit.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "ifc911840d48143ab986f373c91c5509e_I20210805", "decimals": "INF", "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unique": true, "unitRef": "facility", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "i52c60bcf0bca4abe8bb6d9690b905449_D20210401-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Equity (Parenthetical)", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquityParenthetical", "shortName": "Condensed Consolidated Statements of Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization", "role": "http://www.caretrustreit.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210630.htm", "contextRef": "icf6646f514184a22a1bcd0487659bfea_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 75, "tag": { "ctre_AggregateRequiredFinancingOfCapitalExpendituresAsPercentageOfInitialInvestmentInProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate Required Financing Of Capital Expenditures As Percentage Of Initial Investment In Property", "label": "Aggregate Required Financing Of Capital Expenditures As Percentage Of Initial Investment In Property", "terseLabel": "Aggregate required financing of capital expenditures as percentage of initial investment in property (percent)" } } }, "localname": "AggregateRequiredFinancingOfCapitalExpendituresAsPercentageOfInitialInvestmentInProperty", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "ctre_AnnualCashRentIncreaseUnderAmendedLease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Annual Cash Rent Increase Under Amended Lease", "label": "Annual Cash Rent Increase Under Amended Lease", "terseLabel": "Annual cash rent increase under amended lease" } } }, "localname": "AnnualCashRentIncreaseUnderAmendedLease", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ctre_AssistedLivingFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assisted Living Facility [Member]", "label": "Assisted Living Facility [Member]", "terseLabel": "Assisted living", "verboseLabel": "ALF" } } }, "localname": "AssistedLivingFacilityMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_AtTheMarketOfferingProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At-The-Market Offering Program [Member]", "label": "At-The-Market Offering Program [Member]", "terseLabel": "ATM Program" } } }, "localname": "AtTheMarketOfferingProgramMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_CapitalImprovementsAtTripleNetLeasedFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital Improvements At Triple Net Leased Facilities", "label": "Capital Improvements At Triple Net Leased Facilities [Member]", "terseLabel": "Certain capital improvements at triple-net leased facilities" } } }, "localname": "CapitalImprovementsAtTripleNetLeasedFacilitiesMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "ctre_CascadeCapitalGroupLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cascade Capital Group LLC", "label": "Cascade Capital Group LLC [Member]", "terseLabel": "Cascade Capital Group, LLC" } } }, "localname": "CascadeCapitalGroupLLCMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_CommuniCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CommuniCare [Member]", "label": "CommuniCare [Member]", "terseLabel": "CommuniCare" } } }, "localname": "CommuniCareMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "ctre_ConcentrationRiskNumberOfStates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of states where the entity's major tenants lease the highest concentration of properties.", "label": "Concentration Risk, Number Of States", "terseLabel": "Number of states where Ensign leases the highest concentration of properties" } } }, "localname": "ConcentrationRiskNumberOfStates", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "integerItemType" }, "ctre_DebtInstrumentRedemptionPriceUponChangeOfControlAsPercentageOfPrincipalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument redemption price upon change of control as percentage of principal amount.", "label": "Debt Instrument Redemption Price Upon Change Of Control As Percentage Of Principal Amount", "terseLabel": "Redemption price, percentage upon change of control (percent)" } } }, "localname": "DebtInstrumentRedemptionPriceUponChangeOfControlAsPercentageOfPrincipalAmount", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "percentItemType" }, "ctre_DisposalGroupIncludingDiscontinuedOperationContractPurchasePrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Contract Purchase Price", "label": "Disposal Group, Including Discontinued Operation, Contract Purchase Price", "terseLabel": "Contract purchase price" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationContractPurchasePrice", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ctre_EnsignAmendedTripleNetMasterLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ensign Amended Triple-Net Master Lease", "label": "Ensign Amended Triple-Net Master Lease [Member]", "terseLabel": "Ensign amended triple-net master lease" } } }, "localname": "EnsignAmendedTripleNetMasterLeaseMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_EnsignAndPennantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ensign And Pennant", "label": "Ensign And Pennant [Member]", "terseLabel": "Ensign and Pennant" } } }, "localname": "EnsignAndPennantMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "ctre_EnsignEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ensign Employees [Member]", "label": "Ensign Employees [Member]", "terseLabel": "Ensign employees" } } }, "localname": "EnsignEmployeesMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_EnsignMasterLeaseAmendedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ensign Master Lease Amended", "label": "Ensign Master Lease Amended [Member]", "terseLabel": "Ensign Master Lease Amended" } } }, "localname": "EnsignMasterLeaseAmendedMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "ctre_EnsignMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ensign [Member]", "label": "Ensign [Member]", "terseLabel": "Ensign" } } }, "localname": "EnsignMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "ctre_EquityMethodInvestmentCumulativeContractualPreferredReturn": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Cumulative Contractual Preferred Return", "label": "Equity Method Investment, Cumulative Contractual Preferred Return", "terseLabel": "Cumulative contractual preferred return through acquisition date" } } }, "localname": "EquityMethodInvestmentCumulativeContractualPreferredReturn", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "monetaryItemType" }, "ctre_EquityMethodInvestmentRateOfReturnFloor": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Rate Of Return, Floor", "label": "Equity Method Investment, Rate Of Return, Floor", "terseLabel": "Preferred equity investment minimum yield" } } }, "localname": "EquityMethodInvestmentRateOfReturnFloor", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "percentItemType" }, "ctre_EquityMethodInvestmentsBasisSpreadOnVariableRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investments, Basis Spread On Variable Rate", "label": "Equity Method Investments, Basis Spread On Variable Rate", "terseLabel": "Basis spread of preferred equity investment yield" } } }, "localname": "EquityMethodInvestmentsBasisSpreadOnVariableRate", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "percentItemType" }, "ctre_FiveOaksHealthcareLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Oaks Healthcare LLC", "label": "Five Oaks Healthcare LLC [Member]", "terseLabel": "Five Oaks Healthcare LLC" } } }, "localname": "FiveOaksHealthcareLLCMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_FivePointTwoFiveSeniorNotesDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Point Two Five Senior Notes Due 2025 [Member]", "label": "Five Point Two Five Senior Notes Due 2025 [Member]", "terseLabel": "2025 Senior unsecured notes payable", "verboseLabel": "5.25% Senior Notes due 2025" } } }, "localname": "FivePointTwoFiveSeniorNotesDue2025Member", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails", "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_GAAPRentIncreaseUnderAmendedLease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "GAAP Rent Increase Under Amended Lease", "label": "GAAP Rent Increase Under Amended Lease", "terseLabel": "GAAP rent increase under amended lease" } } }, "localname": "GAAPRentIncreaseUnderAmendedLease", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ctre_IncreaseDecreaseInDeferredFinancingCostsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Deferred Financing Costs Payable", "label": "Increase (Decrease) In Deferred Financing Costs Payable", "terseLabel": "Increased in deferred financing costs payable" } } }, "localname": "IncreaseDecreaseInDeferredFinancingCostsPayable", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ctre_IncreaseDecreaseInDividendsPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase Decrease In Dividends Payable", "label": "Increase Decrease In Dividends Payable", "terseLabel": "Increase in dividends payable" } } }, "localname": "IncreaseDecreaseInDividendsPayable", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ctre_InitialLeaseYield": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Lease Yield", "label": "Initial Lease Yield", "terseLabel": "Initial lease yield (percent)" } } }, "localname": "InitialLeaseYield", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "percentItemType" }, "ctre_LeaseArrangementsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Arrangements", "label": "Lease Arrangements [Axis]", "terseLabel": "Lease Arrangements [Axis]" } } }, "localname": "LeaseArrangementsAxis", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "ctre_LeaseArrangementsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Arrangements", "label": "Lease Arrangements [Domain]", "terseLabel": "Lease Arrangements [Domain]" } } }, "localname": "LeaseArrangementsDomain", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "ctre_LessorAnnualizedCashRevenueForContractsInPlace": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessor, Annualized Cash Revenue For Contracts In Place", "label": "Lessor, Annualized Cash Revenue For Contracts In Place", "terseLabel": "Current Cash Rent" } } }, "localname": "LessorAnnualizedCashRevenueForContractsInPlace", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "monetaryItemType" }, "ctre_LessorOperatingLeaseNumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessor, Operating Lease, Number Of Renewal Options", "label": "Lessor, Operating Lease, Number Of Renewal Options", "terseLabel": "Number of renewal options" } } }, "localname": "LessorOperatingLeaseNumberOfRenewalOptions", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "ctre_LineOfCreditCommitmentFeeBasedOnInvestmentGradeRatingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line Of Credit, Commitment Fee Based On Investment Grade Rating, Percentage", "label": "Line Of Credit, Commitment Fee Based On Investment Grade Rating, Percentage", "terseLabel": "Facility fee on revolving commitment fee based on investment grade ratings (percent)" } } }, "localname": "LineOfCreditCommitmentFeeBasedOnInvestmentGradeRatingPercentage", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "percentItemType" }, "ctre_LineOfCreditFacilityExtensionOptionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of credit facility extension option term.", "label": "Line Of Credit Facility Extension Option Term", "terseLabel": "Extension option term (in months)" } } }, "localname": "LineOfCreditFacilityExtensionOptionTerm", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "durationItemType" }, "ctre_LineOfCreditFacilityNumberOfExtensionOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility, Number Of Extension Options", "label": "Line Of Credit Facility, Number Of Extension Options", "terseLabel": "Number of extension options" } } }, "localname": "LineOfCreditFacilityNumberOfExtensionOptions", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_LineOfCreditSubfacilityCapacityAsPercentageOfAvailableRevolvingCommitments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line Of Credit, Subfacility, Capacity As Percentage Of Available Revolving Commitments", "label": "Line Of Credit, Subfacility, Capacity As Percentage Of Available Revolving Commitments", "terseLabel": "Subfacility capacity as percentage of available revolving commitments (percent)" } } }, "localname": "LineOfCreditSubfacilityCapacityAsPercentageOfAvailableRevolvingCommitments", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "percentItemType" }, "ctre_LoanReceivableExtensionOptionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Receivable, Extension Option, Term", "label": "Loan Receivable, Extension Option, Term", "terseLabel": "Extension option term (in months)" } } }, "localname": "LoanReceivableExtensionOptionTerm", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "durationItemType" }, "ctre_LoanReceivableNumberOfBedsInPropertyUtilizedToSecureLoan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Receivable, Number Of Beds In Property Utilized To Secure Loan", "label": "Loan Receivable, Number Of Beds In Property Utilized To Secure Loan", "terseLabel": "Number of beds in facility used to secure loan" } } }, "localname": "LoanReceivableNumberOfBedsInPropertyUtilizedToSecureLoan", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "integerItemType" }, "ctre_LoanReceivableNumberOfExtensionOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Receivable, Number Of Extension Options", "label": "Loan Receivable, Number Of Extension Options", "terseLabel": "Number of extension options" } } }, "localname": "LoanReceivableNumberOfExtensionOptions", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "integerItemType" }, "ctre_LoanReceivableNumberOfFacilitiesInAgreementSecuredByMembershipInterests": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Receivable, Number Of Facilities In Agreement Secured By Membership Interests", "label": "Loan Receivable, Number Of Facilities In Agreement Secured By Membership Interests", "terseLabel": "Number of facilities in agreement secured by membership interests" } } }, "localname": "LoanReceivableNumberOfFacilitiesInAgreementSecuredByMembershipInterests", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "integerItemType" }, "ctre_LoanReceivableNumberOfFacilitiesUtilizedToSecureMortgageLoan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Receivable Number Of Facilities Utilized To Secure Mortgage Loan", "label": "Loan Receivable, Number Of Facilities Utilized To Secure Mortgage Loan", "terseLabel": "Facilities utilized to secure mortgage loan" } } }, "localname": "LoanReceivableNumberOfFacilitiesUtilizedToSecureMortgageLoan", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "integerItemType" }, "ctre_LoanReceivablePeriodOfUnpaidInterestPaymentsDueUponPrepayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Receivable, Period Of Unpaid Interest Payments Due Upon Prepayment", "label": "Loan Receivable, Period Of Unpaid Interest Payments Due Upon Prepayment", "terseLabel": "Period of unpaid interest payments due upon prepayment" } } }, "localname": "LoanReceivablePeriodOfUnpaidInterestPaymentsDueUponPrepayment", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "durationItemType" }, "ctre_LoansReceivableExitFeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loans Receivable, Exit Fee, Percent", "label": "Loans Receivable, Exit Fee, Percent", "terseLabel": "Loans receivable exit fee (percent)" } } }, "localname": "LoansReceivableExitFeePercent", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "percentItemType" }, "ctre_LoansReceivableFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loans Receivable, Fixed Interest Rate", "label": "Loans Receivable, Fixed Interest Rate", "terseLabel": "Loan receivable interest rate (percent)" } } }, "localname": "LoansReceivableFixedInterestRate", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "percentItemType" }, "ctre_LoansReceivableLIBORFloorPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loans Receivable, LIBOR Floor, Percentage", "label": "Loans Receivable, LIBOR Floor, Percentage", "terseLabel": "LIBOR floor for loan (percent)" } } }, "localname": "LoansReceivableLIBORFloorPercentage", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "percentItemType" }, "ctre_MantecaValleyPostAcuteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manteca Valley Post Acute [Member]", "label": "Manteca Valley Post Acute [Member]", "terseLabel": "MCRC, LLC" } } }, "localname": "MantecaValleyPostAcuteMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "ctre_MetronSkilledNursingFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Metron Skilled Nursing Facilities [Member]", "label": "Metron Skilled Nursing Facilities [Member]", "terseLabel": "Metron skilled nursing facilities" } } }, "localname": "MetronSkilledNursingFacilitiesMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_MezzanineLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mezzanine Loan", "label": "Mezzanine Loan [Member]", "terseLabel": "Mezzanine loan receivable" } } }, "localname": "MezzanineLoanMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "ctre_MortgageLoanCombinedPrincipal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Mortgage Loan, Combined Principal", "label": "Mortgage Loan, Combined Principal", "terseLabel": "Combined principal amount of loan" } } }, "localname": "MortgageLoanCombinedPrincipal", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "monetaryItemType" }, "ctre_MultiServiceCampusPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Multi-Service Campus Properties [Member]", "label": "Multi-Service Campus Properties [Member]", "terseLabel": "Multi-service campuses(3)" } } }, "localname": "MultiServiceCampusPropertiesMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "ctre_NewRevolvingFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Revolving Facility [Member]", "label": "New Revolving Facility [Member]", "terseLabel": "New Revolving Facility" } } }, "localname": "NewRevolvingFacilityMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_NewTermLoanFeb2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Term Loan Feb 2019 [Member]", "label": "New Term Loan Feb 2019 [Member]", "terseLabel": "Term Loan" } } }, "localname": "NewTermLoanFeb2019Member", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_NextVAStarRealtyHoldingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Next VA Star Realty Holdings LLC", "label": "Next VA Star Realty Holdings LLC [Member]", "terseLabel": "Next VA Star Realty Holdings LLC" } } }, "localname": "NextVAStarRealtyHoldingsLLCMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "ctre_NobleTripleNetMasterLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noble Triple-Net Master Lease", "label": "Noble Triple-Net Master Lease [Member]", "terseLabel": "Noble triple-net master lease" } } }, "localname": "NobleTripleNetMasterLeaseMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_NobleVAHoldingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noble VA Holdings LLC", "label": "Noble VA Holdings LLC [Member]", "terseLabel": "Noble" } } }, "localname": "NobleVAHoldingsLLCMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_NumberOfBedsOrUnitsInPropertiesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Beds Or Units In Properties Acquired", "label": "Number Of Beds Or Units In Properties Acquired", "terseLabel": "Number of Beds/Units" } } }, "localname": "NumberOfBedsOrUnitsInPropertiesAcquired", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfBedsPlannedForConstruction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Beds Planned For Construction", "label": "Number Of Beds Planned For Construction", "terseLabel": "Number of beds planned for construction" } } }, "localname": "NumberOfBedsPlannedForConstruction", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfOperationalBeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Operational Beds", "label": "Number Of Operational Beds", "terseLabel": "Number of operational beds" } } }, "localname": "NumberOfOperationalBeds", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfOperationalBedsAndUnitsInFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Operational Beds And Units In Facilities", "label": "Number Of Operational Beds And Units In Facilities", "terseLabel": "Number of operational beds and units in facilities" } } }, "localname": "NumberOfOperationalBedsAndUnitsInFacilities", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OrganizationDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfPropertiesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Properties Acquired", "label": "Number Of Properties Acquired", "terseLabel": "Number of Properties", "verboseLabel": "Number of properties acquired" } } }, "localname": "NumberOfPropertiesAcquired", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfPropertiesSold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Properties Sold", "label": "Number Of Properties Sold", "terseLabel": "Number of properties sold" } } }, "localname": "NumberOfPropertiesSold", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfPropertiesToBeSold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Properties To Be Sold", "label": "Number Of Properties To Be Sold", "terseLabel": "Number of properties held for sale" } } }, "localname": "NumberOfPropertiesToBeSold", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfPropertiesTransferred": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Properties Transferred", "label": "Number Of Properties Transferred", "terseLabel": "Number of properties transferred" } } }, "localname": "NumberOfPropertiesTransferred", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfPropertiesWithRightToOperate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Properties With Right To Operate", "label": "Number Of Properties With Right To Operate", "terseLabel": "Number of properties with right to operate" } } }, "localname": "NumberOfPropertiesWithRightToOperate", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfPropertiesWithTenantPurchaseOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Properties With Tenant Purchase Option", "label": "Number Of Properties With Tenant Purchase Option", "terseLabel": "Properties" } } }, "localname": "NumberOfPropertiesWithTenantPurchaseOption", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfUnitsAndBedsInFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Units And Beds In Facilities", "label": "Number Of Units And Beds In Facilities", "terseLabel": "Number of beds and units in facilities" } } }, "localname": "NumberOfUnitsAndBedsInFacilities", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "integerItemType" }, "ctre_OfficerAndEmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Officer And Employee", "label": "Officer And Employee [Member]", "terseLabel": "Officers and employees" } } }, "localname": "OfficerAndEmployeeMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_OperatingLeasesAnticipatedInitialAnnualLeaseRevenues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Leases, Anticipated Initial Annual Lease Revenues", "label": "Operating Leases, Anticipated Initial Annual Lease Revenues", "terseLabel": "Initial Annual Cash Rent", "verboseLabel": "Initial annual cash rents" } } }, "localname": "OperatingLeasesAnticipatedInitialAnnualLeaseRevenues", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "ctre_OperatingLeasesAnticipatedInitialAnnualLeaseRevenuesSubjectToFixedEscalatorInFirstTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Leases, Anticipated Initial Annual Lease Revenues, Subject To Fixed Escalator In First Twelve Months", "label": "Operating Leases, Anticipated Initial Annual Lease Revenues, Subject To Fixed Escalator In First Twelve Months", "terseLabel": "Initial rent subject to a fixed escalator in first twelve months" } } }, "localname": "OperatingLeasesAnticipatedInitialAnnualLeaseRevenuesSubjectToFixedEscalatorInFirstTwelveMonths", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "ctre_OperatingLeasesAnticipatedInitialAnnualLeaseRevenuesSubjectToFixedEscalatorInYearTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Leases, Anticipated Initial Annual Lease Revenues, Subject To Fixed Escalator In Year Two", "label": "Operating Leases, Anticipated Initial Annual Lease Revenues, Subject To Fixed Escalator In Year Two", "terseLabel": "Initial rent subject to a fixed escalator in second year" } } }, "localname": "OperatingLeasesAnticipatedInitialAnnualLeaseRevenuesSubjectToFixedEscalatorInYearTwo", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "ctre_OtherRealEstateInvestmentsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Real Estate Investments", "label": "Other Real Estate Investments [Text Block]", "terseLabel": "Other Real Estate Investments, Net" } } }, "localname": "OtherRealEstateInvestmentsTextBlock", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNet" ], "xbrltype": "textBlockItemType" }, "ctre_PaymentsToAcquireEquipmentFurnitureAndFixturesAndDevelopRealEstateAssets": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Equipment, Furniture And Fixtures And Develop Real Estate Assets", "label": "Payments To Acquire Equipment, Furniture And Fixtures And Develop Real Estate Assets", "negatedTerseLabel": "Purchases of equipment, furniture and fixtures and improvements to real estate" } } }, "localname": "PaymentsToAcquireEquipmentFurnitureAndFixturesAndDevelopRealEstateAssets", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ctre_PortionOfCommitmentSubjectToRentIncreaseAtTimeOfFunding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion Of Commitment Subject To Rent Increase At Time Of Funding", "label": "Portion Of Commitment Subject To Rent Increase At Time Of Funding", "terseLabel": "Portion of funding commitment subject to rent increase at time of funding" } } }, "localname": "PortionOfCommitmentSubjectToRentIncreaseAtTimeOfFunding", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "ctre_PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Equity Investment Cascadia Development Boise ID", "label": "Preferred Equity Investment Cascadia Development Boise ID [Member]", "terseLabel": "Cascadia Development, Boise ID" } } }, "localname": "PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "ctre_PriorityManagementGroupLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Priority Management Group LLC", "label": "Priority Management Group LLC [Member]", "terseLabel": "PMG" } } }, "localname": "PriorityManagementGroupLLCMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationMarch2029NextOption2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration March 2029, Next Option 2022", "label": "Properties With Purchase Option, Lease Expiration March 2029, Next Option 2022 [Member]", "terseLabel": "Lease Expiration March 2029, Next option 2022" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationMarch2029NextOption2022Member", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationNovember2030NextOption2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration November 2030, Next Option 2022", "label": "Properties With Purchase Option, Lease Expiration November 2030, Next Option 2022 [Member]", "terseLabel": "Lease Expiration November 2030, Next option 2022" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationNovember2030NextOption2022Member", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationNovember2034NextOption2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration November 2034, Next Option 2024", "label": "Properties With Purchase Option, Lease Expiration November 2034, Next Option 2024 [Member]", "terseLabel": "Lease Expiration November 2034, Next option 2024" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationNovember2034NextOption2024Member", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationOctober2032NextOption2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration October 2032, Next Option 2023", "label": "Properties With Purchase Option, Lease Expiration October 2032, Next Option 2023 [Member]", "terseLabel": "Lease Expiration October 2032, Next option 2023" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationOctober2032NextOption2023Member", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationOctober2034NextOption2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration October 2034, Next Option 2022", "label": "Properties With Purchase Option, Lease Expiration October 2034, Next Option 2022 [Member]", "terseLabel": "Lease Expiration October 2034, Next option 2021" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationOctober2034NextOption2022Member", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationOctober2034NextOption2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration October 2034, Next Option 2026", "label": "Properties With Purchase Option, Lease Expiration October 2034, Next Option 2026 [Member]", "terseLabel": "Lease Expiration October 2034, Next option 2026" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationOctober2034NextOption2026Member", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_PurchaseAndSaleAgreementAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase And Sale Agreement, Amount", "label": "Purchase And Sale Agreement, Amount", "terseLabel": "Purchase and sale agreement amount" } } }, "localname": "PurchaseAndSaleAgreementAmount", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "monetaryItemType" }, "ctre_PurchaseAndSaleAgreementMaturityDateOptionNumberOfDaysAfterTermination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase And Sale Agreement, Maturity Date Option, Number Of Days After Termination", "label": "Purchase And Sale Agreement, Maturity Date Option, Number Of Days After Termination", "terseLabel": "Number of days after termination of purchase and sale agreement for maturity" } } }, "localname": "PurchaseAndSaleAgreementMaturityDateOptionNumberOfDaysAfterTermination", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "durationItemType" }, "ctre_ScheduleOfAssetsAcquisitionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Assets Acquisitions [Table Text Block]", "label": "Schedule Of Assets Acquisitions [Table Text Block]", "terseLabel": "Schedule of Real Estate Acquisitions" } } }, "localname": "ScheduleOfAssetsAcquisitionsTableTextBlock", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "ctre_ScheduleOfShareBasedPaymentAwardPerformanceStockAwardValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Share-Based Payment Award, Performance Stock Award, Valuation Assumptions", "label": "Schedule Of Share-Based Payment Award, Performance Stock Award, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardPerformanceStockAwardValuationAssumptionsTableTextBlock", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "ctre_ScheduleOfTenantPurchaseOptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Tenant Purchase Options", "label": "Schedule Of Tenant Purchase Options [Table Text Block]", "terseLabel": "Schedule Of Tenant Purchase Options" } } }, "localname": "ScheduleOfTenantPurchaseOptionsTableTextBlock", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "ctre_SecuritiesOfferingAuthorizedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Securities Offering, Authorized Amount", "label": "Securities Offering, Authorized Amount", "terseLabel": "Authorized aggregate offering price of common stock" } } }, "localname": "SecuritiesOfferingAuthorizedAmount", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ctre_SecuritiesOfferingRemainingAuthorizedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Securities Offering, Remaining Authorized Amount", "label": "Securities Offering, Remaining Authorized Amount", "terseLabel": "Remaining offering amount available" } } }, "localname": "SecuritiesOfferingRemainingAuthorizedAmount", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ctre_SeniorUnsecuredNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Unsecured Notes [Member]", "label": "Senior Unsecured Notes [Member]", "terseLabel": "Senior unsecured notes" } } }, "localname": "SeniorUnsecuredNotesMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_SeniorUnsecuredTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Unsecured Term Loan [Member]", "label": "Senior Unsecured Term Loan [Member]", "terseLabel": "Senior unsecured term loan", "verboseLabel": "New Term Loan" } } }, "localname": "SeniorUnsecuredTermLoanMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfEqualAnnualInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting, Number of Equal Annual Installments", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting, Number Of Equal Annual Installments", "terseLabel": "Number of equal annual vesting installments" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfEqualAnnualInstallments", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedSpinOffInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options nonvested spin off in period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Spin Off In Period", "terseLabel": "Stock awards unvested during spin-off (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedSpinOffInPeriod", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ctre_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityTermForExpectedVolatility": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Historical Volatility Term For Expected Volatility", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Term For Expected Volatility", "terseLabel": "Historical volatility term basis for expected volatility assumption" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityTermForExpectedVolatility", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "ctre_ShareBasedCompensationArrangementByShareBasedPaymentAwardTSRPerformancePercentageToVestRelativeToInitialGrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, TSR Performance, Percentage To Vest Relative To Initial Grant", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, TSR Performance, Percentage To Vest Relative To Initial Grant", "terseLabel": "Percentage of awards to vest relative To initial grant based on TSR performance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTSRPerformancePercentageToVestRelativeToInitialGrant", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "ctre_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingMetricTSRPerformancePeerGroupNumberOfCompanies": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Metric, TSR Performance Peer Group Number Of Companies", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Metric, TSR Performance Peer Group Number Of Companies", "terseLabel": "Number of publicly traded healthcare REITs in peer group" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingMetricTSRPerformancePeerGroupNumberOfCompanies", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_SharesIssuedDuringPeriodAveragePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Issued During Period, Average Price Per Share", "label": "Shares Issued During Period, Average Price Per Share", "terseLabel": "Average sales price per share" } } }, "localname": "SharesIssuedDuringPeriodAveragePricePerShare", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails" ], "xbrltype": "perShareItemType" }, "ctre_SkilledNursingAndCampusFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing And Campus Facilities", "label": "Skilled Nursing And Campus Facilities [Member]", "terseLabel": "Skilled nursing and campus facilities", "verboseLabel": "SNF / Campus" } } }, "localname": "SkilledNursingAndCampusFacilitiesMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_SkilledNursingFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing Facility [Member]", "label": "Skilled Nursing Facility [Member]", "terseLabel": "Skilled nursing facility", "verboseLabel": "SNF" } } }, "localname": "SkilledNursingFacilityMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "ctre_SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities", "label": "Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities [Member]", "terseLabel": "Skilled nursing, multi-service campuses, assisted living and independent living facilities" } } }, "localname": "SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_SkilledNursingPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing Properties [Member]", "label": "Skilled Nursing Properties [Member]", "terseLabel": "Skilled nursing", "verboseLabel": "Skilled nursing properties" } } }, "localname": "SkilledNursingPropertiesMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "ctre_SwinglineLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swingline Loan [Member]", "label": "Swingline Loan [Member]", "terseLabel": "Swingline loan" } } }, "localname": "SwinglineLoanMember", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_ThreePointEightSevenFiveSeniorNotesDue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Eight Seven Five Senior Notes Due 2028", "label": "Three Point Eight Seven Five Senior Notes Due 2028 [Member]", "terseLabel": "2028 Senior unsecured notes payable", "verboseLabel": "3.875% Senior Notes due 2028" } } }, "localname": "ThreePointEightSevenFiveSeniorNotesDue2028Member", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ctre_TransferOfPreacquisitionCostsToAcquiredAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transfer Of Preacquisition Costs To Acquired Assets", "label": "Transfer Of Preacquisition Costs To Acquired Assets", "terseLabel": "Transfer of pre-acquisition costs to acquired assets" } } }, "localname": "TransferOfPreacquisitionCostsToAcquiredAssets", "nsuri": "http://www.caretrustreit.com/20210630", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r36", "r38", "r86", "r87", "r200", "r240" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails", "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Board of Directors" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r157", "r263", "r265", "r420" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r199", "r239", "r276", "r279", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r419", "r421", "r442", "r444" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r199", "r239", "r276", "r279", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r419", "r421", "r442", "r444" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r157", "r263", "r265", "r420" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "srt_OfficerMember": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "label": "Officer [Member]", "terseLabel": "Officers" } } }, "localname": "OfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r199", "r239", "r266", "r276", "r279", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r419", "r421", "r442", "r444" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r199", "r239", "r266", "r276", "r279", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r419", "r421", "r442", "r444" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]", "terseLabel": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]", "terseLabel": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r37", "r38", "r86", "r87", "r200", "r240" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails", "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r98", "r277" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r98", "r103", "r277" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r98", "r103", "r182", "r277", "r369" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r158", "r363" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]", "terseLabel": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.", "label": "Accounts Payable and Other Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r16", "r401", "r427" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, after Allowance for Credit Loss", "terseLabel": "Accounts and other receivables" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDistributionsInExcessOfNetIncome": { "auth_ref": [ "r426" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount as of the balance sheet date by which cumulative distributions to shareholders (or partners) exceed retained earnings (or accumulated earnings).", "label": "Accumulated Distributions in Excess of Net Income", "negatedLabel": "Cumulative distributions in excess of earnings" } } }, "localname": "AccumulatedDistributionsInExcessOfNetIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDistributionsInExcessOfNetIncomeMember": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Cumulative distributions to shareholders (or partners) in excess of retained earnings (or accumulated earnings).", "label": "Accumulated Distributions in Excess of Net Income [Member]", "terseLabel": "Cumulative Distributions in Excess of Earnings" } } }, "localname": "AccumulatedDistributionsInExcessOfNetIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r17" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r90", "r91", "r92", "r297", "r298", "r299", "r319" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r280", "r282", "r302", "r303" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Amortization of stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r253", "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedTerseLabel": "Issuance of common stock, net" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r282", "r294", "r301" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Amortization of stock-based compensation", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r72", "r219", "r228", "r229", "r350" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of deferred financing costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r310", "r311", "r312", "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Purchase Price", "verboseLabel": "Aggregate purchase price" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets": { "auth_ref": [ "r310", "r311", "r312" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tangible and intangible assets included as part of consideration transferred in asset acquisition, classified as other. Excludes cash.", "label": "Asset Acquisition, Consideration Transferred, Other Assets", "terseLabel": "Prepaid rent component" } } }, "localname": "AssetAcquisitionConsiderationTransferredOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r85", "r143", "r147", "r153", "r165", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r314", "r316", "r338", "r364", "r366", "r384", "r402" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup": { "auth_ref": [ "r173" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets held-for-sale that are not part of a disposal group.", "label": "Assets Held-for-sale, Not Part of Disposal Group", "terseLabel": "Assets held for sale, net" } } }, "localname": "AssetsHeldForSaleNotPartOfDisposalGroup", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r283", "r296" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Amount" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r6", "r22", "r74" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r8", "r75", "r383" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r67", "r74", "r80" ], "calculation": { "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash as of the end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash as of the beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r67", "r339" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental schedule of noncash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r31", "r181", "r390", "r408" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r178", "r179", "r180", "r183", "r429" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Common dividends (in usd per share)", "verboseLabel": "Dividends declared per share" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquityParenthetical", "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r90", "r91", "r319" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r253" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding (shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15", "r366" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01 par value; 500,000,000 shares authorized, 96,296,673 and 95,215,797 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r135", "r136", "r157", "r335", "r336", "r428" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r135", "r136", "r157", "r335", "r336", "r425", "r428" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r135", "r136", "r157", "r335", "r336", "r425", "r428" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Concentration of Risk" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRisk" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r135", "r136", "r157", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk (percent)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r133", "r135", "r136", "r137", "r335", "r337", "r428" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r135", "r136", "r157", "r335", "r336", "r428" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r52", "r381" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Independent living facilities" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r51" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r134", "r157" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer concentration risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r81", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r213", "r220", "r221", "r223", "r232" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r9", "r10", "r11", "r84", "r88", "r196", "r197", "r198", "r199", "r200", "r201", "r203", "r209", "r210", "r211", "r212", "r214", "r215", "r216", "r217", "r218", "r219", "r226", "r227", "r228", "r229", "r351", "r385", "r387", "r400" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails", "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r11", "r224", "r387", "r400" ], "calculation": { "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Principal Amount", "verboseLabel": "Outstanding amounts" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r196", "r226", "r227", "r349", "r351", "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument face amount", "verboseLabel": "Senior unsecured notes payable - face value" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r29", "r197" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate (percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r30", "r84", "r88", "r196", "r197", "r198", "r199", "r200", "r201", "r203", "r209", "r210", "r211", "r212", "r214", "r215", "r216", "r217", "r218", "r219", "r226", "r227", "r228", "r229", "r351" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails", "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "Period prior to June 30 2024" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Three [Member]", "terseLabel": "Period after March 30 2028" } } }, "localname": "DebtInstrumentRedemptionPeriodThreeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Two [Member]", "terseLabel": "Period prior to March 30 2028" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price of notes (percent)" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount of debt redeemed.", "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed", "terseLabel": "Percentage of principal amount (percent)" } } }, "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r30", "r84", "r88", "r196", "r197", "r198", "r199", "r200", "r201", "r203", "r209", "r210", "r211", "r212", "r214", "r215", "r216", "r217", "r218", "r219", "r222", "r226", "r227", "r228", "r229", "r254", "r257", "r258", "r259", "r348", "r349", "r351", "r352", "r399" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r350" ], "calculation": { "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "negatedTerseLabel": "Deferred Loan Fees" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r25", "r209", "r350" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Deferred financing costs, net" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r72", "r176" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r72", "r142" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization (including below-market ground leases)" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "auth_ref": [ "r1", "r2", "r3" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Discontinued Operations, Held-for-sale [Member]", "terseLabel": "Held for sale" } } }, "localname": "DiscontinuedOperationsHeldforsaleMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r175", "r177" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposed of by sale" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r174", "r175", "r177" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Held for sale" } } }, "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r275", "r278" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Date the declared dividend will be paid, in YYYY-MM-DD format.", "label": "Dividends Payable, Date to be Paid", "terseLabel": "Dividends payment date" } } }, "localname": "DividendPayableDateToBePaidDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r260", "r397" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Common Stock", "negatedLabel": "Common dividends", "terseLabel": "Dividends payable as of record date" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity", "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCommonStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividends, Common Stock [Abstract]", "terseLabel": "Dividends on common stock" } } }, "localname": "DividendsCommonStockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsDeclaredTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.", "label": "Dividends Declared [Table Text Block]", "terseLabel": "Schedule of Dividends on Common Stock" } } }, "localname": "DividendsDeclaredTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r10", "r12", "r386", "r403" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable", "verboseLabel": "Dividends payable" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format.", "label": "Dividends Payable, Date of Record", "terseLabel": "Dividends record date" } } }, "localname": "DividendsPayableDateOfRecordDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails" ], "xbrltype": "dateItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r48", "r95", "r96", "r97", "r98", "r99", "r104", "r107", "r118", "r121", "r122", "r126", "r127", "r320", "r321", "r393", "r414" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in usd per share)", "verboseLabel": "Earnings per common share, basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r48", "r95", "r96", "r97", "r98", "r99", "r107", "r118", "r121", "r122", "r126", "r127", "r320", "r321", "r393", "r414" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in usd per share)", "verboseLabel": "Earnings per common share, diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r123", "r124", "r125", "r128" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EarningsPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unamortized stock-based compensation expense related to unvested awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average remaining vesting period related to expense recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r41", "r42", "r43", "r90", "r91", "r92", "r94", "r100", "r102", "r130", "r166", "r253", "r260", "r297", "r298", "r299", "r306", "r307", "r319", "r340", "r341", "r342", "r343", "r344", "r345", "r422", "r423", "r424", "r455" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r46", "r66", "r72", "r412" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Proceeds from Equity Method Investment, Distribution", "terseLabel": "Interest income distribution from other real estate investment" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r23", "r144", "r163" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Preferred equity investment" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r211", "r226", "r227", "r332" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment of Debt, Amount", "terseLabel": "Redemption of debt" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r322", "r323", "r324", "r328" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Items Measured at Fair Value on a Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r322", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r322", "r333" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Summary of Face Value, Carrying Amount and Fair Value of Financial Instruments" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r211", "r226", "r227", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r323", "r371", "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r211", "r226", "r227", "r322", "r329" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r322", "r323", "r325", "r326", "r330" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r211", "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r211", "r267", "r268", "r273", "r274", "r323", "r371" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r211", "r226", "r227", "r267", "r268", "r273", "r274", "r323", "r372" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r211", "r226", "r227", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r323", "r373" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r211", "r226", "r227", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r371", "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r327", "r330" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]", "terseLabel": "Financial liabilities:" } } }, "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Financing Receivable, Past Due [Line Items]", "terseLabel": "Financing Receivable, Past Due [Line Items]" } } }, "localname": "FinancingReceivableRecordedInvestmentPastDueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Financial asset equal to or greater than 90 days past due.", "label": "Financial Asset, Equal to or Greater than 90 Days Past Due [Member]", "terseLabel": "Greater than 90 days past due" } } }, "localname": "FinancingReceivablesEqualToGreaterThan90DaysPastDueMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancingReceivablesPeriodPastDueAxis": { "auth_ref": [ "r160", "r168", "r171" ], "lang": { "en-us": { "role": { "documentation": "Information by period in which financial asset is past due or not past due.", "label": "Financial Asset, Aging [Axis]", "terseLabel": "Financial Asset, Aging [Axis]" } } }, "localname": "FinancingReceivablesPeriodPastDueAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivablesPeriodPastDueDomain": { "auth_ref": [ "r160", "r168", "r171" ], "lang": { "en-us": { "role": { "documentation": "Period in which financial asset is past due or not past due. For past due, element name and standard label in Financial Asset, [numeric lower end] to [numeric higher end] [date measure] Past Due [Member] or Financial Asset, Greater than [low end numeric value] [date measure] Past Due [Member] or Financial Asset, Less than [high end numeric value] [date measure] Past Due [Member] formats.", "label": "Financial Asset, Aging [Domain]", "terseLabel": "Financial Asset, Aging [Domain]" } } }, "localname": "FinancingReceivablesPeriodPastDueDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r172", "r382" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails": { "order": 4.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Identified intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FixturesAndEquipmentGross": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails": { "order": 3.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.", "label": "Fixtures and Equipment, Gross", "terseLabel": "Integral equipment, furniture and fixtures" } } }, "localname": "FixturesAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnTerminationOfLease": { "auth_ref": [ "r353" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeaseLeaseIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.", "label": "Gain (Loss) on Termination of Lease", "terseLabel": "Lease termination revenue" } } }, "localname": "GainLossOnTerminationOfLease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r72", "r230", "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r230", "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.", "label": "Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost", "negatedTerseLabel": "Loss on redemption price" } } }, "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnSalesOfInvestmentRealEstate": { "auth_ref": [ "r49", "r50", "r72", "r391", "r415", "r416", "r417", "r418" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net gain (loss) resulting from sales and other disposals of real estate owned for investment purposes.", "label": "Gains (Losses) on Sales of Investment Real Estate", "negatedTerseLabel": "Loss on sale of real estate", "terseLabel": "Loss on sale of real estate", "verboseLabel": "Gain (loss) on sale of real estate" } } }, "localname": "GainsLossesOnSalesOfInvestmentRealEstate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r53" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r275", "r278" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r71" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r71" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts and other receivables" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r71" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets, net" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r108", "r109", "r110", "r122" ], "calculation": { "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Dilutive market condition stock awards" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestAndFeeIncomeLoansCommercialRealEstate": { "auth_ref": [ "r394" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest and fee income generated from loans secured by commercial properties. Examples of properties commonly securing commercial real estate loans may include office buildings, apartment buildings, shopping centers, industrial property, and hotels.", "label": "Interest and Fee Income, Loans, Commercial, Real Estate", "terseLabel": "Interest income" } } }, "localname": "InterestAndFeeIncomeLoansCommercialRealEstate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndOtherIncome": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 3.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).", "label": "Interest and Other Income", "terseLabel": "Interest and other income" } } }, "localname": "InterestAndOtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r44", "r141", "r347", "r350", "r395" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "terseLabel": "Interest income related to preferred equity investments" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r65", "r69", "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentBuildingAndBuildingImprovements": { "auth_ref": [ "r410" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements.", "label": "Investment Building and Building Improvements", "terseLabel": "Buildings and improvements" } } }, "localname": "InvestmentBuildingAndBuildingImprovements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r7", "r24" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LessorLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessor, Lease, Description [Line Items]", "terseLabel": "Lessor, Lease, Description [Line Items]" } } }, "localname": "LessorLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorLeaseDescriptionTable": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessor's leases.", "label": "Lessor, Lease, Description [Table]", "terseLabel": "Lessor, Lease, Description [Table]" } } }, "localname": "LessorLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]", "terseLabel": "Future Contractual Minimum Rental Income" } } }, "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r358" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received", "totalLabel": "Total" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "auth_ref": [ "r358" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 6.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Five", "terseLabel": "2026" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "auth_ref": [ "r358" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 5.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "terseLabel": "2025" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Total Future Contractual Minimum Rental Income" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r358" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "terseLabel": "2022" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": { "auth_ref": [ "r358" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year", "terseLabel": "2021 (six months)" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "auth_ref": [ "r358" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 7.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r358" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 4.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "terseLabel": "2024" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r358" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "terseLabel": "2023" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeaseRenewalTerm": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Renewal Term", "terseLabel": "Lease renewal term (in years)" } } }, "localname": "LessorOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LessorOperatingLeaseTermOfContract": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Term of Contract", "terseLabel": "Initial lease term (in years)" } } }, "localname": "LessorOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r28", "r85", "r148", "r165", "r185", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r315", "r316", "r317", "r338", "r364", "r365" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r85", "r165", "r338", "r366", "r388", "r406" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Equity:" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r11", "r387", "r400" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Unsecured revolving credit facility" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Facility fee on revolving commitment fees (percent)" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r26", "r84" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Unsecured revolving credit facility", "verboseLabel": "Revolving Facility" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LoansReceivableBasisSpreadOnVariableRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage added to reference rate used to compute variable rate on loan receivable.", "label": "Loans Receivable, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate for loan (percent)" } } }, "localname": "LoansReceivableBasisSpreadOnVariableRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LoansReceivableFairValueDisclosure": { "auth_ref": [ "r162" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of loan receivable, including, but not limited to, mortgage loans held for investment, finance receivables held for investment, policy loans on insurance contracts.", "label": "Loans Receivable, Fair Value Disclosure", "verboseLabel": "Mezzanine loan receivable" } } }, "localname": "LoansReceivableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An amount of money or property, or a portion thereof, leant to a borrower (debtor) in exchange for a promise to repay the amount borrowed plus interest at a date certain in the future.", "label": "Loans Receivable [Member]", "terseLabel": "Other loans receivable" } } }, "localname": "LoansReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r11", "r210", "r225", "r226", "r227", "r387", "r404" ], "calculation": { "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Outstanding borrowings", "totalLabel": "Carrying Value" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r30" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loans Payable, Noncurrent", "terseLabel": "Senior unsecured term loan, net" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails", "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r30", "r184" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails", "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MortgageReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amounts due the Company for loans secured by the collateral of specified real estate property and which loan the borrower (debtor) is obligated to repay in accordance with a predetermined set of payments.", "label": "Mortgage Receivable [Member]", "terseLabel": "Mortgage loan receivable" } } }, "localname": "MortgageReceivablesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r67" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r67" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r67", "r70", "r73" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r4", "r39", "r40", "r43", "r47", "r73", "r85", "r93", "r95", "r96", "r97", "r98", "r101", "r102", "r115", "r143", "r146", "r149", "r152", "r154", "r165", "r185", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r321", "r338", "r392", "r413" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity", "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r95", "r96", "r97", "r98", "r104", "r105", "r117", "r122", "r143", "r146", "r149", "r152", "r154" ], "calculation": { "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Numerator for basic earnings available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r106", "r111", "r112", "r113", "r114", "r117", "r122" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Numerator for basic and diluted earnings available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": { "auth_ref": [ "r77", "r78", "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.", "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received", "terseLabel": "Sale of real estate settled with note receivable" } } }, "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other loss:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableFairValueDisclosure": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of notes payable.", "label": "Notes Payable, Fair Value Disclosure", "terseLabel": "Senior unsecured notes payable" } } }, "localname": "NotesPayableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableGross": { "auth_ref": [ "r160", "r167", "r168", "r169", "r170", "r171", "r451", "r452", "r453" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of financing receivable.", "label": "Financing Receivable, before Allowance for Credit Loss", "terseLabel": "Mortgage loan receivable" } } }, "localname": "NotesReceivableGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r16", "r159", "r169" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.", "label": "Financing Receivable, after Allowance for Credit Loss", "terseLabel": "Loan receivable" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfRealEstateProperties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of real estate properties owned as of the balance sheet date.", "label": "Number of Real Estate Properties", "terseLabel": "Number of facilities" } } }, "localname": "NumberOfRealEstateProperties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of states the entity operates in as of the balance sheet date.", "label": "Number of States in which Entity Operates", "terseLabel": "Number of states with properties" } } }, "localname": "NumberOfStatesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OrganizationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLeaseIncome": { "auth_ref": [ "r129", "r357", "r362" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 }, "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income", "terseLabel": "Rental income", "totalLabel": "Total" } } }, "localname": "OperatingLeaseLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": { "auth_ref": [ "r129", "r361" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLeaseIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income, Lease Payments", "terseLabel": "Contractual rent due" } } }, "localname": "OperatingLeaseLeaseIncomeLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "auth_ref": [ "r129", "r362" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of components of income from operating lease.", "label": "Operating Lease, Lease Income [Table Text Block]", "terseLabel": "Schedule of Rental Income" } } }, "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r5", "r318" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment", "terseLabel": "Funding commitment" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]", "terseLabel": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]", "terseLabel": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r62" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid on common stock" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r64" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedTerseLabel": "Payments of deferred financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r64" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedTerseLabel": "Proceeds from (costs paid for) the issuance of common stock, net", "terseLabel": "Commissions paid on stock issuance" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r62" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Net-settle adjustment on restricted stock" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireCommercialRealEstate": { "auth_ref": [ "r59" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the acquisition of property as primarily intended to generate income for its owner.", "label": "Payments to Acquire Commercial Real Estate", "negatedTerseLabel": "Acquisitions of real estate, net of deposits applied", "terseLabel": "Payment to acquire facility" } } }, "localname": "PaymentsToAcquireCommercialRealEstate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireLoansReceivable": { "auth_ref": [ "r58" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of loan receivable arising from the financing of goods and services.", "label": "Payments to Acquire Loans Receivable", "negatedTerseLabel": "Investment in real estate mortgage and other loans receivable" } } }, "localname": "PaymentsToAcquireLoansReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance stock award" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14", "r237" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14", "r237" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r14", "r366" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued and outstanding as of June 30, 2021 and December 31, 2020" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other assets, net" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]", "terseLabel": "Prime Rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromCollectionOfLoansReceivable": { "auth_ref": [ "r55" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the collection, including prepayments, of loans receivable issued for financing of goods and services.", "label": "Proceeds from Collection of Loans Receivable", "terseLabel": "Principal payments received on real estate mortgage and other loans receivable" } } }, "localname": "ProceedsFromCollectionOfLoansReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Net proceeds from issuance" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "auth_ref": [ "r56", "r66" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.", "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital", "terseLabel": "Repayment of other real estate investment", "verboseLabel": "Return of initial investment" } } }, "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r60" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Gross proceeds(1)", "verboseLabel": "Proceeds from (costs paid for) the issuance of common stock, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": { "auth_ref": [ "r61" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.", "label": "Proceeds from Issuance of Unsecured Debt", "terseLabel": "Proceeds from the issuance of senior unsecured notes payable", "verboseLabel": "Gross proceeds from issuance" } } }, "localname": "ProceedsFromIssuanceOfUnsecuredDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Proceeds from Loans", "terseLabel": "Proceeds from settlement of loan" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r61" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Borrowings under unsecured revolving credit facility" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfRealEstateHeldforinvestment": { "auth_ref": [ "r57" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from the sale of real estate that is held for investment, that is, it is part of an investing activity during the period.", "label": "Proceeds from Sale of Real Estate Held-for-investment", "terseLabel": "Net proceeds from sales of real estate", "verboseLabel": "Proceeds from sale" } } }, "localname": "ProceedsFromSaleOfRealEstateHeldforinvestment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Real Estate [Abstract]", "terseLabel": "Real Estate [Abstract]" } } }, "localname": "RealEstateAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RealEstateDisclosureTextBlock": { "auth_ref": [ "r439", "r440", "r441", "r443", "r445" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for certain real estate investment financial statements, real estate investment trust operating support agreements, real estate owned, retail land sales, time share transactions, as well as other real estate related disclosures.", "label": "Real Estate Disclosure [Text Block]", "terseLabel": "Real Estate Investments, Net" } } }, "localname": "RealEstateDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_RealEstateHeldforsale": { "auth_ref": [ "r411" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of investments in land and buildings held for sale, excluding real estate considered to be inventory of the entity.", "label": "Real Estate Held-for-sale", "terseLabel": "Net carrying value" } } }, "localname": "RealEstateHeldforsale", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "auth_ref": [ "r409" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes.", "label": "Real Estate Investment Property, Accumulated Depreciation", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "auth_ref": [ "r410" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, at Cost", "totalLabel": "Real estate investments" } } }, "localname": "RealEstateInvestmentPropertyAtCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyNet": { "auth_ref": [ "r410" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, Net", "terseLabel": "Real estate investments, net", "totalLabel": "Real estate investments, net" } } }, "localname": "RealEstateInvestmentPropertyNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentsJointVentures": { "auth_ref": [ "r410" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The book value of investments in real estate joint ventures including direct and indirect investments.", "label": "Real Estate Investments, Joint Ventures", "terseLabel": "Other real estate investments" } } }, "localname": "RealEstateInvestmentsJointVentures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "http://www.caretrustreit.com/role/OrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Real Estate [Line Items]", "terseLabel": "Real Estate [Line Items]" } } }, "localname": "RealEstateLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstatePropertiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Real Estate Properties [Line Items]", "terseLabel": "Real Estate Properties [Line Items]" } } }, "localname": "RealEstatePropertiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstateTable": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about real estate investment companies including, but not limited to, real estate investment trusts, real estate owned, retail land sales, and time share transactions.", "label": "Real Estate [Table]", "terseLabel": "Real Estate [Table]" } } }, "localname": "RealEstateTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstateTaxExpense": { "auth_ref": [ "r305" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A tax based on the assessed value of real estate by the local government. The tax is usually based on the value of property (including the land).", "label": "Real Estate Tax Expense", "terseLabel": "Property taxes" } } }, "localname": "RealEstateTaxExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.", "label": "Receivable [Domain]", "terseLabel": "Receivable [Domain]" } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesFairValueDisclosure": { "auth_ref": [ "r21", "r35", "r389", "r407" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables.", "label": "Receivables, Fair Value Disclosure", "terseLabel": "Loan receivable" } } }, "localname": "ReceivablesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r63" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-term Lines of Credit", "negatedTerseLabel": "Payments on unsecured revolving credit facility" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r80", "r383", "r405" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails", "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted stock award" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "terseLabel": "Vesting of restricted common stock, net of shares withheld for employee taxes (in shares)" } } }, "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "terseLabel": "Vesting of restricted common stock, net of shares withheld for employee taxes" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r139", "r140", "r145", "r150", "r151", "r155", "r156", "r157", "r262", "r263", "r381" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Independent living facilities" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.", "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]", "terseLabel": "Independent living facilities, revenue services" } } }, "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r45", "r85", "r139", "r140", "r145", "r150", "r151", "r155", "r156", "r157", "r165", "r185", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r338", "r396" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving credit facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r355", "r356" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use asset obtained in exchange for new operating lease obligation" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]", "terseLabel": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r135", "r157" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Rental income, exclusive of operating expense reimbursements" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r308", "r309" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r30", "r88", "r226", "r228", "r254", "r257", "r258", "r259", "r348", "r349", "r352", "r399" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Debt Instruments" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Reconciliation of Weighted-Average Common Shares Outstanding Used in Calculation of Basic EPS to Diluted EPS" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EarningsPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r282", "r293", "r301" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFinancingReceivablesPastDueTable": { "auth_ref": [ "r168", "r171" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about aging analysis for financing receivable.", "label": "Financing Receivable, Past Due [Table]", "terseLabel": "Financing Receivable, Past Due [Table]" } } }, "localname": "ScheduleOfFinancingReceivablesPastDueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRealEstatePropertiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning real estate properties and units within those properties by ownership of the property.", "label": "Schedule of Real Estate Properties [Table]", "terseLabel": "Schedule of Real Estate Properties [Table]" } } }, "localname": "ScheduleOfRealEstatePropertiesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of real estate properties and units in those properties that are included in the discussion of the nature of an entity's operations.", "label": "Schedule of Real Estate Properties [Table Text Block]", "terseLabel": "Summary of Investment in Owned Properties" } } }, "localname": "ScheduleOfRealEstatePropertiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r283", "r296" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r32", "r82", "r131", "r132", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r242", "r246", "r251", "r254", "r255", "r256", "r257", "r258", "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r13", "r14", "r15", "r234", "r235", "r236", "r254", "r255", "r256", "r257", "r258", "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Summary of the At-The-Market Offering Program" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior unsecured notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "terseLabel": "Shares forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of awards granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Award grant date fair value (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Unvested stock awards outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Valuation Assumptions" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield (assuming full reinvestment)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r281", "r285" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r289", "r300" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected service period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r33", "r41", "r42", "r43", "r90", "r91", "r92", "r94", "r100", "r102", "r130", "r166", "r253", "r260", "r297", "r298", "r299", "r306", "r307", "r319", "r340", "r341", "r342", "r343", "r344", "r345", "r422", "r423", "r424", "r455" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r90", "r91", "r92", "r130", "r381" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r14", "r15", "r253", "r260" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, net, (in shares)", "verboseLabel": "Number of shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity", "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r14", "r15", "r253", "r260" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Share repurchase program authorization" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r18", "r19", "r85", "r161", "r165", "r338", "r366" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r83", "r238", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r252", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StraightLineRent": { "auth_ref": [ "r71" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLeaseIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between actual rental income due and rental income recognized on a straight-line basis.", "label": "Straight Line Rent", "negatedTerseLabel": "Straight-line rental income", "terseLabel": "Straight-line rent" } } }, "localname": "StraightLineRent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r346", "r368" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r346", "r368" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r346", "r368" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r346", "r368" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r367", "r370" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r15", "r253", "r260" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Shares repurchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of cost from product sold and service rendered.", "label": "Cost, Product and Service [Extensible Enumeration]", "terseLabel": "Independent living facilities, cost of services" } } }, "localname": "TypeOfCostGoodOrServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "auth_ref": [ "r116", "r119", "r120" ], "calculation": { "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.", "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic", "negatedLabel": "Less: Net income allocated to participating securities" } } }, "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredLongTermDebt": { "auth_ref": [ "r30" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Unsecured Long-term Debt, Noncurrent", "terseLabel": "Senior unsecured notes payable, net" } } }, "localname": "UnsecuredLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r106", "r122" ], "calculation": { "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average diluted common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator:", "verboseLabel": "Weighted-average number of common shares:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r104", "r122" ], "calculation": { "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average basic common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r54" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.", "label": "Write off of Deferred Debt Issuance Cost", "terseLabel": "Write off of deferred financing costs" } } }, "localname": "WriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 13 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "65", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2793-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "66", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2814-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL77927221-108306" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/subtopic&trid=2196772" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "79", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "80", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123398962&loc=d3e400-110220" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2599-110228" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20,22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6419918&loc=d3e35301-107843" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r318": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13728-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123420820&loc=SL77919311-209978" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r370": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(14)(d))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.1)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123605564&loc=d3e23415-158514" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123605564&loc=d3e23439-158514" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123605587&loc=d3e23528-158515" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=d3e9120-115832" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r439": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "970", "URI": "http://asc.fasb.org/topic&trid=2156125" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r440": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "972", "URI": "http://asc.fasb.org/topic&trid=2134617" }, "r441": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "974", "URI": "http://asc.fasb.org/topic&trid=2156429" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r443": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "976", "URI": "http://asc.fasb.org/topic&trid=2134846" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r445": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "978", "URI": "http://asc.fasb.org/topic&trid=2134977" }, "r446": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r447": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r448": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r449": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r450": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r451": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1404" }, "r452": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(1)" }, "r453": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(2)" }, "r454": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" } }, "version": "2.1" } ZIP 73 0001628280-21-015843-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-21-015843-xbrl.zip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